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ABSTRACT

Cross-disciplinary integration is a key feature of interdisciplinary research and the
collaborative form is often a desired outcome of Team Science endeavors. In 2019 the FDA
began rolling out a new interdisciplinary approach to their cross-disciplinary assessment of
marketing applications, with the key feature being integrated, collaborative review documents
(Woodcock et al., 2020). FDA’s assessment of new drug products to allow them to enter the
marketplace is a critical translational activity to protect the US public’s health that requires teambased integration and transparency (Woodcock, 2018). And, while increased cross-disciplinary
integration through enhanced collaboration and communication is sought through this
intervention, FDA and in fact the Science-of-Team-Science, arguably lack examples of a
rigorous approach to the objective evaluation of integration.
Through a phenomenological descriptive comparative case study we identify, model, and
analyze multiple instances of collaborative integration occurring in different FDA review teams
using either their new interdisciplinary review or their traditional multidisciplinary review
processes to evaluate the impact of the intervention to promote integration (Bugin, 2021). This
study applies a framework of cross-disciplinary integration from the philosophy of Team Science
using an input-process-output (IPO) model (O’Rourke et al., 2016). This framework is coupled
with the FDA’s structured benefit-risk framework for assessing the approvability of new drug
products, and used to guide data collection and analysis, and the interpretation of integration
(FDA, 2018).
Integration is observed in both review processes, confirming that FDA team-based new
drug product marketing application reviews are indeed demonstrating collaborative cross-
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disciplinary research activities per the cross-disciplinary integration framework. Furthermore,
findings indicate that the cross-disciplinary integration framework and associated IPO model can
be applied in the evaluation of collaborative cross-disciplinary integration, and that the method is
sensitive enough to enable analytical comparisons. Through these comparisons, the study
importantly demonstrates that the FDA’s most recent improvement to its assessment of new drug
product marketing applications, a new interdisciplinary review process with the use of more
integrated documentation, is more integrative in comparison to the traditional multidisciplinary
review process as illustrated in multiple integrative analyses and visualizations.
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Chapter 1 Introduction
Overview
The United States Food and Drug Administration (FDA) is charged with protecting and
promoting the public health of the American people. The Center for Drug Evaluation and
Research (CDER) within FDA does its part to fulfill this mission by ensuring the American
public has access to safe and effective new drug products (FDA, 2015). In pursuit of this
mission, CDER operates a regulatory program known as the New Drugs Regulatory Program
that oversees the clinical research of investigational new drugs, assesses the safety and
effectiveness of new drugs before they are legally marketed, and monitors their use in the
marketplace to ensure the expected benefits of approved new drug products continue to outweigh
the potential risks of their use in the United States (US). The assessment of safety and
effectiveness of new drug products is therefore a critical function performed by FDA’s CDER
and necessary in the US healthcare system.
CDER’s assessment of safety and effectiveness for new drug products is changing. In
2018, the Center Director for CDER, Dr. Janet Woodcock, stated the case for having more
integration in the assessment of new drug products when she described upcoming changes to the
New Drugs Regulatory Program:
“Setting standards for approval and assessing innovative new drugs requires large and
well-coordinated teams of highly trained professionals with many different types of
expertise. CDER’s Office of New Drugs (OND) has a staff of more than 1,000
individuals who work together in many ways. New drug development and approval also
requires coordination across many offices within CDER, including the Office of
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Translational Sciences (OTS), the Office of Surveillance and Epidemiology (OSE) and
the Office of Pharmaceutical Quality (OPQ). A central component of our proposed
changes involves stronger integration of our talented staff so they can better work
together – within and across offices, a concept we refer to as “integrated assessment”.
Previously, CDER reviewers would seek consults from specialists in other scientific
disciplines (as issues were identified in the course of review). For greater collaboration, a
cross-disciplinary team will be assigned to work on a new drug application at the outset”
(Woodcock, 2018).
This vision marks an important milestone in the evolution of the assessment of new drug
product applications, one that began more than a decade and a half ago surrounding public drug
safety issues related to the withdrawal of Vioxx, a pain medicine for the treatment of
osteoarthritis, in 2004. As a result of those issues, numerous internal organizational and cultural
concerns related to the assessment of new drugs at the FDA were raised that led to the
development of the 21st Century Review Initiative and efforts to improve benefit-risk
determinations in the assessments of new drug products. The 21st Century Review Initiative,
originally launched in 2008, included a set of processes and standards to address both quality and
performance of “drug reviews that involve multiple offices” and promote a more organized,
integrated, and accountable review of new drugs (FDA, 2018e). This approach is described
extensively in the 21st Century Desk Reference Guide for New Drug Marketing Application
Reviews (FDA, 2014).
The 21st Century Review processes and standards contributes to a highly coordinated
team-based approach to conducting the review of new drugs. In this approach individual team
members work independently but following a pre-determined process to review the new drug
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product application then produce documentation of their assessments, known as a review. These
individual reviews are often voluminous in size and contain redundant information across the
review documents (e.g., repeated summaries of the same study, descriptions of similar issues)
because each review document must stand alone.
At the end of this process a single individual, usually from the clinical discipline, known
as the cross-disciplinary team lead would integrate the assessments from each individual
document into a summary review document. This summary review document includes a
completed benefit-risk framework (BRF) and a recommendation for the overall decision (or
action to be taken) for the new drug product. This approach could most accurately be described
as a multi-disciplinary approach to conducting the review of a new drug product application with
a single integrator recommending a decision at the end. While integration is most certainly
occurring in this approach, it is unclear if this integration is effectively cross-disciplinary or
collaborative. Furthermore, this intensive, multi-disciplinary documentation and review process
often obscures the underlying basis for FDA’s decisions because information and insights would
be spread out across the individual assessments and review documents of each individual team
member in those separate, often voluminous review documents (McDonagh et al., 2013). The
2018 vision from Dr. Woodcock intends to enhance the key components of this now traditional
approach to the review of new drug products and is part of FDA’s continued commitment to the
improvement of the new drug product review processes and the communication of its decisions
(FDA, 2019h).
As mentioned earlier, the assessment of a new drug’s benefits and risks, and the decision
that the benefits outweigh those risks became the center of controversy following the very public
postmarket safety issues related to the Vioxx drug withdrawal and other notable new drug
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withdrawals in the early 2000s. In fact, many external stakeholders to the FDA believed drug
withdrawals were a key indicator of FDA’s failure to adequately weigh benefits and risks due to
the occurrence of several withdrawals at that time (Institute of Medicine, 2006). The three most
notable withdrawals in the early 2000s were Vioxx as has already been mentioned, Bextra, and
Baycol/Lipobay. These three withdrawals led to a perceived erosion of confidence in FDA’s
ability to adequately assess drug safety and protect public health and made the agency’s
assessment of new drug risk the focus of major concern for the pubic and legislators (Committee
on finance United States senate, 2004; Wysowski & Swartz, 2005).
As the most controversial and public of these withdrawals, Vioxx serves as a useful
reference case for the greater focus on the benefit-risk assessment of new drug products. Vioxx
was approved in 1999 for the reduction of signs and symptoms of osteoarthritis. Following
several clinical studies examining gastrointestinal complications of the drug, additional
cardiovascular adverse events emerged that changed the safety profile of the drug such that it
was ultimately withdrawn voluntarily from the market in 2004 by its manufacturer, Merck
(Wysowski & Swartz, 2005). This particular series of events would lead to a congressional
hearing, an FDA commissioned report from the Institute of Medicine (IOM), and important
legislative changes to FDA’s authority in the Food and Drug Administration Amendments Act of
2007 (Committee on finance United States senate, 2004; FDA, 2007b; Institute of Medicine,
2006). In the IOM’s report, IOM pointed out challenges at the FDA related to its safety culture,
the science of safety, communications, and operations and management. One key takeaway for
the FDA following the events that led up to the Vioxx drug safety crisis and the IOM's
commissioned report was that FDA needed to develop and incorporate more quantitative or
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semi-quantitative tools to aid the assessment of benefit and risk, which would help with the
science of its decision-making, internal alignment, and communications (FDA, 2007b).
And so, beginning in 2013, the FDA began the implementation of a more structured
approach to the benefit-risk assessment by implementing the structured Benefit-Risk Framework
(BRF) (FDA, 2013). The BRF was a tool intended to facilitate a more balanced and consistent
consideration of factors associated with benefits and risk during the new drug product review
process and ensure transparency through improved communication of the FDA’s decisions and
decision-making process. The BRF adds structure to the determination of benefits and risks. And,
builds on the origins of the review process for a new drug product to find a product “safe” and
“effective”.
Effectiveness is a regulatory definition that refers to the regulatory determination that is
made through an assessment of clinical efficacy and other data of the potential benefits to
patients associated with a new drug’s use (FDA, 1998). This assessment is an important
precursor to determining that the potential benefits to patients outweigh the known and possible
risks to patients, otherwise considered the “safety” of a new drug (FDA, 2013). In totality, this
assessment of benefits, and that benefits outweigh risks, otherwise known as the benefit-risk
assessment, is the core decision to be made by FDA when approving a new drug product. The
BRF therefore would facilitate this process in the FDA new drug product review by providing
the FDA with a consistent, structured, semi-qualitative approach to focus the assessment process
and analyze the benefits and risks in the final benefit-risk determination.
The structured approach to decision-making that the BRF provides also facilitates clarity
and consistency in the way FDA communicates its decisions by intending to more clearly
articulate the FDA’s assessment of evidence and uncertainty related to its decision. These
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decisions are made by a signatory, a leader from the clinical discipline, who has the authority,
delegated from the Secretary of Health and Human Services, for approving a new drug product
(FDA, 2018d).
Initially, CDER implemented the BRF through its incorporation into the clinical
discipline’s review and the final summary review of the application authored by the signatory
authority of the FDA team. Other members of the FDA team would still complete their own
disciplinary reviews and document these reviews in individual review documents. This multidisciplinary approach to conducting the benefit-risk assessment and determiniation, with distal
integration led by a single discipline, had its challenges and may not have fully realized the goals
of implementing the BRF across the entire new drug product review process and across all
disciplines.
In 2017, as part of the New Drugs Regulatory Program Modernization, a multi-year,
multi-phase improvement initiative, CDER began designing and planning for the implementation
of a more interdisciplinary process for the review of new drug products with an integrated, teambased approach to its review process and documentation from the start (Woodcock, 2018). The
BRF is an integral component of this new approach and in fact serves again as a framework for
the FDA team members to collaboratively integrate the insights gleaned from their assessments
into a more comprehensive assessment of benefit-risk. This in turn was expected to contribute to
more robust, integrated team-based decision-making and documentation (Woodcock et al.,
2020).
As noted earlier, the FDA’s traditional review process follows an approach to crossdisciplinary team science that is multidisciplinary, where team members coordinate to bring
together their individual disciplinary/professional perspectives, knowledge, data, information,
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and methods but do not change the individual disciplinary components (Thompson Klein, 2014;
Wagner et al., 2011).With the existing FDA “multidisciplinary review” process, the integration of
insights from across disciplines may occur, but occurs late in the review process when individual
disciplinary reviews were completed, often resulting in only a small subset of the team being
involved in the integration process and decision-making (FDA, 2014). FDA’s new “integrated
review” process proposes a more collaborative approach that uses the BRF, a shared conceptual
framework, to orient the team’s assessment process and documentation from the onset of their
work rather than late in the review process (Woodcock, 2019).
As part of the New Drugs Regulatory Program Modernization, the FDA also initiated a
reorganization of the CDER offices involved in the review of new drug products (FDA, 2019g).
The reorganization is part of the FDA’s broader strategy to promote scientific leadership and
enable more integrated assessments by creating greater therapeutic alignment across the offices
and strengthen cross-functional interactions (Bugin et al., 2020). It is expected that the improved
alignment will contribute to more efficient internal review processes, including those that
contribute to collaboration and integration in the integrated review, and external interactions with
stakeholders in new drug product development (FDA, 2019i).
With the shift to more collaborative and integrated approaches to conducting and
documenting assessments, the amount of documentation produced by FDA new drug product
assessment teams has also decreased. Individual disciplinary analyses and assessments are still
documented in the integrated review, in discipline-specific appendices, but reference
information, such as study descriptions and results are shared by team memebers, thereby
reducing redundant documentation. This decrease in the overall quantity of documentation is a
point of contention or concern for FDA critics, with some even claiming that key information or
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knowledge from the review process is lost in the Integrated Review (Herder et al., 2020). With
the release of the first example of this new review process and template, some have criticized
FDA for decreased transparency (Silverman, 2019). Demonstrating and communicating to
stakeholders that FDA’s new integrated review process and documentation maintains its expected
rigor and depth—is truly more integrative, and not just less documented—will be important for
maintaining FDA’s credibility and transparency (Woodcock et al., 2020).
Lastly, the shift to greater integration and cross-disciplinary collaboration in new drug
product application assessments conducted by the FDA is more aligned to preceding research
and development process of new drug products that informs these applications. New drug
research and development includes numerous activities from an intensive cross-disciplinary
process in its own right, which includes clinical and nonclinical investigations of safety and
tolerability of new drug products and the exploration and confirmation of efficacy or
effectiveness (Burley & Park, 2005; FDA, 2018c). The development process unfolds over many
years and incorporates clinical trials conducted through the drug development phases from small
phase 1 studies in healthy volunteers to large, multi-center phase 3 confirmatory studies in
patients (DiMasi et al., 2016; Hwang et al., 2017). Ensuring FDA has a similarly matched crossdisciplinary collaborative process to assess the diversity of data and information submitted seems
therefore critical.

Statement of the Problem
The FDA assessment of marketing applications for new drug products is a critical
translational research activity on the biomedical research continuum (Caruso et al., 2014; Drolet
& Lorenzi, 2011). FDA’s decision is necessary for safe and effective new drug products to enter
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the U.S. marketplace and become subsequently incorporated into clinical practice. FDA forms
cross-disciplinary teams to conduct these assessments, and these teams follow standard
procedures and processes for their assessments and decision-making (FDA, 2014). Traditionally,
this assessment requires multiple disciplines to work separately but in a highly coordinated way
to share, verify, validate, and ultimately integrated their findings related to the submitted
scientific data and information. With a shift in FDA’s review process from this traditional
multidisciplinary approach to a more integrative interdisciplinary approach, with the “Integrated
Review”, the teams must collaborate from start to finish with the intent to integrate their
assessments (Woodcock et al., 2020). Such integration processes can be challenging for multiple
reasons, such as those described by Michael O’Rourke and colleagues, including the number of
disciplines involved, the types of inputs into the process, and the nature of the integration itself
(e.g., connecting, mixing, transforming) (2016).
This highly collaborative, end-to-end integration can be considered an especially
thorough form of cross-disciplinary research (Klein, 2012). Such extensive cross-disciplinary
integration is necessary to make CDER’s assessments of greater quality and ensure the
assessments contribute to robust decision-making. Due to the changes in process and procedures,
including for documentation, resulting from the implementation of the Integrated Review,
external stakeholders of the FDA have concerns over a loss of knowledge and information
(Herder et al., 2020). Without an understanding of the nature of collaborative cross-disciplinary
integration occurring in CDER’s new drug product assessment, the FDA may have challenges in
evaluating its efforts and defending its new approach to team assessments.
The key phenomenon involved in cross-disciplinary research is integration and has been
defined or characterized in different ways over the years by cross-disciplinary researchers
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(Bammer, 2013; Bergmann., 2012; Klein, 1990; Newell, 2001; O’Rourke et al., 2013; Repko &
Szostak, 2014). In the context of the FDA’s assessment of a new drug product, FDA team
members assess premarket evidence (inputs) from multiple disciplinary or cognitive domains
then combine the insights from their individual assessments around various dimensions (outputs)
of benefit and risk in the BRF to form integrated assessments. This input to output process of
collaborative integration closely aligns with the framework for cross-disciplinary integration
developed by Michael O’Rourke and colleagues (O’Rourke et al., 2016). Such a framework
could inform the modelling of collaborative cross-disciplinary integration in FDA review teams’
products and their processes. Modelling integration in collaborative FDA new drug reviews
would enable the FDA to better document the integration in new drug product reviews, enabling
stakeholders to better understand the process that led to a final regulatory decision on a new drug
product, and what information or knowledge was involved in the integration. Finally, being able
to confirm and/or trace the integration process is critical to FDA’s internal management of
information and decisions related to precedents, contributes to transparency in FDA’s decisionmaking, and communicating the bases of FDA decisions to all stakeholders (i.e., FDA knowledge
management) (FDA, 2019h).
Furthermore, a greater understanding of the underlying collaborative cross-disciplinary
integration process in the FDA’s regulatory review of new drug marketing applications,
particularly the new integrated review is needed to evaluate the success of the new integrated
review and develop practical guidelines or supporting resources (i.e., training) that would
promote integration. In addition, by creating a model of the integration in FDA reviews, both
new and old, the FDA could better explain the integration process and confirm that changes in
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documentation have achieved an increased degree of integration in addition to the reduction in
redundancy.
Beyond the FDA, understanding what integration looks like and how it occurs in
collaborative, cross-disciplinary research has been the focus of researchers of science teams and
interdisciplinary science for decades (Klein, 1990; National Research Council, 2015; O’Rourke
et al., 2013; Repko, 2006; Wagner et al., 2011). Researchers and practitioners alike understand
that better knowledge of the processes and conditions in which integration occurs and how to
measure it are key to being able to further the effectiveness of our team science activities since it
has been found that interdisciplinary teams require certain skills and abilities at the individual,
team, and organizational level to be effective. These skills and abilities depend on the degree and
nature of the integrative processes (Salazar et al., 2012; Stokols, Misra, et al., 2008a).
Due to the knowledge gap that exists regarding the interdisciplinary integration process
that occurs within FDA new drug product assessment teams, FDA is hampered in its ability to
defend its new approaches to team-based assessments and to develop practical guidelines and
trainings for its teams to promote the effectiveness of its team-based assessments of new drug
products. Most importantly, FDA is limited in its ability to evaluate the success of its recent
improvement initiatives under the New Drugs Regulatory Program Modernization that aim to
promote more integrated assessments without a clear way to evaluate integration in pre- and
post-implementation new drug reviews.

Purpose and Research Questions
This research was conducted using a phenomenological descriptive comparative case study
of new drug product assessments using either the new integrated review process and team-based
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template, or the traditional multidisciplinary review process and individual review templates.
This research study also involves the development of an approach to modelling the process by
which integration occurs in collaborative, cross-disciplinary FDA new drug product reviews and
a greater understanding of how collaborative cross-disciplinary integration occurs. The focus of
the research is primarily at the meso level of the teams and the processes that affect their
integration. More specifically, the unit of analysis is the FDA review team and discrete instances
of collaborative cross-disciplinary integration that occur related to benefit-risk review issues. The
research questions are:
1. What are examples of integration in a “multidisciplinary review” and an “integrated
review” of an FDA new drug product?
2. What are the specific differences in integration between a “multidisciplinary review” and
an “integrated review” of an FDA new drug product?
As discussed in the introduction, a conceptual framework, the BRF, was created to
structure the decision-making process for new drug product application assessments. But the
process of integrating insights and evidence from multiple team members to inform a now much
more collaborative benefit-risk assessment process in the integrated review is a new use and not
well understood by the FDA. Without an approach to evaluate collaborative cross-disciplinary
integration, the FDA will be unable to promote efficient and effective team processes that
contribute to effective integration and robust decision-making. The FDA needs a strong
understanding of integration in order to design training and guidelines for staff to promote
greater team effectiveness in the completion of integrated assessments of new drug products,
support the evaluation of improvement initiatives aimed at creating and supporting more
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integrated assessments, and promote greater transparency to external stakeholders on the FDA’s
assessment and decision-making process.
In addition, the Science-of-Team-Science includes numerous theoretical and conceptual
models of cross-disciplinary integration and collaborative cross-disciplinary, but none are geared
towards the practical evaluation of integration. The lack of a measurement tool for integration
limits the Science-of-Team-Science in its quest to better understand the key factors that influence
team science.

Statement of Potential Impact
Creating a model of collaborative cross-disciplinary integration in FDA new drug product
reviews, both the multidisciplinary review and integrated review, enables a greater understanding
of the team processes and other factors that influence integration, a key outcome for the FDA.
The ability to assess integration in a more rigorous, analytical way allows FDA to evaluate the
implementation of the new integrated review, measure performance of teams, compare its new
approach to previous approaches, and address concerns from stakeholders related to otherwise
superficial changes to the outputs of the review processes.
In addition, the models of integration found in both an integrated review and
multidisciplinary review helps identify the key points or features in the integration process that
are distinctly different between the two approaches, as well as those that are working well and
those that may need additional support for teams to achieve them. Such knowledge is critical for
the FDA to achieve its strategic objective of having a truly integrated assessment. The modelling
approach developed as part of this research may also be used to define the integrative processes
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of FDA review teams in other contexts, such as the assessment of safety signals in pre-market
and post-market development.
The FDA review of new drug products requires teams of scientific, medical, legal, and
regulatory experts to collaborate in the review of evidence of safety and efficacy generated in the
premarket development of a new drug product and benefit-risk decision-making. The evidence
generation process of drug development is in itself a cross-disciplinary phenomenon, involving
numerous disciplines and domains (Ettouati et al., 2013; Settleman & Cohen, 2016; Stojanovic &
Kessler, 2011). It is natural that the FDA take similar cross-disciplinary approaches in its
assessment of this evidence. That the FDA assesses information produced by pharmaceutical
company sponsors generated by their cross-disciplinary teams of scientific, manufacturing and
commercial experts during the premarket development of new drugs, makes knowledge gained
from this study generalizable beyond FDA teams. And, the outcomes of this shift at FDA will be
impactful to the pharmaceutical industry and researchers given the importance of making and
communicating effective benefit-risk decisions in those contexts as well (Settleman & Cohen,
2016; Stojanovic & Kessler, 2011)
Lastly, the use of a theoretical framework from the Science-of-Team-Science to model
collaborative cross-disciplinary integration in FDA new drug product reviews is a robust
practical application of this model and subsequently a huge contribution to the literature on
interdisciplinary theory and the Science-of-Team-Science. By having an established practical
model of integration that highlights the “moving parts” in the collaboration researchers,
including those at the FDA, can identify in a systematic way how to ensure, influence, and
control the collaborative cross-disciplinary integration process.
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Theoretical Foundation and Conceptual Framework
This study is primarily guided by a framework from the Science-of-Team-Science,
specifically a philosophical framework for cross-disciplinary integration (O’Rourke et al.,
2016). In addition to this philosophical framework for cross-disciplinary integration, a typology
of integration in interdisciplinary research from Julie Thompson Klein offers a qualitative way to
distinguish between the traditional multidisciplinary forms of integration and those expected in
the integrated review (Thompson Klein, 2014). Finally, the BRF for US FDA regulatory new
drug decision-making is used as a conceptual framework to operationalize the philosophical
framework for cross-disciplinary integration in the context of a new drug product review (FDA,
2018a).

Figure 1: Cross-disciplinary Integration Framework
(O’Rourke et al., 2016)

In Figure 1, above, O’Rourke et al. describe a framework for integration using a “generic
combination process” (O’Rourke et al., 2016, p. 67). In this combination process, inputs are
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combined, and the output is produced. This combination process from input to output can be
characterized by examining the quality and quantity of inputs, the process, and the outputs. Once
characterized, the combination process, or “integration”, can be modelled using as an Inputs >
Process > Outputs chain or logic model. In Figure 2, below, the framework for cross-disciplinary
integration from O’Rourke et al. is operationalized with contextual elements from the BRF that
guides a new drug product assessment. For example, in the figure below the known potential
disciplines from a new drug product assessment have been outlined as clinical, statistics, clinical
pharmacology (clin pharm), pharmacology/toxicology (PTOX), quality, or regulatory. These
disciplines are responsible for inputs into the cross-disciplinary integration process. To illustrate
the contextualization further, the below figure includes examples of potential inputs that you
might find in a new drug product application and in the benefit-risk framework for the
assessment. In this figure, one can conceptualize how the framework for cross-disciplinary
integration can be used to model integration in a new drug product assessment.
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Figure 2: Analytical Framework for IPO Model of Integration in New Drug Product Reviews
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Together these theories and frameworks come together to create a conceptual and
analytical framework on which this study is centrally guided. In conjunction with the goals of the
study and the research questions, an overall study design emerges; see figure 3, below. In this
figure a Maxwell diagram of study alignment details the alignment of the research questions,
conceptual frameworks, study goals, and methods (Maxwell, 2013). The goals of the study are to
characterize the integration occurring in FDA’s new drug product review teams and then explore
differences in integration through a comparison of a traditional multidisciplinary review and an
integrated review. These goals are furthered by targeted research questions on the integration in
FDA new drug product reviews and the differences in multidisciplinary and integrated reviews.
The conceptual frameworks discussed earlier provide the necessary tools, lens, and theories to
both collect data, conduct analyses, and interpret the analyses necessary to answer the research
questions. A phenomenological philosophy, constructivist ontology, qualitative epistemology,
and descriptive case study methodology most naturally aligns with these goals and the research
questions for this study, as discussed more below. And, lastly, the validity of this study is
enhanced through randomization and blinding, triangulation, and the researcher’s experience
with new drug product reviews.
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Figure 3: Study Alignment
(Maxwell, 2013)
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Summary of the Methodology
This study is a qualitative descriptive comparative case study of a traditional FDA
multidisciplinary review and a new FDA integrated review of a new drug product marketing
application to model instances of collaborative cross-disciplinary integration and identify
differences and similarities in the integration in the two cases. The study was conducted through
a combination of the document analysis of final FDA review team documentation, semistructured interviews with review team members of each case, and a member checking of the
integration examples. The data collection from the document analysis is guided by the crossdisciplinary integration framework (O’Rourke et al., 2016) and the BRF (FDA, 2018b), which
allows the content of the review to be analyzed as relevant to an instance of integration around a
key benefit-risk review issue and coded as either inputs, outputs, or process related. Semistructured interviews and member checking with the cross-disciplinary team members involved
in integration will further inform the process variable of the framework of integration. Data
collected, guided through the cross-disciplinary integration framework, will be modelled
logically as inputs > process > outputs chains for further analyses.
Through the document analysis and interviews, descriptive elements of each case are
catalogued, including details about the teams (e.g., size of team, composition of team), the new
drug product being reviewed (e.g., new molecular entity, combination product, small molecule),
and the assessment itself (e.g., length of documentation, final decision). These case descriptions
inform the contextual parameters of the IPO framework and when combined with data on the key
variables of the integration process gathered from the document review allows each case of
integration to be thoroughly described and modelled, enabling comparisons.
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Limitations
This study is focused primarily on modelling the phenomenon of collaborative, crossdisciplinary integration that occurs within an FDA review team conducting either a
multidisciplinary review or integrated review. As such the study may not clearly define or
describe other aspects of the FDA review process, such as communication, team dynamics, or
scientific methods of analysis used. Also, while the FDA review process for a multidisciplinary
review and integrated review is generally well-defined, it may not be consistently followed with
fidelity and the effectiveness of the process may reflect individual or team characteristics (i.e.,
differences) rather than process characteristics. For this reason, it may not be possible to make
conclusions about the resulting differences in integration as solely attributable to the
multidisciplinary process or the integrated review process, but it may be possible for the
interviews to help characterize fidelity. In addition, examining two cases with different teams,
different processes, and additional differences in context (e.g., drug products reviews, therapeutic
areas, scientific issues), may affect to the generalizability of some findings related to crossdisciplinary integration in FDA reviews.
Additional limitations of this study are the sample size and sample selection. Only two
cases were selected for this study and therefore the selected samples may greatly influence the
findings. Furthermore, because the integrated review is a newly implemented process there was a
small pool of completed integrated reviews to choose at study start time. And, with the transition
to integrated reviews, the pool of recently multidisciplinary reviews available was also
decreasing. Selection was guided by a priori inclusion and exclusion criteria, described in detail
in Chapter 3. In addition, because reviews can take a long time to complete and some time may
have passed before the review team is contacted in the study, review team members may have
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limited recall of the review. This limitation is mitigated using document analysis, which
leveraged review documentation for the analysis that would have been completed at the time of
the review and not the time of this study.
Lastly, this researcher is considered a member of senior leadership within the
organization responsible for managing new drug review processes and is seen as someone
responsible for the implementation to the new integrated review process therefore having a vest
interest. This may influence subject participation and potentially bias the findings due to lack of
transparency or accuracy of interviews due to power-status and trust issues. In addition, the
research may have implicit biases related to the new integrated review process and
documentation template. While these risks will be carefully monitored and managed, it may
result in potential limitations in interpretation of the results To address any implicit biases, these
are captured in a subjectivity statement in this document and the informed consent to make the
potential biases explicit (Lincoln, Y.S., Guba, 1985).

Definitions of Key Terms
•

Benefits: “The helpful effects you get when you use them [medicine], such as
lowering blood pressure, curing infection, or relieving pain.” (Department of Health
and Human Services & Food and Drug Administration, 2018)

•

Benefit-Risk Framework (BRF). A structured approach for drug benefit-risk
assessments conducted by FDA, that serves as a tool to convey the basis of FDA’s
regulatory decisions in drug approvals (FDA, 2013).

•

Commensurability: Assessment of integrable the inputs are (i.e., their difference or
conflict between) (O’Rourke et al., 2016).
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•

Comprehensiveness: Assessment of how comprehensive the output(s) reflect or
include the inputs (O’Rourke et al., 2016).

•

Cross-disciplinary Research. Approaches to research that combine disciplines in
various degrees from multidisciplinary to transdisciplinary (O’Rourke & Crowley,
2013).

•

Discipline: FDA defined disciplines for the different members of the review team for
a new drug product marketing application, and are defined in the 21st Century Review
Desk Reference Guide (FDA, 2014).

•

Effectiveness: Effectiveness is a regulatory definition that refers to the regulatory
determination of or for a new drug product that is made on the basis of clinical
efficacy and other data (Food and Drug Administration & FDA, 1998).

•

Integration. The process and product of cross-disciplinary research that relates to the
bringing together of inputs from multiple disciplines and creating a new whole,
whether that be a simple combination of the parts into the whole or some change to
the inputs and therefore some reduction of the inputs into the final output (O’Rourke
et al., 2016). Integration can manifest across the range of cross-disciplinarity,
although minimally in the case of multidisciplinary research.

•

Interdisciplinary Research. Approaches to cross-disciplinary research that integrate,
and potentially change, separate disciplinary perspectives, knowledge, data,
information, and methods to create a more comprehensive overall view or
understanding of a complex issue (Thompson Klein, 2014; Wagner et al., 2011).

•

Integrated Review: The Integrated Review is the name of a newly proposed approach
to the review of new drug product applications that involves a team-based,
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interdisciplinary approach to the assessment of the application and an integrated,
issue-focused review of the application (FDA, 2019h).
•

Multidisciplinary Research. Approaches to cross-disciplinary research that juxtapose
disciplinary/professional perspectives, knowledge, data, information, and methods but
do not change the individual disciplinary components (Thompson Klein, 2014;
Wagner et al., 2011).

•

Multidisciplinary Review: The traditional FDA approach to conducting a review of a
new drug product application (i.e., NDA, BLA) that involves the coordinated
individual disciplinary review of the application is referred to as a multidisciplinary
review (FDA, 2014).

•

New drug products. A new drug product is a pharmaceutical product that contains a
new molecular entity or an active ingredient that contains no active moiety that has
been previously approved by the Agency in an application submitted under section
505 of the Federal Food, Drug, and Cosmetic Act, or has been previously marketed as
a drug in the United States (FDA, n.d.).

•

New drug review process: The review activities required for new drug application abd
biologic licensing applications, including the procedures and requirements described
in both the FDA’s “Guidance for Review Staff and Industry: Good Review
Management Principles and Practices for PDUFA Products (GRMP)”, and PDUFA
agreements (FDA, 2014, 2018d).

•

Safety: The potential risks, or patient’s adverse effects to new drugs, to patient health
from the use of a new drug as labeled per the Federal Food, Drug, and Cosmetic Act
(FDCA) (Federal Food, Drug, and Cosmetic Act, 1938).
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•

Transdisciplinary Research. Research that is interdisciplinary and addresses complex,
broad societal problems and involves non-academic stakeholders (Frodeman et al.,
2017). And/or research that involves either the creation of a new interdisciplinary
field or a “transcending” of disciplines (O’Rourke et al., 2013).

•

Scale: Assessment of how many disciplines or disciplinary input types involved and
the overall impact (i.e., global--the entire application vs local--a specific
problem/issue) (O’Rourke et al., 2016).
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Chapter 2 Review of the Literature
Introduction
This literature review aims to describe the available literature related to drug
development and FDA’s benefit-risk assessment of a new drug product, the Science-of-TeamScience, cross-disciplinary research, and collaborative cross-disciplinary integration. The
literature on drug development and FDA new drug product review provides important contextual
information for the application of theories and frameworks from the Science-of-Team-Science
research on collaborative cross-disciplinary integration. The review of literature from the
Science-of-Team-Science explains approaches to measuring or studying collaborative crossdisciplinary research and the specific phenomenon of collaborative cross-disciplinary research,
integration, that is the focus of this study. Lastly, literature on the phenomenon of crossdisciplinary integration is presented to identify the current state of research on the matter, gaps in
existing evidence, and elicit the most appropriate tools or methods to study integration in this
context.
Literature searches to inform the review of each domain use a combination of key terms
and wildcards and are conducted across multiple databases to ensure adequate breadth of search,
including Scopus, CINAHL, PubMed, and Mendeley. Searches were limited to English language
publications, but the year range was not limited due to the paucity of research found initially in
these domains. In addition, searches are included for literature related to the FDA new drug
product review required searching federal websites and regulatory documents. Search methods
and keywords are listed in Table 1, below.
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Table 1: Literature Search Strategies for key Domains

•

•

•

Domain 1:
FDA Assessments

FDA AND new drug*
OR drug* AND
assessment* OR
review*
translational research
AND FDA AND new
drug OR new drugs OR
drug* AND assessment
OR assessments OR
review*
translational research
AND drug development

•
•
•
•
•
•
•
•
•
•

Domain 2:
Science-of-Team-Science

interdisciplin*
cross-disciplin*
translational research AND interdisciplin*
translational research AND cross-disciplin*
collaborative OR collaboration AND
interdiscipline* OR cross-disciplin*
Team Science
Science of Team Science
Collaboration Science
measurement AND interdisciplin* OR crossdisciplin*
measurement AND Team Science OR
Collaboration Science

Domain 3:
Cross-disciplinary Research

• integration AND
interdisciplin*
• integration AND crossdisciplin*
• integration AND collaboration
• integration AND collaborative
interdisciplin* OR crossdisciplin*
• measurement AND integration
AND interdisciplin* OR
cross-disciplin*
• measurement AND
interdisciplinary integration

* this symbol denotes a wildcard to include the multiple variations of disciplinarity or pluralities

Literature that fell outside of these domains was included when it included a key piece of
supporting evidence for another aspect of the literature review (e.g., integration in philosophy) or
provided useful context for this study. Literature was also considered for inclusion in this
literature review based on certain evidentiary thresholds, in the following order: prior literature
reviews or systematic reviews, followed by studies, books or book chapters, editorials and
commentaries, and finally web postings or other grey literature. This hierarchy is motivated by a
heuristic of evaluating the strength of scientific evidence that is routinely leveraged by
biomedical researchers and those practicing evidence-based medicine research (Burns et al.,
2011). It is worth noting that strong literature reviews exist in the domain of cross-disciplinary
research, collaborative, cross-disciplinary research, Team Science and the Science-of-TeamScience and these enabled rapid identification of strong and seminal literature (Choi & Pak,
2006; Mâsse et al., 2008; National Research Council, 2015; Stokols, Misra, et al., 2008a).
Citation mining and authorship influence in the space was used to further guide selection of
literature. Full text copies of all identified literature were obtained and then loaded into
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Mendeley, a free reference manager and an academic social network produced by Elsevier
(Elsevier, 2008). Literature was reviewed and annotated in Mendeley, and in some cases the
Mendeley network was leveraged to identify additional relevant literature through its social
network and citations network features.
Drug development & FDA new drug review
New drug products are developed by pharmaceutical companies, academic medical
centers, etc. via series of research and development activities that occur over a great number of
years and an even greater number of scientific and clinical studies. According to literature, in
totality this has been characterized as a process that takes anywhere from 5-15 years, involves
dozens of studies and experts, costs hundreds of millions of dollars, and is wrought with high
failure (DiMasi et al., 2016). In addition, this drug development process is cross-disciplinary—it
requires that dozens of scientific, medical, commercial, and regulatory experts to collaborate
regularly to translate an early basic scientifically plausible innovation to something for use at the
patient’s bedside (Settleman & Cohen, 2016). At the 2005 Keystone Symposium on “Meeting the
Challenges of Drug Discovery”, keynote speaker Leslie Brown described a new
multidisciplinary set of goals for the drug development process: “use the right technology to find
the right drug modulating the right target in the right patient” (Burley & Park, 2005, p. 1). These
drug development goals have evolved over the years and included a greater emphasis on the
culture of an organization’s clinical research and commercialization programs, which relates to
effective decision-making in the process (Cook et al., 2014), demonstrating a growing
appreciation for the individuals and teams that make the process possible. This literature
illustrates the cross-disciplinary nature of the drug development process and the complexity of
the problems to be solved. These goals feed into a complex, multi-step sequential process, with
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numerous activities including, but not limited to, the discovery of novel drug candidates,
preclinical animal and toxicology research, conducting clinical studies (e.g. Phase 1, 2, and 3),
submitting regulatory documents (e.g., Investigational New Drug [IND] applications, New Drug
Application [NDA]), and initiating post-approval commitments (Ettouati et al., 2013). This
process is described in Figure 4, below.

Figure 4: Drug Development Process

The outcome of this cross-disciplinary process for the research and development of a new
drug is the generation of knowledge and evidence to support its safety and effectiveness in
clinical practice. The requirements of the research and development process and the evidence
that must be submitted to FDA to support its assessments are outlined by the Food Drug and
Cosmetic Act (FD&C), FDA regulations, specifically title 21 of the Code of Federal Regulations
sections 312 and 314 (Part 314 — Applications for FDA Approval to Market a New Drug, 2002;
Part 312 - Investigational New Drug Application, 2004), and the many guidance documents
generated by FDA review staff. The evidence generated from a product’s development program
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is compiled by a collaborative cross-disciplinary team into a marketing application, referred to as
a New Drug Application (NDA) for a new chemical entity or a Biologics Licensing Application
(BLA) for an original biologic product (Ciociola et al., 2014; Ettouati et al., 2013; FDA, 2014;
Stojanovic & Kessler, 2011). These marketing applications can contain dozens of studies and
thousands of pages of information and data.
A variety of disciplines are leveraged to design and conduct the studies during drug
development. These studies generate evidence of the product’s treatment effect (e.g., efficacy),
its effects in the patient and effects of the patient’s body on the new drug (e.g.,
pharmacokinetics/pharmacodynamics) and patient’s safety of the product at various doses, in a
very specific patient population under intensely controlled settings (Fielding, 2014). While a
variety of disciplines’ expertise is needed in drug development, the disciplines must work
together towards a common goal that is to develop evidence to support a target product profile
for the investigational new drug product, similar to key elements of a draft prescribing
information (FDA, 2007a). The target product profile represents the features of a drug that need
to be characterized during development to ensure the new drug product will be safe, effective,
and competitive on the market (Breder et al., 2017).
As studies are completed and important milestones in the new drug research and
development process are reached, massive amounts of data and information are summarized and
submitted to decision-makers, such as pharmaceutical executives and health authorities, for
ongoing review, feedback, and decision-making. This summarization or synthesis process goes
beyond any single discipline and even the multidisciplinary interactions needed to generate
evidence. It requires a more comprehensive understanding of a product at this late stage of

31
development and this understanding requires a certain cross-disciplinary integration of insights
formed during the new drug research and development process (Ettouati et al., 2013).
Furthermore, the commercial and regulatory decisions, such as should a product move
forward to phase 3 confirmatory testing or should a product be made available on the US market,
respectively, require transcending the disciplinary ontologies and methodologies involved in the
new drug research and development process to make a final determination, or judgment, of the
new drug product’s benefits and risk. These processes for decision-making are frequently
referred to as benefit-risk assessments and attempts have been made to improve these
assessments with structured frameworks due to the complexity of the decision (Walker et al.,
2015). The complexity of benefit-risk assessments comes from not only the multitude of sources
of inputs for data and information into the benefit-risk frameworks but also the necessary
integration and evaluation that is required (Walker et al., 2015). These benefit-risk decisions and
the inherent integration requires a collaborative approach as research has found that the inability
to collaborate and communicate across diverse functions may lead to suboptimal decisionmaking (Stojanovic & Kessler, 2011). Literature therefore demonstrates that the drug
development process and the ultimate benefit-risk determination are both cross-disciplinary and
collaborative.
While the pharmaceutical industry and others are primarily leading the drug research and
development process, the FDA is ultimately responsible for ensuring that new drug products
marketed in the U.S. are safe, effective and of high quality (FDA, 2015). This is arguably a
translational activity and therefore a brief review of translational research is necessary.
Translational science or translational research is focused on how scientific knowledge is
translated from basic science and discovery to public health impact (Drolet & Lorenzi, 2011). A
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more narrow view suggests the truly translational activity occurs only in the gaps in the
translational continuum between different forms of research (Austin, 2018).
In the Drolet and Lorenzi conceptualization of translational research, the activities of
both the FDA and Sponsors of new drug products during drug development fit neatly in the basic
and clinical research spaces, but it is the FDA’s assessments of a marketing application that are
truly boundary spanning. These assessments conducted by the FDA must be completed before a
new drug product can be marketed in the US and it can used in practice. Therefore, in the Austin
conceptualization the work of the FDA to assess clinical and basic research information and
make benefit-risk assessments clearly exists in and even spans the gap between basic research
and clinical practice.
Returning to the FDA’s assessment of a new drug product, this assessment occurs when
the drug development program concludes the generation and compilation of substantial evidence,
both laboratory, clinical and in some cases social, to support the product’s safety and
effectiveness (Food and Drug Administration & FDA, 1998). This compilation of evidence is
submitted in the form of a new drug application (NDA), or in the case of therapeutic biologics a
Biologics License Application (BLA), to the FDA for a determination of safety and effectiveness
(FDA, 2018c). The determination of adequate safety and effectiveness marks the “approval” of
the product. This “approval” may appear simple on its face given that a standard or definition of
‘substantial evidence’ of safety and effectiveness is provided simply in regulations (Part 314 —
Applications for FDA Approval to Market a New Drug, 2002) but it is worth noting that the
evidence to meet this standard will be from various sources (e.g., animal research, clinical
research, laboratory research, qualitative research), related to multiple attributes of new drug
products or the diseases they are intended to treat can vary greatly, and ultimately it is the totality
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of this evidence that must be carefully weighed in the context of its intended use. This careful
weighing is known as a benefit-risk assessment (Ciociola et al., 2014).
The assessment of benefits and risks has been described as a careful examination of
several factors, such as therapeutic context, the evidence submitted, uncertainties, FDA’s
regulatory options, and values of and tradeoffs between benefits and risks (Duke Margolis Center
for Health Policy, 2019). Therapeutic context relates to the context in which the new drug
product will be used, including the unmet needs of patients and the seriousness or severity of the
disease the drug is intended to treat. “Evidence” of safety and effectiveness was discussed above.
Uncertainties result from the inevitable incompleteness of evidence that is generated
during development and submitted in a marketing application, which will require scientific,
medical, and regulatory judgment to determine if a benefit-risk determination can be made
despite this uncertainty. FDA has regulatory tools to address the uncertainty inherent in new drug
product applications and decisions, such as requiring additional clinical studies after approval,
safety labeling, and risk evaluation and mitigation strategies (Darrow et al., 2017). Due to the
variety of sources of evidence and the inherent uncertainty in clinical research and drug
development, coupled with the FDA’s assessment strategies, the benefit-risk assessment is a
complex decision (McDonagh et al., 2013; Myers & Moore, 1987).
Core to making the decision to approve a new drug product is the benefit-risk assessment
and this assessment is not a purely research endeavor. It leads to determination that has major
implications on patient and population health. The benefit-risk assessments and the decisions
they support have received much attention over the years from the public, FDA, industry, and
Congress due to some of the ambiguity in these standards of safety and effectiveness. Drug
withdrawals in the early 2000s led to the reignition of public claims that the FDA was too close
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with industry and was favoring speedy approvals over public safety (Institute of Medicine,
2006). As a result of these public claims, the FDA commissioned an Institute of Medicine
committee report to independently assess the FDA’s “system for evaluating and ensuring drug
safety postmarketing” (Medicine, 2006, pg 3, Box S-1). The committee described the assessment
process as follows:
“It is impossible to know everything about a drug at the point of approval because drugs’
mechanisms of action are complex, and because the clinical testing that happens before
approval is generally conducted in controlled settings in defined, carefully selected
populations that may not fully represent the wide range of patients who will use the drug
after approval, some chronically, and in combination with other drugs. Thus, the
understanding of a drug’s risk-benefit profile necessarily evolves over the drug’s
lifecycle. CDER staff who review regulatory submissions, such as new drug applications,
must strike a delicate balance in judging the drug’s risks and benefits, and whether the
need for more study to increase certainty before approval warrants delaying the release of
the drug into the marketplace and into the hands of health care providers and their
patients." (Medicine, 2006, pg 17)
FDA would release a report in response to the commissioned report a year later calling for a
number of improvements, including more quantitative or semi-quantitative tools to aid the
assessment of benefit and risk (FDA, 2007b). In the same report, the FDA would also
acknowledge the importance of using “an interdisciplinary team approach to assessment” (FDA,
2007, pg 3).
It would take many years to develop these benefit-risk assessment tools due to the
complexity and delicate nature of the assessment and the importance of the decisions they
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inform. During the congressional hearing on Vioxx in 2004, the deputy director of the Office of
New Drugs aptly said:
“…all drugs pose some safety risk, and that some drugs pose a greater risk than others.
But there is no magic formula for deciding what drug is the biggest risk of all. If there
were a magic formula, our jobs would be very much easier… Every drug has risks and
benefits, and it is important not to get so focused on the risks that one forgets to look at
the benefits. In evaluating any individual medication, our job is to do just that.”
(Committee on finance United States senate, 2004, pg 63)
This quotation clearly articulates the challenge FDA faces in its assessments of benefit and risk.
It would take more than five years, beginning shortly after the withdrawal events from the early
2000s, for regulators from the US and Europe to develop more structured benefit-risk
frameworks for the assessment of benefits and risks. In 2009, the European Medicines Agency
released its report on its Benefit-Risk Methodology to inform regulatory decisions about
medicinal products, after its working group’s three year effort to review methods of benefit-risk
assessments and practical application (EMEA, 2009). Also in 2009, FDA would begin
considering a similar structured assessment, which would be finalized and implemented in 2013
(FDA, 2013). Industry faced similar challenges and during this time period began its own effort
to develop an improved benefit-risk assessment. In 2005, the Pharmaceutical Research and
Manufacturers of America (PhRMA) convened an action team, the Benefit Risk Action Team
(BRAT), to develop a new framework for benefit-risk assessment (Coplan et al., 2011). Five
years later, the BRAT would release its own framework.
Due to the ambiguity in the statutory requirements for evidence of safety and
effectiveness and FDA’s regulations and guidance, external stakeholders regularly question the
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standards for evidence used by the FDA and demand greater understanding of the bases of FDA’s
decisions (Downing et al., 2014). To promote clarity and transparency of its decision-making
process, FDA implemented its structured benefit-risk framework directly in the review process in
2013 (FDA, 2013). This was the culmination of much work to help characterize how evidence
and uncertainty related to a new drug’s safety and effectiveness was assessed by the FDA
(Caruso et al., 2014). As of 2018, this framework is used by more than 87% the FDA review
teams in all new drug product assessments, with a desired utilization rate of 100% (FDA, 2018b).
FDA review team members assess information submitted in the NDA or BLA, to characterize the
evidence and their uncertainties about key concepts of the benefit-risk determination.
The assessment process for a marketing application entails a verification and validation
process of the design of the research, conduct of the research, and the analyses (FDA, 2018c).
This process is conducted by an FDA review team of multiple disciplines. The FDA review
teams responsible for the assessment of these marketing applications are formed following the
receipt of a new drug product application to the Office of New Drugs in CDER. Initially, a
regulatory project manager and a clinical team leader are assigned based on the therapeutic area
for the product. These two co-leads of the review team then form a team of reviewers with
specialized expertise to assess the evidence submitted in the marketing applications. Because the
team will formulate insights about the new drug product’s benefits and risks, it is important that
these teams include multiple, but relevant, disciplines and that they collaborate effectively.
In addition to the evidence generated during the development program of a new drug
product, the regulatory assessment is also informed by additional factors, including: the severity
of the underlying condition, patients’ unmet medical needs, uncertainty about how the premarket
experience with a new drug will extrapolate to real-world use and whether known and potential
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risks are manageable. The Food and Drug Administration’s assessment and the decision the
assessment supports must also be in accord with the earlier mentioned FD&C Act and
regulations, and to some extent prior guidance or precedents from earlier regulatory decisions.
This verification and validation process of the evidence can be time consuming
depending on the scale of the development program and the complexity of the product or disease.
Evidence can be generated from any number of scientific domains, but primarily biological and
clinical. FDA review teams are carefully composed of subject matter experts from across
multiple disciplines in order to assess evidence from the appropriate disciplinary perspective
(e.g., a toxicologist to review animal toxicology studies, clinical pharmacologist to review
human pharmacology data). Following the marketing application assessment, individual FDA
review team members can characterize the evidence and uncertainties that contribute to the
FDA’s conclusions related to the key dimensions of the benefit-risk framework. In this way, the
FDA benefit-risk framework helps structure the review team’s assessment across each factor and
dimension of the benefit-risk framework (Duke Margolis Center for Health Policy, 2019). This
integration process is critical for making and communicating FDA’s benefit-risk decisions in its
assessment of new drug products.
During the assessment of the sponsor’s marketing application information, issues may be
identified related to product or its key attributes and dimensions of the benefit-risk
determination, such as its benefits, risks, or quality related to manufacturing processes of the new
product, such as the final manufactured product’s purity and potency. Such issues require crossdisciplinary collaboration of the team to fully understand the issue. For example, a robust signal
of drug induced liver injury (DILI) may be identified in an animal toxicology study and a similar
signal, albeit less certain, is found in a large clinical study. To fully understand the animal signal,
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the pharmacology/toxicology experts must fully understand the animal study and subsequent
pathology of the DILI signal, and translational implications for humans. The clinical reviewer, a
physician, must understand the design of the clinical study and the context in which the clinical
signal was identified. Both experts must work collaboratively to determine the importance of the
DILI signal and to characterize potential risks to patients (Avigan et al., 2014). In these ways, the
assessment of new drug products is cross-disciplinary in nature. Insights and conclusions
formulated during the assessment and review process are then integrated by the team to inform a
cross-disciplinary assessment known as the benefit-risk integrated assessment (FDA, 2018b), as
part of the BRF. This integration process is managed by the cross-disciplinary team leader, often
but not always a clinical team leader, and the regulatory project manager.
In conclusion, the review of a new drug product by the FDA is cross-disciplinary in
nature and involves both an assessment of evidence generated by a long and complex drug
development process and an assessment of benefits and risks, that requires an integration of
insights from multiple disciplines, to inform the decision that a product is safe and effective
before it can be approved. This decision by the FDA on a new drug product marks an important
bridging of the translational gap between clinical research and clinical practice (Austin, 2018).
Cross-disciplinary Research
The next domain in this literature search is cross-disciplinary research, a key method
deployed in Team Science, and has been increasingly recognized in translational research for its
ability to generate solutions to complex problems that cannot be solved by a single discipline
alone (Klein, 1990). This form of research involves drawing upon the insights or inputs of more
than one discipline. More specific forms of cross-disciplinary research have been characterized.
These more specific characterizations are frequently referred to as multidisciplinary,
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interdisciplinary, and transdisciplinary (Klein, 1990; Repko & Szostak, 2014; Klein, 2014).
While each specific form differs in several ways, a key differentiating factor, and relevant to this
research, is how insights are integrated. In the case of multidisciplinary research, the inputs from
two or more disciplines are brought together but do not necessarily change or result in something
new. On the other hand, interdisciplinary research involves a more involved integration of inputs
or insights into a more comprehensive output or understanding (Newell, 2001).
Transdisciplinary research was introduced as a further refinement or enhancement of
cross-disciplinary research that transcends the disciplinary bounds of both multi- and
interdisciplinary research, with definitions that at times are confusing (Rosenfield, 1992). In the
Oxford Handbook of Interdisciplinarity, transdisciplinary research is primarily referred to as
interdisciplinary, but stress is placed on the importance of addressing the most complex and
broad societal problems and involving non-academic stakeholders (Frodeman et al., 2017). In
some definitions of cross-disciplinary research transdisciplinary research is one that involves
either the creation of a new interdisciplinary field or a “transcending” of disciplines (O’Rourke et
al., 2013). In any case, it is important to note that while all forms of cross-disciplinary research
may be conducted by a single individual, this form of research may also be conducted by teams.
For the former, many interdisciplinarians have over time created models and guidance for
conducting individual cross-disciplinary research (Newell, 2001; Repko & Szostak, 2014).
In order to understand the study of cross-disciplinary research in teams, or collaborative,
cross-disciplinary research, it is important to understand the broader field of team science.
Collaborative, or team-based, research has been steadily on the rise since the early 1990s and has
become a key feature of successful science programs (Stokols, Hall, et al., 2008). The shift from
individually conducted science to more team-based science has been seen in literature
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publications and citations since the 1990s (Jones et al., 2007). This is perhaps a byproduct of the
increasing rapidity with which science evolved into greater specialized fields which would then
necessitate those individual specialized sciences coming back together to solve complex
problems. Also, public agencies and private foundations have increasingly promoted team
science through funding initiatives and priorities (Stokols, Hall, et al., 2008). This growth of
team science and investment in team science has sparked research into the effectiveness of team
science, its antecedents, processes and methods, and the performance or outcomes (including
value or impact) of it. The study of these features of team science has become known as the
Science-of-Team-Science (SciTS).
The Science-of-Team-Science
Perhaps the first use of the term Science-of-Team-Science came with a conference
organized by the National Institutes of Health in October 2006 (NCI, 2006). At this conference,
SciTS was defined as:
“[a] rapidly emerging field concerned with understanding and managing the
circumstances that facilitate or hinder the effectiveness of large-scale research, training,
and translational activities…” (NCI, 2006).
Following the discussions of this conference, this nascent field of study was further developed
and described in an American Journal of Preventive Medicine supplemental issue (AJPM). It was
in this issue of AJPM that several seminal articles on the SciTS were published (Hall et al., 2008;
Mâsse et al., 2008; Stokols, Hall, et al., 2008; Stokols, Misra, et al., 2008a). The field would
further grow through its first annual International SciTS conference in 2010 and the formation of
an international society in 2018, the International Network for the Science of Team Science
(INSciTS).

41
There are several subdomains or areas of research interest in the field of SciTS. These
domains evolved from an original six groupings suggested by Stokols et al (2008b):
interpersonal, intrapersonal, physical environmental, organizational, societal and political, and
technologic. In 2011, Holly Falk-Krzesinski et al. conducted a concept-mapping evaluation of
research in the SciTS field (Falk-Krzesinski et al., 2011). The following concepts were identified
through the mapping exercise and would inform a future research roadmap in SciTS:
“Definitions and Models of Team Science, Measurement and Evaluation of Team Science,
Disciplinary Dynamics and Team Science, Structure and Context for Teams, Characteristics and
Dynamics of Teams, Institutional Support and Professional Development for Teams, and
Management and Organization for Teams” (Falk-Krzesinski et al., 2011, pg. 18). These concepts
or domains of SciTS were thoroughly reviewed and updated in the National Academy of
Sciences’ 2015 consensus report titled, “Enhancing the Effectiveness of Team Science”. This
report was produced by a committee of experts from SciTS to “recommend opportunities to
enhance the effectiveness of collaborative research in science teams, research centers, and
institutes” (Council, 2015, p.3). When the 2015 NAS report was introduced it organized research
around individual and team factors, including individual indicators of collaboration to team
processes, such as cross-disciplinary research; team composition and assembly; education for
team science; leadership of teams; and, institutional or organizational factors that contribute to
team science. A new watermark would be achieved with the release of “Advancing Social and
Behavioral Health Research through Cross-Disciplinary Team Science: Principles for Success”,
including a new set of domains for the state of the science (“Strateg. Team Sci. Success,” 2019).
Understanding these domains is important for this study, as it sets the stage and represents the
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short but rich history of the science. But the key focus for this study is on one domain, that of
cross-disciplinary integration and this is discussed in the next section of this literature review.
Before discussing cross-disciplinary integration, a brief review of what the other domains
or subdomains of SciTS have in common is in order. The commonality is the focus on the
measurement or investigation of key indicators and factors that influence the effectiveness of
team science. The measurement or study of Team Science is after all what makes SciTS a new
science or discipline. As a seminal example, Caroline Wagner and colleagues in 2011 conducted
a comprehensive literature review of performance measures, management and evaluation of
interdisciplinary research (IDR) in response to a request from the U.S. National Science
Foundation (Wagner et al., 2011). Wagner attempted to establish metrics, but limitations were
noted and further research at the time was still warranted.
Wagner et al.’s review also points out that at the time of writing, SciTS was for the most
part focused on understanding the antecedent conditions, collaborative processes, and outcomes
associated with Team Science and its impact. Several quantitative and qualitative approaches are
discussed. Lastly, two important points or limitations are offered by Wagner et al. that are
relevant for this study. First, that knowledge integration is a critical concept to incorporate in
future research and second it must be recognized that this integration can occur both within a
single mind and as part of a team. Integration continues to be described as one of the defining
processes and outputs of Team Science, worthy of further research, and this further supports the
impact of this research (Huutoniemi et al., 2010; O’Rourke et al., 2013; Repko & Szostak, 2014;
Salazar et al., 2012; Science, 2014; Thompson Klein, 2014).
Several seminal articles in the SciTS space attempt to assess the outputs or
outcomes/value of team science through a quantitative lens, whether for integration or other
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characteristics of cross-disciplinary research. Some of these studies leverage bibliometric
approaches, such as the work of Hall et al. that explored the bibliometric indicators of
publications from research initiatives supported by the National Cancer Institute and the National
Institutes of Health (Hall et al., 2012). This study marked a more focused and nuanced use of
bibliometrics to assess the impact of Team Science. Bibliometrics can also be used to explore the
role of scientific research networks on cross-disciplinary research, another potential antecedent
or input, as detailed in Leydesdorff’s 2018 work titled, “Betweenness and diversity in journal
citation networks as measures of interdisciplinarity—A tribute to Eugene Garfield” (Leydesdorff
et al., 2018). While bibliometrics offer a unique tool for evaluating Team Science it does not
target integration directly.
Taking a more qualitative approach, surveys and interviews have also seen wide use in
the SciTS field to explore both the individual factors or characteristics of researchers that
promote Team Science (Lotrecchiano et al., 2016; Van Rijnsoever & Hessels, 2011) but also
more comprehensive assessments of the conditions that either facilitated or challenged Team
Science (Mâsse et al., 2008; Vogel et al., 2014). Building on this qualitative approach, several
studies have even attempted to combine qualitative and quantitative elements to empirically
evaluate Team Science. These mixed method approaches have been used to evaluate Team
Science in proposals (Hall et al., 2008; Huutoniemi et al., 2010; Nichols, 2014) and even assess
integration in dissertations on other interdisciplinary topics (Mitrany & Stokols, 2005). There are
some important insights from these mixed methods approaches for this study.
First, in the research approaches of Hall, Huutoniemi, Stokols, and others, while exciting
and relevant to integration generally, the integration is only indirectly measured by an
investigation of number, type, and diversity of contributions to the research, such as the
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disciplines or contributions of those disciplines to the research being studied. In fact, Huutoniemi
et al.’s investigation of research proposals in the Netherlands uses integration, a defining
characteristic of interdisciplinarity, to inform their typology, offering a useful sub-categorization
of the integration as follows: “to analyze multiple kinds of empirical material”, “to combine
methods of several disciplines”, and “to work on theoretical tools for integrative analysis”
(Huutoniemi et al., 2010, p.84). next, and somewhat more pertinent to this study is research from
the philosophy of science on integration and especially recent work on the application of
philosophy in the facilitation of cross-disciplinary research (Eigenbrode et al., 2007; O’Rourke et
al., 2016; O’Rourke & Crowley, 2013). This will be explored further in the next section on
integration.
These comprehensive studies offer perspective on the breadth of research in SciTS and
inform a worldview of SciTS used in this study. Understanding the breadth of research in SciTS
helps to set this study in translational context as much SciTS research has led to the development
of recommendations to promote collaborative cross-disciplinary research and communication
(O’Rourke et al., 2013). The historic overview of SciTS is important context for this study but, a
deeper understanding of the integration and integration processes involved in Team Science,
particularly the theories and frameworks related to cross-disciplinary integrated are needed to
inform this study. The literature supporting these theories and frameworks are described below.
Cross-Disciplinary Integration
The literature on cross-disciplinary research, which includes both interdisciplinary
research and transdisciplinary research is rich. The literature specifically on the phenomenon of
integration that is central to cross-disciplinary research is also rich and extensive, ranging from
theoretical to more practical. Important early contributions to this knowledgebase came from
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Maurice de Wachter in 1982 who discussed new approaches to problem-solving in bioethics that
began to illustrate interdisciplinary integration (de Wachter, 1982). However, de Wachter focused
the integration on inputs and outputs and essentially avoided the process by which the integration
occurred. This model of interdisciplinary integration would find its way eventually into Julie
Thompson Klein’s thinking about integration that would be discussed in her 1990 review of
interdisciplinary research (Klein, 1990). Information integration theory from Norman Anderson
is another example of an early theory of integration that would influence the developing thinking
on cross-disciplinary integration (Anderson, 1970) with an almost formulaic approach to
integration suggested. Following Klein’s discussion of integration in 1990 research and
directions on integration would begin to formulate into 3 areas: interdisciplinary research
integration (Newell, 2001; Repko, 2007), transdisciplinary research integration (Bammer, 2013;
Bergmann., 2012), and integration for cross-disciplinary research, which would include both
interdisciplinary and transdisciplinary research (Klein, 2012; O’Rourke et al., 2016).
Interdisciplinary research and the concept of synthesis or integration was described by the
theorist William Newell in his “A Theory of Interdisciplinary Studies” (2001), as a formulaic
process, building on the initial work of Klein to describe the interdisciplinary process (1990). It
is important to note that this approach to interdisciplinary research is considered more
individualistic than it is team-based. Newell stressed the important prerequisite of
interdisciplinary research being that a problem was complex by articulating important
connections between interdisciplinary research and complexity science, particularly the sheer
necessity for interdisciplinary approaches to tackle problems of complex systems. The two major
activities of the interdisciplinary research process were: “(1) draw on disciplinary perspectives
and (2) integrate their insights through construction of a more comprehensive understanding”
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with several sub-steps (Newell, 2001). Lastly, it is important to note that Newell believed this
process could be performed by a single interdisciplinary researcher or interdisciplinarian. He
would continue to refine his process for inclusion in a 2007 book chapter titled “Decision
Making in Interdisciplinary Studies” (Newell, 2007). These steps are outlined below, and while
they are useful in some of the theories they build on, such as common ground and integration,
they are not entirely applicable to this study given the individual view:
1. Drawing on disciplinary perspectives
•

Defining the problem (question, topic, issue)

•

Determining relevant disciplines (including interdisciplines and schools of
thought)

•

Developing a working command of the relevant concepts, theories, and methods
of each discipline

2.

•

Gathering all relevant disciplinary knowledge

•

Studying the problem from the perspective of each discipline

•

Generating disciplinary insights into the problem.

Integrating their insights through construction of a more comprehensive understanding
•

Identifying conflicts in insights by using disciplines to illuminate each other’s
assumptions, or by looking for different concepts with common meanings or
concepts with different meanings, through which those insights are expressed

•

Evaluating assumptions and concepts in the context of the specific problem

•

Resolving conflicts by working towards a common vocabulary and set of
assumptions

•

Creating a common ground
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•

Identifying (nonlinear) linkages between variables studied by different disciplines

•

Constructing a new understanding of the problem

•

Producing a model (metaphor, theme) that captures the new understanding

•

Testing the understanding by attempting to solve the problem.
(Newell p.248, 2007)

Allen Repko is another interdisciplinarian who shared an interest in interdisciplinary
research or interdisciplinarity. Repko similarly focused on integration and common ground as
key components of interdisciplinary research conducted by interdisciplinary researchers, both
individuals and teams (Repko, 2007). Repko’s research added insights from cognitive
psychology to the theory of common ground and implications for integration, notably relevant to
this study was the implication that finding common ground as part of integration is a process as
opposed to a method, and that the presence of integration can be used to differentiate
multidisciplinary research from interdisciplinary research (Repko & Szostak, 2016).
In some cases a key dimension or focus of integration is that it takes on some form of
social dimension or real-world application (Bammer, 2013; Bergmann., 2012; Klein, 2012).
These forms of integration are typically found in transdisciplinary research where the focus of
the research from the onset for the pursuit of social and scientific purposes (Bergmann., 2012).
Bergmann also emphasized the importance of not only the expertise of multiple disciplines but
the expertise of partners from the society as well. This model for integration in transdisciplinary
pursuits was best characterized in the following conceptual model from the Institute of SocialEcological Research (Jahn et al., 2012). In this model, transdisciplinary integration occurs in a
completely different phase and serves a unique purpose, apart from interdisciplinary integration.
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Figure 5: ISOE Transdisciplinary Research Process (Jahn et al., 2012, p. 5)

Bammer would add an important contribution to the understanding of integration with the
characterization of integration as a planned process. However, a large distinction in Bammer’s
integration was that it would be expected to be primarily collaborative and involve experts
working together (Bammer, 2013). In addition, Bammer describes two forms for this integration
process, either as synthesis or as integration, and lastly adds a unique contribution to the concept
of integration related to the management of the unknowns in decision-making and action. This
last nuance of Bammer’s transdisciplinary integration is relevant to the final decision made by
FDA review teams given how uncertainty must be critically characterized.
While the research on interdisciplinary research and transdisciplinary research is
important to understand as relevant to defining integration, they perhaps lack a universality or
flexibility that could allow them to be easily applied to the context of this study, the FDA review
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of a new drug product. In the review of literature on integration, the theories and frameworks of
integration that are most relevant for this study were those that do not take on such an
algorithmic or formulaic approach. The two theories that have broadest applicability, and by
which this study is informed, come from the revised theory of cross-disciplinary research from
Julie Thompson Klein (Klein, 2012) and a theory for cross-disciplinary integration that built on
available theories of integration at the time from O’Rourke and colleagues (O’Rourke et al.,
2016).
Klein in her 1990 book titled, Interdisciplinary: History, theory, and practice surveyed
the vast field of interdisciplinary research and integration (Klein, 1990). The process of
integration described by Klein in this book was stepwise and could take on either a “soft”
approach – such as simply relying or referring to something from another discipline or a “hard”
approach – where the tools and methods of other disciplines are leveraged. In this process, the
interactions between disciplines were exemplified by different modes, such as “(1) borrowing,
(2) solving problems, (3) increased consistency of subjects or methods, and (4) the emergence of
an interdiscipline” (Klein, 1990, p. 64). The Klein (1990) model for integration included 12 steps
that in summary cover the problem identification and definition, specifying what research and
knowledge would be needed, and finally integrating, with close-out steps to confirm that the
solution or answer to the problem is confirmed. Lastly, while Klein acknowledges that this
process is rather algorithmic and stepwise, it is by no means linear and is subject to iteration. The
key step of integration in Klein’s step-wise model was 3b, “integrating the individual pieces to
determine a pattern of mutual relatedness and relevancy” (Klein, 1990, p.189). This left much to
be desired regarding how the integration is arrived at.
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In the time following her 1990 book, Klein’s theory and model of interdisciplinary
integration would develop further as a result of her own continued research and the application
of her theory by others (e.g., Newell). In 2012, Klein would publish a revised approach to
interdisciplinary integration characterized by 4 principles:
1. “The Principle of Variance: No Universal Formula for Integration”
2. “The Principle of Platforming: Interaction Structure, Integration Potential,
Fundament”
3. “The Principle of Iteration: Moving Back and Forth, Bootstrapping, Triangulation,
Reflective Balance, and Weaving”
4. “The Principle of Communicative Rationality: Shared Language Culture, Social
Learning, Translation-Negotiation-Mediation, Intersubjectivity” (Klein, 2012, p. 293295).
These four principles applied to the theory of interdisciplinary integration would shed much light
on the underlying process of integration, and speak more specifically to the inputs (e.g.,
communication) and outputs (e.g., mutual understanding) into the process. This is a significant
insight and considered foundational in future theories of integration and in understanding the
analytical framework for which this study is based. It is also important to note that Klein selfdescribed the process at this time as no longer algorithmic, which opens the door to more
dynamic, iterative and expansive approaches to integration (Klein, 2012).
As a result of research related to the Toolbox Dialogue Initiative, a new framework of
cross-disciplinary integration would emerge that was more suitable to analyzing inputs, process,
and outputs of the integration process (O’Rourke & Crowley, 2013). This framework would be
further defined and described in 2016 by O’Rourke et al. and is most applicable to this study of
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integration in FDA new drug reviews due to its emphasis on not just the final product or output
of the integrative process but also the process by which integration occurs. Furthermore, the
framework and Input, Process, Output (IPO) cross-disciplinary model associated with it is
purported to have applications across the full range of cross-disciplinary integration (e.g., mutli-,
inter-, and transdisciplinary integration). With the FDA new drug review potentially taking on
either a multidisciplinary or interdisciplinary form depending on the review process, use of this
framework of cross-disciplinary integration and its flexibility may be most appropriate for
modelling it.
The IPO cross-disciplinary integration model lays out integration as a “generic”
combination process, the details of which are determined by the specific contexts in which
particular instances of integration occur” (O’Rourke et al., 2016, p. 67). In this “generic”
process, inputs are combined, and the output is produced. This is much like any other IPO model
or structure and is used in a wide variety of domains. The utility of IPO model from O’Rourke et
al. is the conceptual framework it offers to understand integration in setting of collaborative
cross-disciplinary research. It offers a sort of infrastructure for integration with variables and
parameters with which to understand integration as a process and as a product. It also provides
two dimensions, quality and quantity, along with an analytical framework, in which to organize
“one’s thinking” about the inputs, outputs, and integration process variables of the model, and
“facilitate comparison” (O’Rourke et al., 2016, p.68). This analytical framework is described
below:
Inputs/Outputs
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•

Quality: What is the character of the inputs/outputs? (Are they cognitive? Epistemic?
Social? Are they abstract or concrete?) How do inputs into the process differ? How do
outputs differ?

•

Quantity: How many different kinds of inputs/outputs are there (e.g., inputs/outputs at
different levels of organization, as in Brigandt (2010))? How many inputs/outputs of a
particular kind (e.g., data sets, disciplines) are involved?
(The quantity of inputs is also associated with the scope of the integration process under
consideration. The quantity of inputs also begins to inform and is informed by the
parameters of the IPO model, such as scale and comprehensiveness—discussed below.)

Process
•

Quality: The integration puts or brings together inputs in some integrative relation:
“fusing”, “melding”, “amalgamating”, “knitting”, “linkage”, “making sense
together”, “interconnection”, and “harnessing differences”, or a disintegrative
relation: “dissociation”, “differentiation”, and “boundary setting”, or combinational
relation: “assembling”. Was the integration process purposive? Algorithmic?
Heuristic or constructivist?

•

Quantity: How many specific changes to inputs were required to produce the
outputs? What degree of change (low: process leaves inputs alone but connects them
v. high: process transforms inputs into something new or reconceived collectively
when combined)?

Parameters
•

Scale (Global/Local):
o What is the scale of cross-disciplinary integration?
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o Does integration operate globally (e.g., the domain level, such as all of
biology), locally (e.g., data sets, specific problems), or somewhere in
between (e.g., disciplines, fields)?
*This will affect inputs, process, and outputs.
•

Commensurability (High conflict/Low conflict):
o Are the inputs integrable, or must conflict be reduced before they can be
combined?
o Does the integration process leverage conflicting differences while
transcending them?
o Can integration take place if conflict is minimized?
*This parameter will affect inputs and process.

•

Comprehensiveness (High/Low):
o How comprehensive will the output be, relative to the inputs? For
example, will the integration process result in a cross-disciplinary output
that provides a more comprehensive view of a problem than the
disciplinary inputs, or will it result in an innovative but focused crossdisciplinary output that is a “vector sum” of the inputs without being more
comprehensive)?
o This parameter will affect inputs, process, and outputs.
(O’Rourke et al., 2016, p. 69)

Leveraging this extensive theoretical and analytical framework from O’Rourke et al
(O’Rourke et al., 2016), the integration occurring in the FDA new drug review process, whether
that be a multidisciplinary or interdisciplinary process, can be modelled and subsequently
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defined. And as mentioned earlier, this framework is best fit for this study due to its flexibility
and customization with multiple customizable parameters and variables to analyze data across
the integration process. While it remains to be determined if the IPO model of cross-disciplinary
integration developed by O’Rourke et al is truly as universal as it is proposed, this study may in
fact shed light on the application of this model and framework for collaborative crossdisciplinary research in a new context. In addition, the validation of a potentially universal
framework for studying integration would add an important evaluation tool for cross-disciplinary
integration, and the SciTS.
The final insight from the literature on cross-disciplinary integration comes from an
assessment of collaborative interdisciplinary reasoning from Bethany Laursen (2018). Laursen
refers to collaborative interdisciplinary reasoning as “the attempted integration of disciplinary
contributions to exchange, evaluate, and assert claims that enable shared understanding and
eventually action in a local context (Laursen, 2018, p. 81)”. This definition of the integration
process and its focus on the disciplinary contributions has great relevance and similarities to the
IPO framework and proposed approach to modelling cross-disciplinary integration used in this
study. To operationalize this definition and study collaborative interdisciplinary reasoning,
Laursen leveraged a Sankey modelling approach to diagram the flow of the integration process.
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Figure 6: Sankey Diagram of Collaborative Interdisciplinary Reasoning
(Laursen, 2018, p. 86)

In the flow diagram of collaborative interdisciplinary reasoning, dialogue was analyzed to
capture the flow of words from speakers to disciplines, premises, and conclusions. The number
of words from a speaker would dictate the width of the originating flow and how they fed into
the disciplinary contributions to a premise and subsequent conclusion can then be diagrammed.
This approach helps illustrate the dynamism of the integration process. A similar approach could
be used in this study to help diagram the disciplinary contributions to benefit-risk review issues
and how those contributions (inputs) fed into process activities and subsequent outputs
(recommendations or actions).
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Inferences for Forthcoming Study
The domains discussed in this literature review inform the overall conceptual framework
for this study that borrows knowledge from the context of FDA new drug product assessments to
contextualize the IPO framework for investigating integration in cross-disciplinary research; See
Figure 6. Additional knowledge and insights from cross-disciplinary and particularly
collaborative cross-disciplinary research creates a foundation for explaining the importance of
the types of key input and output variables, describing changes to inputs and outputs, and a
theoretical framework for the understanding the integrative nature of the change process.

Figure 7: Key Literature Domains

Literature from the topics of interdisciplinary research and cross-disciplinary research
was rich and informative. After reviewing for relevancy to this study, 57 articles related to
interdisciplinary research and 43 articles, many overlapping, on cross-disciplinary research were
included. As expected, a roughly similar number (41) of articles on integration in inter/cross-
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disciplinary research were found as integration is considered a key characteristic of crossdisciplinary research.
When exploring assessments or measurements of integration there was a paucity
literature available, and among the research identified the methods varied from study to study
suggesting more work is needed. In the context domains of drug development and FDA benefit
risk assessments, a much smaller number of references were identified and included. There is
very little research on cross-disciplinary research in drug development and no research at the
FDA on cross-disciplinary research, including integration. Figure 8 illustrates the quantity of
literature included in the bibliography for this study.

% Does not include full analysis of literature library.
* Wildcard in search term.
# Includes previous search terms in addition.

Figure 8: Analysis of Literature%
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From the literature (and gaps) identified, several insights for this study can be inferred.
First, while literature exists on the new drug development process, and FDA’s assessment of new
drug product applications, little literature exists on the collaborative research or integration
processes in the FDA’s assessment. A tremendous amount of literature exists on the benefit-risk
assessment of new drug products and FDA’s framework for these assessments, the BRF.
However, how this benefit-risk assessment or the BRF is translated into the FDA new drug
product review processes and documentation has not been extensively discussed in literature.
Secondly, integration is a key characteristic that occurs in collaborative cross-disciplinary
research. While there is literature and research on integration in cross-disciplinary research, there
is little on collaborative or team-based integration. This suggests that research on collaborative
cross-disciplinary integration will be a useful contribution to the field of team science.
Furthermore, there is very little literature or research on collaborative cross-disciplinary research
at the FDA, and none on integration. Thirdly, the literature also suggests that the underlying
phenomenon of the integration process may not yet be fully understood, at least not to the
universal extent needed to reliably measure it across the diverse range of teams and team-based
science activities that use it in cross-disciplinary research in Team Science. More specifically, the
gaps appear to be either in attempts to measure integration in the products (outputs) of
integration or the antecedents of the integration (inputs), without much focus on measuring the
integration process itself. As such, a need exists to understand the complete picture of integration
by exploring the process from end-to-end and measuring evaluation as both a process and an
output. This need aligns to the goals of this study to understand the integration that is occurring
in FDA collaborative cross-disciplinary research, and if it is even occurring. Lastly, the approach
to the study and the conceptual framework are informed by the application of O’Rourke et al.’s
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framework and IPO model of integration. The use of the IPO model as a conceptual framework
is an ideal fit for this study because potential use as a “universal model” and subsequent
adaptability to a variety of contexts (Laursen & O’rourke, 2019). More specifically, it is the
ability of the model to handle multiple iterations levels of integration, across the full
collaborative, cross-disciplinary experience rather than a single integration event.

Theoretical and Conceptual Frameworks
This study is guided by a series of theories and frameworks from the fields of crossdisciplinary research, Science-of-Team-Science, and regulatory decision-making for medical
products. The first theoretical foundation for this study comes from Julie Thompson Klein’s
theory of interdisciplinarity and the core process of interdisciplinary work, integration (Klein,
1990). Klein’s view of interdisciplinary research is that it is research that involves two or more
disciplines and involves a greater degree of integration than purely disciplinary or
multidisciplinary work. Such a continuum of integration for thinking about research can be
useful in assessments and in fact Klein and her collaborators have done just that in previous
research. In the 2010 study conducted by Huutoniemi, Klein, Bruun, and Hukkinen (Huutoniemi
et al., 2010), an empirical approach to analyzing the interdisciplinarity of research proposals was
described, including a typology of interdisciplinarity that included:
•

Encyclopedic multi-disciplinarity

•

Contextualizing multi-disciplinarity

•

Composite multi-disciplinarity

•

Empirical inter-disciplinarity

•

Methodological inter-disciplinarity
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•

Theoretical inter-disciplinarity

The application of such a continuum of cross-disciplinary research to an empirical
analysis of the research proposals was guided by four elements: background and objectives,
expertise and implementation, results, and significance. The continuum is represented in Figure
9, below. The continuum that represents this theory serves as a useful guide for this study,
because it suggests certain forms of integration that might occur in different degrees of
integration, which might be expected in FDA’s new drug product reviews, which are selfdescribed as either multidisciplinary or interdisciplinary. More specifically these elements, and
the continuum that they exist in, helps provide “signposts” by which to characterize the
transformation of inputs to outputs in an integration process.

Figure 9: Continuum of Cross-Disciplinary Research

(Thompson Klein, 2014)
The next theoretical framework that is core to this study is one related to the phenomenon
of integration in interdisciplinary research. Over the years the concept of integration has been an
integral component of interdisciplinarity and has been discussed and researched by many
theorists, such as Newell, Repko, Klein and Bammer (Bammer, 2013; Frodeman et al., 2017;
Klein, 1990, 2012; Newell, 2001; Repko, 2007). In 2016, Michael O’Rourke, Stephen Crowley,
and Chad Gonnerman of the Toolbox Dialogue Initiative developed a philosophical and more
practical theoretical model of integration (O’Rourke et al., 2016). This framework offers a
schematic parameterized inputs-process-outputs (IPO) model for cross-disciplinary integration;
see Figure 10, below.
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Figure 10: Cross-disciplinary Integration IPO Model

From this theoretical framework, several variables related to the inputs, process, and outputs of
an integration process can be defined, such as the quality and quantity of the inputs, the process,
and the outputs. These variables will become the basis of an analysis of integration in FDA new
drug product reviews. In addition, the contextual parameters of scale, commensurability, and
comprehensiveness allow the model to be used more universally at different levels of crossdisciplinary research and to better characterize the integration.
In order to use O’Rourke et al.’s 2016 parameterized IPO model of cross-disciplinary
integration as the basis of an empirical analysis of integration in FDA new drug product reviews
it must be contextually adapted. The inputs to FDA new drug product review can vary greatly
depending on the development program but tend to be generated from and assessed by the
following FDA disciplines: clinical, clinical pharmacology, nonclinical
pharmacology/toxicology, biostatistics, pharmaceutical quality, regulatory/legal, and experts on
gathering patient experience. The outputs of the integration process are organized around the
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evidence and uncertainty related to four dimensions of the US FDA BRF (FDA, 2018a). The
BRF is shown in Figure 11, below.

Figure 11: US FDA Benefit-Risk Framework

The BRF has become a tool for FDA new drug product review teams to process evidence
and create common ground to support decision-making. In addition, through its structure, it has
become the basis by which the integration of disciplinary insights occurs. The rows in the BRF
outline the key dimensions of the assessment, related to the therapeutic context (i.e., analysis of
condition and current treatment options) and the product-specific assessments of benefit and risk
and risk management. The columns differentiate between the evidence and uncertainties that are
pertinent to the benefit-risk assessment and the FDA’s conclusions and reasons supporting the
strength of evidence and the potential significance of findings or review issues (Duke Margolis
Center for Health Policy, 2019). Lastly, an integrated assessment of benefits and risks brings
together all the dimensions and considers whether the evidence and uncertainties for the benefits
outweigh the risks for a favorable decision in the context of treatment.
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The May 2019 Discussion Document outlines several key considerations for FDA’s
benefit-risk assessment which could serve to guide the document collection and thematic
analysis of inputs and outputs in the completed BRFs of both multidisciplinary and integrated
reviews (Duke Margolis Center for Health Policy, 2019). See reproduced table below.
Table 2: Potential codes for BRF analysis
BRF Section
Analysis of
Condition

Key Considerations
• Context of use for proposed indication:
intended medical use, target patient population
• Relevant clinical aspects of the condition
• Patient-focused disease burden

Common Sources of Uncertainty
• Ability to define target population
• Complexity of disease (e.g., effect on understanding
drug’s mechanism of action)
• Extent of patient input on disease burden

Current
Treatment
Options

• Goals of current standard of care
• Efficacy and safety of available therapies
• Burden of treatment (e.g., administration)
• Aspects of disease burden not addressed by
current therapies

• Patient utilization of treatments
• Extent of evidence about therapies not FDA-approved
for the indication
• Extent of patient input on unmet needs

Benefit

• Strengths/limitations of clinical trial data:
potential implications for assessing drug efficacy
• Clinical relevance of the study endpoints: ability
to measure or predict clinical outcomes of
importance to patients
• Demonstrated results and their clinical
significance, informed by:
• Magnitude, duration of treatment effects
• Nature of benefit (e.g., disease modifying,
symptom reduction)
• Distribution of effects in the study population
• Potential effect on future clinical outcomes
(e.g., death, organ damage)
• Ability to predict which patients may benefit
• Ability for patient/provider to assess
individual benefit
• Patient perspectives on benefit
• Generalizability of the clinical trial evidence to
the to-be-marketed patient population in the
postmarket setting

• Program or trial design; e.g., less than two
randomized controlled trials, use of single arm-designs,
use of observational data
• Statistical uncertainty
• Relationship between study endpoint and clinical
outcomes
• Extent of patient input on the significance of
expected benefits
• Populations not included or underrepresented in
clinical trials
• Quality and integrity of data

Risk and
Risk
Management

• Strengths/limitations of safety evaluation:
potential implications on assessing drug risks
• Serious adverse events or safety signals—clinical
significance and remaining uncertainties,
considering:
• Magnitude, duration, severity of harms
• Reversibility of harm (e.g., upon cessation of
treatment)

• Size and extent of safety population; background rate
of adverse event in the treated population (e.g., trials
may be underpowered to identify all safety risks)
• Understanding of the relationship between safety
endpoints and clinical outcomes
• Potentially susceptible patient groups (e.g., elderly,
patients with co-morbidities) not included or
underrepresented in clinical trials
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Conclusions
Regarding
Benefit-Risk

• Distribution of harms in the study population
• Potential effect on future clinical outcomes
(e.g., death, organ damage)
• Ability to predict which patients may be at
risk
• Ability to prevent, detect, and mitigate harms
• Patient perspectives on risks
• Adverse effects (e.g., nausea) that could affect
tolerability or adherence
• Potential impact of product quality or device
issues on effectiveness or safety
• Additional safety issues considering how
prescribers and real-world use in the postmarket
setting may differ from the clinical trial setting
• Effectiveness of strategies to manage risks

• Quality and integrity of data
• Challenges or barriers to quality health care delivery
• Untested risk management strategies
• Potential differences between the development
batch of the drug versus commercial scale

• How therapeutic context affects threshold for
benefits and tolerance for risk and uncertainty
• Benefit and risk values and tradeoffs, including
patient perspectives
• How the product, if approved, may enhance the
treatment armamentarium
• Importance of unresolved uncertainties
• Need for labeling (e.g., boxed warning) or REMS
to support favorable benefit-risk assessment
• Need for postmarketing evidence to address
uncertainty

• Extent of patient and other inputs on benefit and risk
values and tradeoffs
• Ability to generate the desired evidence of safety or
benefit (e.g., through randomized control trials or
observational studies) in the postmarket setting

A new theoretical model that contextualizes the IPO model for FDA new drug product
reviews was created to support the conceptual framework of this study, see Figure 12, below.
This model is based on regulatory documents that describe the new drug product review
processes, both traditional and newly proposed, and information from the FDA-Duke Margolis
Center for Health Policy Discussion Document to support the May 2019 workshop titled,
“Benefit-Risk Assessment Throughout the Drug Lifecycle” (Duke Margolis Center for Health
Policy, 2019). As illustrated in this new theoretical model of integration in new drug product
reviews, inputs to the process can originate from a multitude of disciplinary domains, and these
inputs then contribute to more comprehensive insights about the new drug product, such as the
product’s benefits and risks. For example, clinical efficacy data of statistical significance
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generated from robust clinical trials may be considered alongside data on patient experience with
the new drug product, thereby by forming a more comprehensive understanding of the benefit of
the product that is both statistically significant and clinically meaningful. This process by which
inputs (i.e., assessments of benefits and risks) come together and ultimately lead to a benefit-risk
assessment is through an integration process that is informed by the BRF.
As discussed previously, the nature of the combination process, or integrative nature to be
more specific, can be understood using the theory of interdisciplinarity and then further
characterized by examining the quality and quantity of the inputs, process, and outputs
(O’Rourke et al., 2016; Thompson Klein, 2014). Because the IPO model from O’Rourke et al. is
considered universally applicable framework that can serve to model integration in multiple
contexts, but it must be contextualized for the collaborative, cross-disciplinary activities involved
in new drug product review. As the BRF serves as the framework and anchor for new drug
product review teams it offers a useful set of elements to contextualize the IPO mode (e.g.,
disciplines or cognitive domains, data types). A theoretical model of how these theories and
models come together to support the complex lens through which this study will be conducted is
offered below, in Figure 12.
In the next chapter, a qualitative comparative case study design will be described that
addresses the outstanding gaps in knowledge related to how collaborative, cross-disciplinary
integration occurs in FDA new drug product reviews. This study is intended to not only describe
the processes by which the FDA review team assessments are translated into a benefit-risk
assessment, and overall determination, but also characterize the nature of collaborative crossdisciplinary research that may be occurring in FDA review teams. In both areas, very little
research exists. Beyond the FDA new drug product reviews and the review teams that generate
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them, the study will also contribute to a growing body of knowledge related to integration in
collaborative cross-disciplinary research, including a method for reliably evaluating integration.
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Figure 12: Theoretical Model of Integration in New Drug Product Reviews
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Chapter 3 Methods
Overview of Methodology
As discussed previously, while Integration is a desired outcome in FDA’s new integrated
assessment approach, how this integration occurs is unknown. The Science-of-Team-Science
offers some insight into how to evaluate integration, including potential frameworks, but a
pragmatic and contextualized instrument for FDA does not exist. This study aims to characterize
integration within FDA new drug product reviews, a collaborative cross-disciplinary research
activity, using a contextualized cross-disciplinary integration model. The qualitative comparative
case study methodology best aligned with the purpose and research questions of this.
Integration in collaborative cross-disciplinary FDA team science is a phenomenon of
process that occurs between the individuals on the FDA review team over the course of the
review and to understand this phenomenon from the perspective of the review team members a
phenomenological approach is needed (Creswell & Poth, 2016). The comparative case study
design allows for the purposeful selection of cases that would be expected to include integration
enabling comparisons of integration between two different approaches to FDA new drug review
(Creswell & Poth, 2016), the new integrated review and the multidisciplinary review. In addition,
the case study design allows for the replication of the procedures used for data collection and
analysis in two cases to enhance credibility and reliability of findings. As a reminder, the
research questions are:
1. What are examples of integration in a “multidisciplinary review” and an “integrated
review” of an FDA new drug product?
2. What are the specific differences in integration between a “multidisciplinary review” and
an “integrated review” of an FDA new drug product?
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A case study is a qualitative research method where a researcher explores a program,
event, activity, process, or one or more individuals in depth with multiple forms of data
collection (Creswell & Poth, 2016). The specific case study method deployed in this study is a
descriptive case study, sometimes referred to as an intrinsic case study by Creswell (2016). The
descriptive case study approach is needed to describe the cases (i.e., new drug product reviews)
and the examples of integration in a sufficiently robust way to allow comparisons to be made
between the two approaches to the FDA new drug product review (e.g., traditional
“multidisciplinary review” vs new “integrated review”). In this descriptive case study, three
forms of data collection are deployed: document analysis of completed work products of the
team (i.e., reviews), semi-structured interviews with select members of the team that are found to
have contributed to integration in the reviews, and a member checking following the interviews
to validate the data collected.
That the phenomenon of cross-disciplinary integration in FDA new drug product reviews
can be understood through a descriptive case study is based on a constructivist ontology, or view
of reality, that suggests that the interpretations of those experiencing a phenomenon are key to
understanding it. This ontology is best aligned to an epistemology that the qualitative descriptive
case study fits in, which is that the world is constructed through a person’s lived experiences
(Creswell & Poth, 2016). The constructivist ontology and the qualitative epistemology are rooted
in this researcher’s view that the collaborative integration process is heavily dependent on the
experiences of the individuals that contribute to the process, not just the final outputs or the
inputs into the work. This study design and the richness of data collected ensures the research
questions can be answered fully because data is collected for multiple dimensions of the case and
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of the integration that occurs, allowing the integration process to be modelled and compared in
each case.
Through the document analysis of completed FDA new drug product reviews, descriptive
elements of each case are catalogued, including details about the teams (e.g., size of team,
composition of team), the new drug product being reviewed (e.g., new molecular entity,
combination product, small molecule), and the assessment itself (e.g., length of documentation,
final decision). Key variables of the integration process can be described quantitatively and
qualitatively through a thematic coding and analysis process informed by the IPO model of
O’Rourke et al. (2016) by way of the document analysis. The nature of the integrative process by
which the inputs become the outputs can be difficult to interpret from the document analysis
alone, since changes may occur at different times or in cycles over the course of the new drug
review process. Therefore, semi-structured interviews of team members are conducted to identify
how integration occurs (i.e., the quality or nature of the integration, such as combine, mix,
transform) and participants’ perceptions of how the integration is taking place, which can
indicate whether the integration was purposeful and deliberate. Member checking with team
members interviewed post-analysis is leveraged to check the validity of the integration(s) as
modelled. An alignment of the research questions, epistemology, research methods, and the
rationale for their selection is described briefly in the Table 3, below.
Table 3: Research Alignment

Research Question
1.

What are examples of
integration in a
“multidisciplinary
review” and an
“integrated review”
of an FDA new drug
product?

Research Methods
and Techniques

Rationale

Document analysis,
semi-structured
interviews, and focus
groups
(Bowen, 2009; Miles,
Matthew B., 1994)

Minimally invasive;
efficient and aligned to
retrospective analysis;
individual perception
captured
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2.

What are the specific
differences in
integration between a
“multidisciplinary
review” and an
“integrated review”
of an FDA new drug
product?

Intrinsic, descriptive,
and comparative case
study analysis
(Creswell & Poth,
2016; Seawnght &
Gerring, 2008)

Modeling integration in
two richly descriptive
cases allows a
comparison between
the two cases,
specifically a
comparison of the
components that affect
integration

Qualitative Inquiry
The primary line of qualitative inquiry in this research is that of a descriptive case study
using a document analysis, semi-structured interviews of select team members, and member
checking of the interviewed team members, which is one of Creswell’s eight validation strategies
for qualitative research (Creswell, 2014; Creswell & Poth, 2016). The richness and depth of
detail from a descriptive case study approach allows the integration processes in each case, either
FDA’s new integrated review or the traditional multidisciplinary review, to be thoroughly
described and modelled, which in turn allows for the differences between the two approaches to
be compared.
Document analysis is a systematic analysis process for qualitative research that relies on
evaluating documents (Bowen, 2009). Document analysis was chosen because the primary
research question involves identifying analyzing integration in instances of FDA benefit-risk
review issues of new drug products, and these review issues are required to be documented in the
team’s review documents. In addition, the review documents are prepared in standardized ways,
following set processes and procedures, which makes a document analysis more effective and
efficient (Corbin & Strauss, 2008). Similar studies of FDA review documents have been
successfully conducted through document analysis, such as the FDA’s commissioned study of
BRF adoption (FDA, 2018a). The standardization in review documents also increases the
likelihood that the final reviews are reliable reflections of the integration process because the
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context or cases in which these documents are created are of a similar nature. Lastly, document
analysis is a low-cost way to obtain empirical data in an unobtrusive and nonreactive way
(Bowen, 2009). Furthermore, the O’Rourke et al. IPO model of cross-disciplinary integration, an
operational/analytical lens for thinking about integration, lends itself to a document analysis
since the primary variables related to the inputs and outputs can be quantitatively described and
qualitatively coded from the final review documents and the parameters (e.g., scale,
commensurability, and comprehensiveness), which help with making comparisons across cases,
can be identified from the document analysis.
As mentioned above, semi-structured interviews and member checking with select team
members, identified through the document analysis are conducted to understand and confirm,
respectively, the “nature of integration” that occurred in the two cases. Combining the document
analysis with semi-structured interviews and focus groups of the team members not only
provides additional data for the modelling of integration, specifically that related to process, but
also helps to triangulate the data. Through triangulation of data, evidence is generated from
multiple methods to boost credibility and reliability of the data collected (Creswell, 2014).
Triangulation is achieved by combining data on the two cases from document analysis with data
from the semi-structured interviews and then validating the data from the two member checking
focus groups.
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Figure 13: Triangulation of Data

Research Procedures
Study design and settings
As previously mentioned, this study uses a descriptive case study design to explore
integration in two specific cases of FDA new drug product reviews using document analysis,
semi-structured interviews of select team members involved in identified instances of integration
in the document analysis and focus groups for member checking. The setting of this study was
the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration
(FDA) headquarters in Silver Spring, MD. Data was collected through qualitative document
analysis, interviews, and member checking focus groups of FDA review staff.
Access to the review documents for the initial analysis for this study is through the
publicly available Drugs@FDA database. Access to participants is provided through the
researcher’s status as an employee of CDER. Document analysis was conducted both onsite at
FDA and offsite using a secured laptop computer with controlled access that uses two-factor
authentication (i.e., password and a RFID-enabled ID badge). The setting of the semi-structured
interviews was virtual due to the COVID-19 pandemic and these interviews were audiorecorded, transcribed, and combined with field notes captured electronically on a secured iPad
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(iOS13) via tablet notations converted to Adobe PDF. Any recordings, transcriptions, or PDF
notes from interviews are electronically stored on a local, secured laptop computer with a backup
to a password protected external hard drive with 128-bit AES encryption with a 256-bit key. This
secured storage includes consent documents and the results of the data collection and analysis.
Participants: Inclusion and Exclusion
The sampling frame for this study is of the completed reviews and the review team
members for the completed reviews of new drug product reviews between May 2019 and May
2020. Two pools are created from the listing of completed, publicly available reviews in this 12
month window based on whether they used the multidisciplinary review or the integrated review
approach. The two pools of cases were then screened and curated based on the following
Inclusion/Exclusion criteria:
Inclusion:
-

505(b)(1) New Drug Applications

-

351(a) Original Biologics Licensing Applications

-

New Molecular Entity (NME) or Original Biologic due to the increased complexity
associated with such novel products and their development programs, which would be
expected to require greater cross-disciplinary collaboration and integration

Exclusion:
-

Any supplemental New Drug Applications

-

505(b)(2) New Drug Application that relies on previous FDA findings of safety and
effectiveness, and may have a fewer than average number of review staff or
disciplines involved

-

351(k) Biosimilar Biologics License Application
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Cases are purposively selected from these two pools of completed, publicly available
review documents—a strategy to improve transparency, increase credibility through
reproducibility, and minimize risks to disclosure of information. There were 60 applications in
total in the sampling frame. Of the 60 applications, 5 applications were interdisciplinary
(integrated review) applications. From the initially screened pools of cases, cases were assigned
a random number and one case from each group was selected at random using a randomizer. This
random selection of cases minimized bias even though the selection is purposive (Seawnght &
Gerring, 2008).
Of the applications randomly selected from the two pools, the review team members were
identified. These review team members were contacted with a recruitment communication via
email to ascertain interest and willingness to participate. A copy of this recruitment email can be
found in Appendix 1. The initial case selected randomly from the multidisciplinary review pool
was ZEPOSIA. For this potential case, the researcher failed to obtain enough interested review
team members to participate in the interviews and the case was considered a screen fail. Another
multidisciplinary review, RINVOQ, was randomly selected and subsequently passed screening
with enough review team members agreeing to participate.
This selection process was discussed and reviewed with another member of the research
team before potential case participants were contacted. The final selection of cases was
confirmed following screening of participants for the semi-structured interviews. This dual
screening ensures eligible cases are selected and that access to participants for interviews can be
ensured.
Because the FDA review documents generated by the two teams used in this case study
were publicly available documents anonymity cannot be maintained, which carries some risk.
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However, all attempts were made to maintain confidentiality of the participants participation in
this study through safeguarding of collected data and reporting of any findings without
attribution, and where possible in aggregate form. It may be possible to link feedback related to
an instance of modelled integration from a case back to participants due to the descriptive nature
of the integration model (e.g., descriptions of the inputs, outputs, and process) and the
description of the case itself due to the inclusion of team member information in public review
documentation, including their discipline and organizational affiliation. Risks of such breaches to
confidentiality, while likely minimal and not more than normal, were thoroughly conveyed to
participants through the informed consent process.
It is possible that this risk led some participants to decline to participate in the case of
ZEPOSIA. It was also possible for the participants’ choice to participate was affected by the role
or status of the principal researcher in this study. The principal researcher has held a leadership
role in the development and implementation of FDA’s new integrated review and other
organization development projects as part of the New Drugs Regulatory Program Modernization
(FDA, 2019h). To address this risk of coercion, a subjectivity statement was included in the
informed consent, see Appendix 2, and is discussed later in this chapter.
Document Analysis
Data collection from the document analysis was conducted on review documents
generated by the FDA review teams conducting the review of a new drug product. The
documents targeted for document analysis are a rich source of insights and data on the
integration process that contributes to the benefit-risk determination because they include not
only the final benefit-risk determination but the bases of this determination, including
documentation of the review staffs’ assessments of evidence and uncertainty of key benefit/risk
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issues, and therapeutic context that contributed to the determination. All data collected through
document analysis and interviews or focus groups was included in NVivo 12 for Mac, a
qualitative analysis software platform (QSR International, 2019). As noted above, document
analysis is a systematic analysis process for qualitative research that relies on evaluating
documents (Bowen, 2009). The document analysis in this case involves an iterative qualitative
coding of the key variables and parameters of integration (Miles, Matthew B., 1994).
The source document for the document analysis in the interdisciplinary case is the
‘Integrated Review’ in its entirety since this document reflects the collective work product of the
team. For the traditional multidisciplinary review case, multiple documents will need to be
sourced: first, the Summary Review, which in some ways reflects an “integrated” review, then
the individual reviews from the key review disciplines that make up the review team in that case,
typically clinical, nonclinical, statistics, clinical pharmacology, and quality.
The data targeted for collection in the document analysis is related to the defining
characteristics of the integration process, viz., the inputs, outputs, and integration process itself,
along with the parameters. Data collection was operationally guided by an analytic framework,
the O’Rourke et al.’s IPO framework of cross-disciplinary integration. This framework was then
contextualized by the researcher’s experience with new drug product reviews and recent public
discussions related to the benefit-risk framework.
After downloading, the documents were loaded into NVivo 12 for Mac. In both cases, the
document analysis process was iterative. The first review enables familiarization with the content
and thus promote a more effective document review (Bowen, 2009). In this first review,
documents were collected and categorized based on their title and other high-level descriptors. In
the next review, all documents were scanned briefly to confirm contents and familiarize the

78
reader with the documents’ contents. Following the scan, key documents were reviewed in more
detail. It is during the detailed review that content is identified or coded thematically as either
related to “inputs”, “process”, or “outputs”, and other key parameters of each case. It is through
this iterative document analysis and coding process that the contents of the document become
data for qualitative study (Creswell & Poth, 2016).
The documents were analyzed in NVivo to initially identify instances of integration by
reviewing the documents for benefit-risk review issues (i.e., issues with the application that
impacted approvability or the benefit-risk determination) and then coding these issues with a
code, such as CYP3A4 Issue. CYP3A4 refers to the Cytochrome P4503A enzyme complex is
that is critical to much of drug metabolism (Wilkinson, 1996). If any evidence or basis of the
review issue is cited, such as a submitted study, dataset, or data analysis, this was coded as an
input. The final recommendation for regulatory action was also noted and coded as an output.
Document analysis was targeted initially to improve efficiency and given that the review
documents can be quite voluminous (i.e., greater than 300 pages in length). In the case of the
Integrated review, this targeting entailed reviewing the executive summary section and the
interdisciplinary assessment section to identify review issues that impacted the benefit-risk
determination. For the multidisciplinary review case, the Summary Review in its entirety was
reviewed in addition to the executive summary of each individual disciplinary review, where a
disciplinary BRF was sometimes found. For the interdisciplinary review case, additional data on
the inputs would be described in the integrated assessment section of the Integrated Review and
its appendices. For the multidisciplinary review, the individual disciplinary reviews needed to be
reviewed to collect additional data on the inputs.
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The inputs and outputs associated with each review issue were further coded, based on
the document analysis, as either concrete or abstract. And the disciplines associated with the
input or output were coded. An input or output is considered concrete if it includes tangible,
physical elements, such as data, literature, or analyses. Conversely, an output is considered
abstract if it is cognitively based, such as a perspective, an expert opinion, insights, or
conversation/discussions. The inputs and outputs were coded based on the FDA defined
disciplines for the different members of the review team who were responsible for originating the
input or who would be responsible for reviewing or assessing the input. In some cases, multiple
disciplines were responsible for either identifying the input or contributing to the
review/assessment of the input. If there was mention of activities that were conducted following
the identification of the issue and that led to the final regulatory action, then these items were
coded in the document analysis as a “process”.
Inputs in this framework include both the disciplines and the antecedents of a regulatory
decision or benefit-risk determination. These inputs can be concrete and tangible, such a dataset,
literature article, or new drug applicant’s analysis, or abstract such as a review team member’s
experience or assessment of submitted data/information. Outputs reflect the final regulatory
decision or action taken, such as a recommendation to not approve an applicant’s proposed claim
or that additional labeling is required. Outputs can be either concrete or abstract, such as in the
previous example where the former example (i.e., the recommendation to not approve a proposed
claim) is abstract and the latter example (i.e., requirement for new labeling text) is concrete. The
process by which inputs are changed by the review team before they become the output is more
active or action oriented. For example, these process steps might be discussions, more integrated
analyses or assessments conducted by more than one discipline.
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Through the analytical framework guided document analysis, inputs are identified and
additionally characterized by their quality and quantity. Outputs are similarly catalogued and
characterized. The variables associated with the inputs were the degree of difference in inputs,
which was defined as difference either in the source, disciplines involved, or type. For the process
activities of each review issue, the analysis captured whether the process activities were purposive
(i.e., pre-planned or built-in process/workflow steps). This assessment of purposiveness was based
on available documentation related to the multidisciplinary review and the new integrated review.
Most features of the integration “process” element could be collected via the document analysis,
but that the semi-structured interviews were needed for this component of the framework.
The integrative relationship of the process activities, or change to inputs, was assessed as either
Integrative, Disintegrative, or Combinatorial, relying on descriptions of these relationship from
O’Rourke et al 2016:
-

Integrative - brings together inputs in some way for an irreversible integration

-

Disintegrative - changes aimed at breaking an input down into its constituent parts or
to differentiate between the inputs

-

Combinatorial - an assembling or combining of inputs but is of low change to the
inputs (i.e., stacking)

The degree of change in inputs (found in process) were also assessed as a measurement
of how the process changed the inputs from low to high, such as a simple combining of inputs vs
a process where the inputs are unrecognizable in the integrative output (i.e., something new is
created). In addition to the degree of change in inputs, the degree of difference between the final
output(s) and input(s) was assessed. Lastly, the integration parameters from the O’Rourke et al
framework were captured for each review issue/instance of integration as described below.
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Parameters of each case were collected through the document analysis to facilitate
contextualization of the two cases and any identified instances of integration and enable
comparisons.
-

Commensurability: assessment of integrable the inputs are (i.e., their difference or
conflict between)

-

Scale: assessment of how many disciplines or disciplinary input types involved and
the overall impact (i.e., global--the entire application vs local--a specific
problem/issue)

-

Comprehensiveness: assessment of how comprehensive the output(s) reflect or
include the inputs

Semi-Structured Interviews
As noted earlier, additional data collection comes from semi-structured interviews of
select team members. Select team members were interviewed to provide additional data to
support the analysis of the integration process, specifically to describe what was integrated and
how it occurred. The use of semi-structured interviews is important because it may be difficult
during document analysis to objectively describe the integration “process” variables or to
describe it from the document review alone. Team members are selected for the semi-structured
interviews based on the instances of integration initially identified through the document analysis
and were expected to include the clinical reviewer, nonclinical reviewer, clinical pharmacology
reviewer, statistician, and quality (chemistry) reviewer. These five stakeholder groups are
routinely involved in the review of new drug products and are considered the ‘primary’ review
disciplines.
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The interviews are semi-structured because they utilize a set structure and standard, openended questions to guide the conversation and using a set structure ensures conversations are
both productive with regard to data collection but also replicable across the two cases and future
research (Creswell, 2014; Miles, Matthew B., 1994). The use of open-ended questions in a semistructured interview allows the team members to freely express their perception of the
integration process (Creswell, 2014). The interview guide was informed by data collected via the
document analysis leading to concurrent data collection and analysis, subsequently making the
data collection and analysis process more efficient and allows for gaps in data collection to be
identified and resolved earlier (Miles, Matthew B., 1994).
The semi-structured interview follows a set of process that includes an opening from the
interviewer to orient the participant to the study and the interview process, then a series of
standardized, open-ended questions (Spradley, 2016). Probes or prompts are used to stimulate
deeper introspection and sharing from the participant, as needed (Miles, Matthew B., 1994).
Total length of the interview was planned for 60 minutes and is outlined in a planned interview
guide, below. However, as noted in Chapter 4, the interview guide was adapted into a
PowerPoint presentation due to the virtual nature of the interviews, see Appendix 3.
Once rapport was established, the interview would focus on (1) confirming the identified
application-specific benefit-risk review issues and (2) obtaining a thorough description of the
integration process for each review issue. Since the document analysis represented an
independent (outside) perspective, it was important to give the participants an opportunity to
identify gaps in the initial list of identified instances of integration before proceeding with
descriptions of the integration process for the preliminary list. This was done via a specific grand
tour question to have the participant describe their role, the overall review of the application, and
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any review issues. During this process, the researcher can cross-check against the list of
preliminarily identified review issues to confirm or revise the list. Then for each review issue a
mini-tour grand tour question is used to have the participant describe the end-to-end integration
process that occurred for the review issue in their own words. Probing questions are used to
ensure critical features of the integration process, guided by the O’Rourke et al. IPO framework,
are described. At the conclusion of the interview, the participant is thanked, advised of status of
study, and expected completion date. The interview was audio-recorded using Zoom,
subsequently transcribed via Rev.com, and combined with field notes in NVivo 12 for Mac for
data analysis.

Planned Semi-Structured Interview Guide
Application-specific Review Issues
This first question is intended to get the participant to describe in their own words the
application-specific review issues that were found in the application review:
Grand Tour:
1. Can you tell me about your role and about the key application-specific review issue(s)
that you and your team found in your review of this application that impacted the
benefits, risks, or benefit-risk assessment?
Mini-Tour:
Outputs
2. Where did you and your team document the review issue(s) in the Multidisciplinary or
Integrated Review?
• How did you decide where to document the review issue(s)?
• Did you or someone from the team take the lead in documenting the review
issue(s)?
• Was the approach to the assessment of the review issue discussed as a team? Did
you or the team document the approach in the review documents?
Integration for Review Issues
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For the review issues identified by the participant work through the following process questions:
Inputs
3. How did you or your team come to identify the review issue?
• Who initially identified the review issue?
• What role did you play in identifying the review issue?
• What information or data was reviewed that led to the identification of the issue?
• Was there a discussion in a meeting or with a team member regarding the issue as
it was being identified?
4. What information, data, analyses, or discussions did you leverage to work through the
review issue?
• Which disciplines or experts were involved in the review of these information,
data, or analyses?
• Which disciplines were involved in the discussions of this review issue?
Process
5. What strategies did you use to resolve review issue and what was the impact of the
review issue on the benefit-risk determination?
• Who on the review team worked on the review issue?
• Were the steps taken to resolve the review issue planned (e.g., deliberate)?
6. How did you work through the review issue in an integrated way?
a. What information, data, analyses, or discussions did you or the team use?
b. What meetings did you have to discuss the issue?
c. Did you have to work with the Applicant?
7. How would you describe the incorporation of your inputs and contributions into the final
documentation of the review issue in the Multidisciplinary or Integrated Review?
Member Checking
Following the semi-structured interviews a member checking activity was conducted to
validate the descriptions of integration identified through the document analysis and semistructured interviews (Creswell & Poth, 2016). Member checking was done through the creation
of IPO models of the review issues that include collected data on the Inputs, Process, and
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Outputs. Originally, this member checking was to be conducted in person in a focus group. But,
due to the pandemic these models were circulated with the interview participants via email. The
reference models utilized a visual of integration, a logical IPO model, illustrated in the figure
below. The purpose of providing models of integration to the interview participants is to validate
the inputs, outputs, and integration process. Any feedback on the integration models will be
collected and included in NVivo for incorporation in finalize analysis and interpretation.

Figure 14: Member Checking Model Example

As mentioned earlier, the combination of data collection from the document analysis,
semi-structured interviews, and member checking helps to triangulate the data collection and
provide the richness of data needed for a descriptive case study of each review. All three methods
of data collection were guided by the operationalization of the O’Rourke et al. IPO model into
guiding questions to ensure alignment. See Table 6, below for a description of the variables of
interest in the data collection, including relevant guiding questions, and sources of data
collection.

86
Table 4: Operationalizing the O’Rourke et al IPO Model
Variables
Inputs and Outputs
including a
description

Process

Guiding Questions
Is the input or output a concrete piece of
evidence (e.g., data or results from a study
or analysis)? Or, is it an abstract insight or
concept from a cognitive domain (e.g., an
expert opinion or recommendation)?

Sources
Document Analysis: Benefit-Risk
Framework from Integrated Review or
Summary Review

Discipline: Disciplinary origin or expertise
required for the input

Document Analysis: Integrated Assessment
and Appendices of Integrated Review or
Individual Disciplinary Reviews

Integrative relationship between inputs and
outputs (Qualitative)

Document Analysis: Benefit-Risk
Framework from Integrated Review or
Summary Review

Purposive change: Yes/No

Semi-Structured Interviews

Number of changes to an input

Semi-Structured Interviews
Document Analysis: Integrated Assessment
and Appendices of Integrated Review or
Individual Disciplinary Reviews

Parameters
(e.g., Scale,
Commensurability,
Comprehensiveness)

•

Scale (Global/Local)

•

Commensurability (High
conflict/Low conflict)

•

Comprehensiveness (High/Low)

Document Analysis: Benefit-Risk
Framework from Integrated Review or
Summary Review
Semi-Structured Interviews

Data analysis and synthesis
An embedded analysis was conducted to understand a very specific aspect of both cases
in this study, the integration process related to key benefit-risk review issues. This qualitative
analysis is thematic in nature but guided by the operationalized analytical framework from the
underlying theory behind O’Rourke et al.’s framework of cross-disciplinary integration. As
detailed above, the data collection and analysis of integration was guided by several guiding
questions related to variables in the IPO model (e.g., type of input or output, nature of integrative
relation) and dimensions of the BRF. These guiding questions and the dimensions of the BRF
can inform emergent coding; see the tables below.
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Table 5: Emergent Input / Output Code Categories Informed by BRF
Inputs
Patient Experience Data
Efficacy and Safety Studies and Data

Outputs

Required labeling to convey or mitigate a risk
Benefits Issue: such as the approvability of a
Clinical Condition and Underlying Pathophysiology
claim or dose
Patient Experience and Clinical Meaningfulness of Treatment Adequacy of Labeling to convey a risk or
inform physciains
Effect
Safety Issues
Pediatric Use Information
Clinical Pharmacology Study(s) and Data
Assessment of Risks
Risk Management Issues
Nonclinical Pharmacology/Toxicology Study(s)
and Data
Drug Quality Issues
Pregnancy and Lactation Information
Drug Use/Utilization Issues
Labeling
Design of Study(s)
Legal or Regulatory Drug-specific Issues
Safety Assessment and Profile
Safety Data
Manufacturing Facility Information and Inspection
Information
Drug Substance/API Information
Drug Product and Formulation Information
Product Attributes
Table 6: Emergent Integrative Relationship Code informed by O’Rourke et al.
Integrative relation:

mixing, linking, making sense together, and harnessing
differences

Disintegrative relation:

dissociation, differentiation, and boundary setting

Combinational relation:

assembling, combining

It is important to note that these codes are not a priori, or provisional, codes because they
are not expected to be specific enough to describe the two cases. However, considering these as
potential categories or types of emergent codes or tags in advance is a useful technique to
jumpstart analysis (Saldaña, 2013). Coding is the systematic review of qualitative information
and linking of data to ideas, and subsequently allowing all data related to that idea to be linked
(Saldaña, 2013). Qualitative coding from both the document analysis and semi-structured
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interview transcripts in both cases was used to identify instances of integration, including
descriptions of the Inputs, Process, and Outputs in each instance of integration. This facilitates
the characterization of representative models of integration (i.e., I>P>O chains) and enables
analyses related to those models.
Once review issues and their inputs, outputs, and process items were coded, the guiding
questions were used in a memoing process to advance thinking and create a record of the coding
process (Creswell & Poth, 2016). This memoing process also helped create a more transparent
process and could be revisited during the analysis and interpretation of results to improve
understanding. The codes for inputs, outputs, process, parameters, and the themes identified from
the analysis, when combined with the thorough descriptions of the two cases, offered a more
complete rendering of the interdisciplinary integration process that unfolded in each FDA new
drug product review (Creswell & Poth, 2016). This rendering or model of the integration process
was used to analyze the similarities and differences of the integration process in the two cases.
In qualitative research, data collection and analysis can often overlap and proceed “handin-hand”, even with the data synthesis steps (Creswell, 2014). Creswell’s linear or hierarchical
approach to data analysis was used in this study and involved building from the bottom up;
however, it is important to point out again, that this process may unfold iteratively (Creswell &
Poth, 2016). In addition, data collection and analysis steps occured concurrently at times and
therefore overlap considerably. This can be beneficial for several reasons, including earlier
identification of gaps, the agility to explore new hypotheses, and the production of interim
reports, which can be used to guide other aspects of data collection (e.g., listings of
inputs/outputs for use in semi-structured interviews) (Creswell & Poth, 2016; Miles, Matthew,
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1994). These steps as they were planned to occur in this study, including their concurrent,
iterative nature, are outlined in the figure below, adapted from Creswell (2014).

Figure 15: Data Collection & Analysis Process
(Creswell, 2014)

Steps 1 and 2 were described in the Study design and settings and Participants sections,
respectively, above. Step 3 involves the document analysis and coding of data related to the key
variables of this study (e.g., inputs, outputs, process, and parameters) and themes. Guiding
questions and emergent codes informed by the O’Rourke et al. IPO model and BRF are
described in Tables 6, 7, and 8, above. Step 4 involves the conduct of semi-structured interviews
and focus groups for member checking, which was described above. Step 5 includes the analysis
through coding of the transcripts from the semi-structured interviews and any feedback from the
focus groups on the integration models from each case. It is possible that following both Steps 4
and 5, coded data needs to be re-reviewed to ensure emergent codes do not require modification.
Sub-step 3 of Step 3 is where the O’Rourke et al. IPO model and operationalized
framework are first leveraged, as described in the data analysis section above. During this step,
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coded data associated with variables of each instance of integration (e.g., inputs, outputs,
process) and relevant parameters (e.g., scale, commensurability, comprehensiveness) were
tabulated, described, and linked in Inputs  Process  Outputs (IPO) logic models. Semistructured interviews provide data that completes these IPO models, with focus groups validating
the models. Analysis of the IPO models of integration found in each case was a critical focus/unit
of analysis in this study. Analysis and themes from Step 6 are further interrelated with other
themes and descriptions of the two cases and IPO models in Step 7. Step 7 is where comparisons
between the two cases can first begin to be made. Following Steps 6 and 7, it was necessary to
revisit the coding. Lastly, the findings of the data analysis are summarized and interpreted for
reporting of findings or results.

Reflections on strengths and weaknesses
The document analysis is not without limitations due to the subjectivity of the reader and
interpreter of the data contained in the documents. In addition, because the documents were
authored by different individuals or teams it is possible that biases of the authors were reflected
in the documents and ultimately collected in the source data. Therefore the initial coding in the
document analysis was thoroughly documented to ensure transparency and reproducibility, and
reviewed by an independent researcher (Creswell & Poth, 2016). In addition, since the semistructured interviews were conducted with only select team members from the teams based on
the identified instances of integration or willingness to participate, it is possible that variations in
the data or interpretations result directly from variations in these individuals and not the entire
teams. The use of a semi-structured approach to the interview and a set list of questions,
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including focus groups for member checking, helps to minimize this risk (Creswell & Poth,
2016).
Key strengths of this study resulted from the use of multiple methods of qualitative data
collection and analysis. These strengths relate to efficiency by which the initial review can be
completed, lack of reactivity and obtrusiveness involved in a document analysis, and
triangulation. In other words, at the onset of the study, participants were not directly affected
(Bowen, 2009) due to the data collection beginning with the document analysis. Given the
availability of review documents another key strength of a document review is the ability to
reproduce the study with future review documents, both internally and externally. Where the
document analysis did not provide insufficient detail to complete the data analysis required to
create the IPO models of integration in each review case, semi-structured interviews of the team
members helps to minimize this weakness by providing additional perspectives and triangulating
findings (Creswell & Poth, 2016). In addition, member checking to validate the integration
models further triangulated the findings. As with all qualitative research approaches, it is
possible that the researcher’s bias impacted the document analysis and influenced participants.
These biases were documented at the study start in a subjectivity statement and provided in the
informed consent to all participants. This subjectivity is described below. This helps make
explicit these biases (Lincoln, Y.S., Guba, 1985).
The Researcher, Kevin Bugin, was the lead for the New Drugs Regulatory Program
Modernization, which to date, has implemented a structural reorganization of the Office
of New Drugs, which is the lead office for the review of new drug products, and created
new, more efficient processes for review of INDs and NDAs/BLAs, including the
interdisciplinary assessment of marketing application (i.e., Integrated Review), which is

92
of interest in this study. Given this close connection to the development of the integrated
review, including the new interdisciplinary processes and documentation template, which
was by design intended to create more integration, the research clearly has implicit biases
for the new integrated review and expects to see greater integration.
In addition to the statement of subjectivity, several other methods were employed to
counteract any potential biases. First, case selection for this study was guided by objective
inclusion and exclusion criteria and a randomization process to avoid the preferential selection of
cases. Secondly, an interrater was used for one round of the document analysis to confirm all
review issues were identified and tagged without bias. A member checking of the review issues
and the associated input, output, and process data was conducted to validate the data collection.
And, lastly, with the multiple qualitative methods deployed, triangulation occurs which helps to
minimize the impact of these biases by offering multiple data sources.
This study is focused primarily on modeling cross-disciplinary integration in two FDA
new drug product reviews that were either multidisciplinary or integrated. As such the study may
not clearly define or describe other aspects of the FDA review process, such as communication,
team dynamics, or scientific methods of analysis and may not be extrapolatable to other review
types (e.g., reviews of generic drugs, postmarket safety assessments). Such conclusions would
require larger sample sizes since FDA review processes are conducted by humans and
consistency may not always be achieved. However, examining two cases with different teams,
different processes, and additional differences in context (e.g., drug products reviews, therapeutic
areas, scientific issues), may contribute to the generalizability of findings to other FDA new drug
product reviews given such differences routinely exist due to the uniqueness of the new drug
product applications and review teams.
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An additional limitation of this study is the sample size and selection, however, the
approach to conducting this study (i.e., descriptive case study) does mitigate this limitation by
providing a high degree of depth and detail on each case. Even so, with the selection of only two
cases it is possible for unique qualities of these two cases, whether related to the focus of the
review (e.g., the product or application) or the review team, may drive the findings. This is
exacerbated by the fact that there was small pool of completed integrated reviews and
multidisciplinary review to select during this transition period (e.g., phased implementation of
the new integrated review replacing the multidisciplinary review. Selection was guided by
inclusion and exclusion criteria mentioned above but was limited given the transition state of
reviews from the traditional multidisciplinary review to the new integrated review. It was
anticipated that at the time of study start there would only be a limited number of completed
integrated reviews. And, over time, there will be fewer available multidisciplinary reviews. So,
this was unavoidable.
Lastly, it is important to acknowledge that this research took place in the context of the
COVID-19 pandemic—with this research study beginning in Spring 2020. While the entire
world was certainly affected by the pandemic, the FDA review staff within the Office of New
Drugs were especially impacted in that they saw major increases in workload both from the
receipt of multiple applications for the use of repurposed and novel therapeutics to treat COVID19, but also the handling of requests for regulatory discretion and flexibility for conducting
clinical research during the pandemic (e.g., increased use of telemedicine), and assistance with
mitigations risks to drug supply chains given the disruption in global supply and trade. This had
at least three known effects on this research and potentially more. First, all interviews had to be
conducted virtually. In some cases, participants did participate with video and in those instances
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without video the rapport may not have been effectively established. Secondly, the plan for
member checking had to accommodate the inability to conduct a live focus group. Instead, a
series of email communications was used to validate the integration models for member
checking purposes. Thirdly, the willingness of subjects to participate was likely driven by their
availability or workload, which as noted above, was greatly impacted by COVID-19. As such, at
multiple cases had to be screened before finding a case with a pool of subjects willing to
participate. Lastly, this researcher was also heavily affected by the COVID-19 pandemic having
been pulled into the US Governments Operation Warp Speed efforts to manage the Therapeutics
Program.

Human Participants and Ethical Precautions
Risks for participation in the study and breaches of confidentiality
The risks to subjects participating in this study was minimal. Most of the data collection
came from publicly available documents that may already contain subject identifying
information. Potential risks to participants were somewhat minimized because the researcher did
not engage directly with subjects and stronger measures to ensure confidentiality were taken
(e.g., deidentifying subject names in documents included in the document analysis or using only
publicly available documents). Given potential influence from the researcher due to status, such
methods were an important study enhancement.
Minimal risk to subjects was possible from their sharing of information during interviews
and could manifest in extreme cases as changes to their working conditions, such as peer or
leadership perceptions of their performance or quality of work. However, this risk is expected to
be minimal through the anonymized collection of interview feedback and masking of any review
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team names and roles with pseudonyms or unique subject identifiers. There are no risks from
breaches of confidentiality because information gathered is from publicly available documents,
and as mentioned above, personally identifying information will not be collected.
Coercion due to researcher’s position or status
As mentioned earlier, the researcher holds a position of status in the organization as the
Director of Special Programs, with responsibilities that relate to driving the New Drugs
Regulatory Program Modernization and other quality improvement initiatives. As such, the
researcher may have been perceived in polarized ways (e.g., always looking for problems and
creating trouble, or always improving work practices and helping others). In addition, the
researcher has known close working relationships with FDA and CDER leadership that may be
result in perceived power or influence over senior leadership. These position/status factors may
have influenced participants’ choice to participate and influenced their contributions during semistructured interviews and/or member checking. It is expected that risks of coercion are low
because subject selection was primarily through convenience sampling and did not require selfselection. In addition, by including a statement of subjectivity, or the researcher’s interests and
relationship to the participants will help mitigate these risks and ensure the participants are free
from coercion. Furthermore, agreement to participate was possibly balanced by reverse coercion,
or the unwillingness to participate due to the researcher’s position or status.
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Chapter 4 Results
Introduction
This study was a phenomenological descriptive comparative case study of the regulatory
review of a new drug product marketing application that used either the traditional approach to
the review (i.e., multidisciplinary review) or the new integrated approach (i.e., interdisciplinary
review) at the FDA. The purpose of the study was to identify instances of integration related to
benefit-risk review issues, if any, and more clearly define the differences and similarities in the
integration process. The study employs a combination of document analysis, semi-structured
interviews, and member checking to characterize the integration found within each case that
centered around the collaborative cross-disciplinary review issues encountered by the review
teams. Data collection and analysis are guided by a philosophical framework for the modelling
of integration from O’Rourke et al and subsequent analyses (O’Rourke et al., 2016).
FDA’s assessment of new drug products before they enter the marketplace is a critical
activity to protect the US public’s health and requires team-based integration and transparency
(Woodcock, 2018). In 2019 the FDA began rolling out a new interdisciplinary approach to the
assessment of marketing applications, with the key feature being integrated, collaborative review
documents (Woodcock et al., 2020). As FDA makes this transition to implementing a more
integrated approach to its review processes and documentation, there are tradeoffs and some
external stakeholders have expressed concerns with a decrease in transparency and loss of
knowledge (Herder et al., 2020). This study is being conducted to better understand how
integration is occurring in the interdisciplinary approach and has occurred in the traditional FDA
multidisciplinary reviews to guide the transition from multidisciplinary review to the new
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interdisciplinary review, and perhaps help address external stakeholder concerns. The research
questions are below.
Table 7: Research Questions and Methods

Research Question

Research Methods and Techniques

1.

What are examples of integration in a
“multidisciplinary review” and an “integrated
review” of an FDA new drug product?

Document analysis, semi-structured interviews, and
member checking
(Bowen, 2009; Miles, Matthew B., 1994)

2.

What are the specific differences in integration
between a “multidisciplinary review” and an
“integrated review” of an FDA new drug
product?

Intrinsic, descriptive, and comparative case study
analysis
(Creswell & Poth, 2016; Seawnght & Gerring, 2008)

The goal of research question one was to identify and model instances of integration of
the cross-disciplinary review assessments in these two cases of collaborative cross-disciplinary
research that were centered around key benefit-risk review issues. Benefit-risk review issues are
issues are identified by the review team of a new drug product application that would impact the
approvability of the application as submitted and lead to some form of regulatory decision or
action related to the marketing of the new drug product. These review issues are rooted in a
benefit-risk assessment and determination guided by the benefit-risk framework (BRF). A
regulatory decision or action is the decision to approve or conversely not approve the marketing
application and the subject product with an indication, a specific dose and administration,
labeling, and any required postmarket studies and commitments. Benefit-risk review issues were
the focus of this study because these are the “problems” that FDA new drug product review
teams work through together in a cross-disciplinary fashion.
The goal of research question two was to then comparatively analyze the differences,
both quantitatively and qualitatively, between the instances of integration identified using the
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models of integration developed from the framework from the O’Rourke et al. for crossdisciplinary integration (O’Rourke et al., 2016).
Following IRB approval, data collection began with a screening process for eligible
applications as discussed in Chapter 3. The screening process was used to identify cases with
available review documents and individuals willing to participate and consent to the study.
Following confirmation of participation from the review team, the documents for the associated
application review were gathered from Drugs@FDA. Drugs@FDA is a public database that
includes publicly available review documents for approved applications. The review documents
used in this study can be found at the following links:
•

RINVOQ
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&var
ApplNo=211675

•

TAUVID
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&var
ApplNo=212123

For the RINVOQ (upadacitinib) case, the following review documents were collected:
•
•
•
•
•
•

Clinical Pharmacology and Biopharmaceutics Review (FDA, 2019a)
Clinical Review (FDA, 2019b)
Non-clinical Review (FDA, 2019c)
Quality Review (FDA, 2019d)
Statistical Review (FDA, 2019e)
Summary Review (FDA, 2019f)

For the TAUVID (flortaucipir F-18) case, only the following document was collected:
•

Integrated Review (FDA, 2020a)

Following document collection, review documents were analyzed to identify benefit-risk
review issues. Review issues were identified through a selection process that was informed by
the BRF since review issues are approvability issues and approvability for a new drug is closely
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linked to the benefit-risk determination. As discussed in Chapter 3, this was an iterative process
that involved an initial review to build familiarity with the case and documents, followed by a
coding analysis of review issues and subsequent coding of the review issue(s) for inputs, outputs,
and process activities (O’Rourke et al., 2016). The BRF again informed analysis underlying the
coding and development of the IPO models as the inputs could be identified through their
connection to either evidence of benefit (i.e., efficacy) or of risk (i.e., safety), and any related
uncertainties. The same was true for the identification of outputs, as these were directly
connected to a key dimension of the benefit-risk determination documented in the application
review.
Interview participants were then contacted to schedule the semi-structured interview and
obtain informed consent. Due to the ongoing COVID-19 pandemic, all semi-structured
interviews were conducted via Zoom with audio recording. Also, due to the COVID-19
pandemic and the nature of FDA review staff’s work related to reviewing therapeutics for
COVID-19, interviews took a considerable amount of time to schedule. Interviews took between
30 and 60 minutes and involved six review team members for the RINVOQ case and seven
review team members for the TAUVID case. A PowerPoint slide deck was used to facilitate the
interview. The slide deck included a few introductory slides on the research study, including its
impetus, and then two slides to walk the participant through the semi-structured interview
questions. This slide deck can be found in the Appendix 3. Audio recordings from the interviews
were transcribed and then analyzed similarly for review issues, inputs, outputs, and process
activities.
After coding the interview transcripts and the coding of the review documents, the transcripts
and review documents were re-analyzed and re-coded for any additional detail or data associated
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with newly identified inputs, outputs, or process activities. This iterative coding, analysis and
interpretation process ensured that an accurate picture of each review issue and its integration
could be collected. The final analysis step encompassed a review of codes with the O’Rourke et
al framework for cross-disciplinary integration (O’Rourke et al., 2016) in mind. Then codes were
inventoried and analyzed in a database of key variables of the inputs, process, and outputs from
the O’Rourke et al. IPO framework. A snapshot of the completed data tables from the
inventories, along with associated data, can be found in the appendices 4 and 5.
The IPO analysis and inventorying were used to inform logical models (i.e.,
Input>Process>Output) of the integration for each review issue. These models were created in
PowerPoint and then distributed to interview participants for validation, or member checking.
Responses were received from all participants and the generated models were considered
validated.
The following sections describe each of the cases, associated review issues, and the
integration found. Each section includes descriptive information on the application and new drug
product, the review team, and the approach used (i.e., multidisciplinary, or interdisciplinary).
Within each case, the review issues are discussed individually, including the integration seen.
Qualitative data from the review documents and interviews are included to support the
identification of review issues, and the inputs, outputs, process, and parameters of the
integration. As a reminder, the IPO parameters are defined as follows:
•

Commensurability: Assessment of how integrable the inputs are (i.e., their difference
or conflict between) (O’Rourke et al., 2016).

•

Comprehensiveness: Assessment of how comprehensive the output(s) reflect or
include the inputs (O’Rourke et al., 2016).
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•

Scale: Assessment of how many disciplines or disciplinary input types were involved
and the overall impact (i.e., global--the entire application vs local--a specific
problem/issue) (O’Rourke et al., 2016).

To help illustrate the integration within each benefit-risk review issue from the cases, a
Sankey flow model was developed for each based on the IPO framework analysis and an
diagraming approach from Laursen (2018). The colors in the Sankey diagram are arbitrary and
are only intended to help the interpreter distinguish between the different disciplines (far left, in
figure below) and their contributions to the inputs (second from the left), then the flow of inputs
into process activities (second from the right) and lastly the flow of those process activities to the
final output (far right). The width of the bars or flows is driven in part by the number of
disciplinary contributions to the inputs, but mostly by the number of process activities these
inputs were involved in. All disciplinary contributions and inputs were counted equally and so
the larger the width of the input “flow” reflects mostly the degree to which this input was
involved in the process activities. As Sankey diagrams were originally intended for the modelling
of thermodynamic systems where energy was contained or conserved in the system, the
remaining flow widths are all driven by the width of the Inputs and how these flow through the
rest of the integration model.
An example from the TAUVID case for review issue 4 is shown below to help describe the
mechanics and key features of what the Sankey diagram depicts. These diagrams are quite useful
in demonstrating the dynamics of the integration that occurred.
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Figure 16: TAUVID Review Issue 4 Integration Model

In the review issue above, two disciplines contributed to a total of three inputs that then were
involved in one process activity to arrive at a single output or conclusion of the crossdisciplinary integration for this review issue. As noted above, for these models the inputs are
counted as equal parts and so are the originating contributions of the disciplines. The differences
seen in the width of flows occur when disciplines contribute to more than one input or when
inputs contribute to more than one process activity. In this example, because there was one
process activity that incorporated all three inputs, these inputs had similar widths.
The section that follows the case descriptions includes results from comparisons of the two
cases, including the applications, teams, review issues, and integration. In addition to cited in the
sections below, underlying data (i.e., direct quotations from review documents and interviews)
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supporting the results of the analyses can be found in appendices 4 and 5 alongside the
integration inventories.
RINVOQ Case
Description of the multidisciplinary case
The multidisciplinary case for this descriptive comparative case study was the new drug
application (NDA) 211675 for RINVOQ (upadacitinib) for the treatment of adult patients with
moderately to severely active rheumatoid arthritis (RA). The NDA was submitted by AbbVie,
Inc. on December 19, 2018 and approved on August 16, 2019. The review was conducted with a
priority review timeline of 8 months. RINVOQ (updadacitinib) is a new molecular entity (NME),
oral small molecule inhibitor of the Janus associated kinases (JAK). While RINVOQ was still a
new molecular entity there were two other JAK inhibitors approved at the time of review:
tofacitinib (Xeljanz, NDA 20321, approved November 6, 2012) and baricitinib (Olumiant, NDA
207924, approved May 31, 2018).
The NDA for RINVOQ was reviewed in the Division of Pulmonary, Allergy, and
Rheumatology Products. As RINVOQ was an NME, the signatory, in other words the final
decision maker, for the application was the Office of Drug Evaluation II Director, who oversees
the review division. The review team was made up of a regulatory project manager, a clinical
reviewer, a statistical reviewer, a clinical pharmacology reviewer, two pharmacometrics
reviewers, a pharmacogenomics reviewer, a nonclinical pharmacology/toxicology reviewer, and
a dedicated quality team with a drug substance reviewer and supervisor, a drug product reviewer,
a process/microbiology/facility reviewer, and a biopharmaceutics reviewer. Each discipline
reviewer was also joined and closely supervised by a discipline team leader. It should be noted
that while some of these disciplines may be similar, they are considered separate and distinct
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within the FDA. For example, the clinical review discipline is focused almost exclusively on
medical topics and clinical research design/conduct. Whereas clinical pharmacology is more
interested in how the drug performs within the human body. For this application, as with many,
the clinical or medical team leader served as the cross-disciplinary team leader. Of this large
review team, the following disciplines consented to participate and were represented in the
interviews: clinical, statistics, clinical pharmacology, biopharmaceutics, process/ microbiology/
facility, and nonclinical pharmacology/toxicology.
The RINVOQ review team utilized a traditional approach to conducting the review of
this application, as defined by the 21st Century Desk Reference Guide for new drug product
application reviews (FDA, 2014). This approach to the review of a new drug application involves
a multidisciplinary review team working initially separately within disciplines to review the
application, with team meetings at key milestones of the review, such as filing, mid-cycle, and
wrap-up. The team writes individual discipline-specific review documents and then the crossdisciplinary team leader—sometimes in partnership with the signatories of the application—
writes a summary review of the discipline-specific reviews to support the final regulatory
decision. For the RINVOQ review, the discipline-specific reviews were completed between four
and two months prior to the action on August 16, 2019, and the Summary review was completed
on July 11, 2019, about one month before the action. These documents were targeted for
document analysis and are listed below.
Table 8: RINVOQ Review Documents

Document
Summary Review
Clinical Review
Nonclinical
Pharmacology/Toxicology
Clinical Pharmacology

Length in
pages
54
243
92
138
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Product Quality
Statistics

38
171

In the multidisciplinary approach, review teams come together during the first 30-60 days
to align on the filing of the application, which is a determination that the application is materially
complete and that it can be reviewed. Benefit-risk review issues and filing issues may be
discussed at this initial meeting. The review team will come back together for a “mid-cycle
meeting” at about the half-way point of the review to discuss major review issues that could
affect approvability. The team will not come back together fully again until a “wrap-up meeting”
towards the end of the review timeline, shortly after all discipline-specific reviews are
completed. In some instances, closely related disciplines may meet separately to confer on
specific issues (i.e., clinical and statistics on safety analyses, pharmacology/toxicology, and
quality on impurities, etc.). Recommendations for the final decision are made by the review team
members at this meeting, to inform the signatory’s final decision. A schematic of the process and
timelines for either a Standard or Priority review is found in the figure below (Standard review
milestones in gray and Priority review milestones in red).
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Figure 17: Multidisciplinary Review Process (FDA, 2014, p. 51)

Description of cross-disciplinary review issues identified
Over the course of the document analysis and interviews with select review team
members, six cross-disciplinary review issues that had or could have had a regulatory impact on
the application review decision were identified based on frequency of reference and emphasis of
impact found in interviews. These six review issues were all considered resolved and therefore
the cross-disciplinary review issue had a complete input to output process. The review issues and
their mentions across the documents and interviews are listed below:
Table 9: RINVOQ Review Issues

Review Issue
Embryofetal Issues
30mg vs 15 mg Issues
Formulation Bridging Issues
CYP3A4 Issue
Impurities Issue
JAK Class Safety Issue

Coding Instances
49
47
15
10
6
6

Figure 18: RINVOQ Review Issues
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The review issues in RINVOQ were described in mostly the same way across review
documents, but because they were mentioned across multiple review documents it was difficult
to confirm the significance of the review issues until the interviews could be analyzed,
triangulating the importance of the issues. The following figure of the Formulation Bridging
Issues, helps illustrate this point.

Figure 19: RINVOQ Formulation Issue Across Objects

Review Issue 1: 30 mg vs 15 mg Issues
The first review issue identified in the RINVOQ application was related to the two doses
studied in the RINVOQ drug development program. Two doses, 30 mg and 15 mg, were studied
over the course of development, including in five pivotal phase 3 studies, which were submitted
in the NDA.
“Patients treated with UP A 30 mg consistently had a numerically higher proportion of
patients with greater ACR50 and ACR 70 responses compared to the UP A 15 mg group;
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however, given the relatively small increase in benefit, the degree of clinical
meaningfulness is uncertain.” (FDA, 2019f)

The review team had to carefully assess the safety and effectiveness, or benefit-risk
profile, for each dose to establish if the benefits would outweigh the risks. This review issue
included 3 inputs and involved 3 disciplines, which are listed in the table below.
Table 10: RINVOQ Review Issue 1 Inputs

Input #
1
2
3

Discipline
Clinical Pharmacology
Clinical, Clinical Pharmacology, and
Statistics
Clinical, Clinical Pharmacology, and
Statistics

Input Description
Exposure-Response Analysis
Integrated Safety Analyses
Results from Five Phase 3 Studies

These three inputs were considered concrete and relatively similar, with a low degree of
difference across them, translating to a relatively high degree of commensurability. The first
input was an exposure-response analysis conducted and described by the clinical pharmacology
reviewer in their review document, along with their findings, as:
“Overall, results from Phase 3 studies and exposure-response analysis support the
proposed 15 mg QD dosing regimen as it provides the optimal benefit-risk balance in
patients with moderately to severely active RA” (FDA, 2019a)
The second input was an integrated safety analysis conducted by the medical and statistical
reviewers. The statistical reviewer described the analyses as integrated as seen in the following
statistical review document excerpt:
“Based on the integrated safety analyses during the placebo-controlled or MTXcontrolled period, there was an observed dose response relationship for key treatment
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emergent AEs such as infections, and serious infections, common to the JAK class.”
(FDA, 2019e)
The third and final input was the overall results seen across the five submitted studies in the
RINVOQ application.
The three inputs for each dose were processed via additional analyses or assessments for
safety, benefits, and then both individually and comparatively for benefit-risk. These activities
are considered best practice or routine for reviews and since the disciplines conducted their
analyses/assessments independently before bringing their findings together in order to make a
consensus decision. Based on the analysis of the review documents and interviews, the process
by which the individual findings were brought together was more a coordinated review of
separate aspects by review team members to come to a combined decision. As such, the process
activities were considered combinatorial with regards to their integrative nature. These process
steps are listed in the table, below.
Table 11: RINVOQ Review Issue 1 Process Steps

Process
Step #
1
2
3

Process Description
(Inputs involved)
Analysis/Assessment of Safety at 15 mg
and 30 mg independently
(1, 2, 3)
Analysis/Assessment of Benefit at 15 mg
and 30 mg independently
(1, 3)
Comparative Analysis of Adverse Event
Profile between 15 mg and 30 mg doses
(1, 2, 3)

Purposive
Yes

Integrative
Nature
Combinatorial

Yes

Combinatorial

Yes

Combinatorial

While each process step represented some change to the inputs, the degree of change was
low as the output of the process was expected by the review team and confirmed the applicant’s
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proposal to not market the high dose (i.e., 30 mg); see following quote from the medical
reviewer interview:
“It is worth noting that the safety analyses included comparisons of AEs between the
UPA 15 mg and 30 mg doses but only the UPA 15 mg dose is being sought for approval
by the Applicant.”
The integration of inputs in this review issue led to a single regulatory decision (output)
that 15 mg dose was found to have favorable benefit-risk profile and approved by FDA, but 30
mg Dose was found to have an unfavorable benefit-risk profile. This output is considered
concrete because it led to an action to approve the 15 mg dose and not the 30 mg dose. Or, as
stated in the Summary Review document:
“The benefit-risk profile of the upadacitinib 15mg dose is more favorable than the 30mg
dose. The small incremental benefit of the 30mg dose does not outweigh the dose-related
safety findings with the 30mg dose of upadacitinib.” (FDA, 2019f)
This output is cross-disciplinary and includes all inputs making its integration comprehensive.
And, this instance of integration is considered global given that the issue is relevant to the entire
application. Additional supporting data, including excerpts from the review documents and
quotes from interviews can be found in appendix 4.A.
Based on these data, the integration found in review issue 1 can be modelled as follows in
the figure, below. As can be seen in the figure below, two of the process activities were inclusive
of all inputs. Also, interesting in this diagram is the contribution of clinical pharmacology to all
inputs and the addition of an input (input 1) that was entirely clinical pharmacology and the
subsequent incorporation of this input in all process activities. This clearly indicates the
extensive reliance on this discipline in the overall review issue.
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Figure 20: RINVOQ 30 mg vs 15 mg Review Issue Sankey Integration Model

Review Issue 2: Formulation Change
The second review issue identified in the RINVOQ multidisciplinary case was an issue
related to the adequacy of the bridging of data to support both a change in the clinical trial
material formulation made during drug development from an Immediate Release to Extended
Release Formulation and a change between Clinical Trial Material (CTM) used in the Phase 3
studies and for the To-Be-Marketed Material. This issue was initially identified by the following
succinct statement in the summary review:
“The phase 3 clinical trial formulation differs from the proposed commercial
formulation.” (FDA, 2019f)
As manufacturing changes, such as formulation changes, can alter the product’s quality and
performance in the clinical setting, providing the bridging data between such changes is
considered to have important regulatory impact. This review issue included six inputs, all
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concrete, and involved two disciplines, as listed in the table, below. The clinical pharmacology
discipline contributed to four inputs related to the bioequivalence study, bioavailability study,
and a population pharmacokinetics analysis. The analysis of the bioequivalence study was
repeated by the clinical pharmacology reviewer, who noted in their interview that it was “critical
… to repeat the data analysis”. As with review issue 1, these inputs were similar in source, type,
and findings making the commensurability or degree of similarity/congruence high.
Table 12: RINVOQ Review Issue 2 Inputs

Input #
1
2
3
4
5
6

Discipline
Clinical Pharmacology
Clinical Pharmacology
Biopharmaceutics
Biopharmaceutics
Biopharmaceutics and Clinical
Pharmacology
Clinical Pharmacology

Input Description
Bioequivalence Study
Repeated Bioequivalence Study
Release Profiles
In Vitro Dissolution Study
Bioavailability Study
Population Based Pharmacokinetics
Analysis

The six inputs for this review issue were processed in two activities, a presentation of
results and a discussion of clinical significance with the review team. The results presentation is
considered purposive as it is routine to present results from either the application or the reviewer
analyses, whereas the discussion of clinical significance was more spontaneous or emergent and
driven by the findings of the reviewer’s assessment of the release profiles. The routine nature of
the review team presentation was noted in the following quote from the clinical pharmacology
reviewer:
“I normally discuss with the team leader first to finalize the slides, and then we presented
with the whole review team”
The results presentation was considered combinatorial as the bioequivalence study was
mostly left to the Clinical Pharmacology team to evaluate and other disciplines relied on that
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assessment—the same was true for the bioavailability study and Biopharmaceutics team. The
discussion of clinical significance of the release profiles on formulation change was considered
integrative because it required multiple disciplines to provide their perspective on the same data
before a conclusion could be reached, as noted by the biopharmaceutics reviewer in the
following interview quote:
“…communications were between both clinical and clinical pharmacology teams in
trying to make sure that the plus or minus 10% [in release profiles] is okay in terms of
establishing the boundaries”
The process steps involved in review issue 2 are listed in the table, below.
Table 13: RINVOQ Review Issue 2 Process Steps

Process
Step #
1
2

Process Description
(Inputs involved)
Results presentation to the Review Team
(1, 2, 3, 4, 5, 6)
Discussion of clinical significance of the
release profiles with the Review Team
(3)

Purposive
Yes

Integrative
Nature
Combinatorial

No

Integrative

The degree of change seen in the inputs during the process steps was low with only a
combination of data from across all phase 3 studies to inform the population-based
pharmacokinetics analysis. These two process steps led to the single regulatory decision (output)
that the formulations were considered bioequivalent, including their release profiles:
“Bioequivalence was established between the to-be-marketed ER tablets and the ER
tablets used in Phase 3 studies”, Clinical Pharmacology Review (FDA, 2019a).
This output was again cross-disciplinary, incorporating all inputs and disciplines, making
the comprehensiveness of the integration high. However, this review issue was localized to the
formulations and therefore had a local scale and considered abstract in that no change to the
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proposed formulation or regulatory action was required. Additional supporting data, including
excerpts from the review documents and quotes interviews can be found in the appendix 4.B.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure, below. While multiple inputs were observed in this review issue, as the model
below illustrates, these inputs were mostly from a single discipline. However, the presentation of
inputs at a review team meeting in process activity 1 (P1) was inclusive of most inputs. What is
not indicated in this model is the integration in process activity 2 (P2), that occurred when the
review team provided additional input to the biopharmaceutics discipline to inform the final
recommendation.

Figure 21: RINVOQ Formulation Change Review Issue Sankey Integration Model
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Review Issue 3: Impurities
The third review issue identified in the RINVOQ multidisciplinary case was related to the
impurities present in the finished drug product. This issue included one concrete input, which
were data and information related to the set of impurities found in the product, and this rose to
the level of a review issue due to the sheer number of impurities that needed to be assessed, as
indicated by this quote from the interview of the pharmacology/toxicology team leader:
“I guess the other complexity to this one was there was, compared to some applications,
kind of a lot to sift through regarding impurities.”
This input involved two disciplines and is concrete since it related to specific impurities, and
their chemical structure, and the data and information related to them. As this was a single crossdisciplinary input, commensurability is not assessable. The input is described further in the table,
below.
Table 14: RINVOQ Review Issue 3 Input

Input #
1

Discipline
Pharmacology/Toxicology and
Chemistry

Input Description
Identified Impurities

This input was processed via three activities, two of which were purposive and
considered routine for assessing impurities. However, due to the large number of impurities to be
assessed, one process step was unplanned and added, that of a computational toxicology consult.
As the pharmacology/toxicology reviewer worked through the nonclinical safety assessment of
the impurities themselves this process step lacks any nature of change. The same can be said for
the computational toxicology consult. This makes the integrative nature of the change not
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applicable. The third process step involved routine collaboration with the chemistry team, as
indicated by the pharmacology/toxicology team leader in their interview:
“requires collaboration with the CMC review team”,
As the additional collaboration was on the original input from the pharmacology/toxicology
team, this was not considered an additional input. And the process activity was integrative due to
the bringing together of perspectives from two different disciplines on the same input. These
process steps are described in the table, below.
Table 15: RINVOQ Review Issue 3 Process Steps

Process
Step #
1
2

3

Process Description
(Inputs involved)
Nonclinical safety assessment conducted
on the range of impurities
(1)
Computational Toxicology Consult was
issued to evaluate the sheer number of
impurities
(1)
Chemistry collaboration to review
impurities
(1)

Purposive
Yes

Integrative
Nature
NA

No

NA

Yes

Integrative

There was a low degree of change seen to the inputs in processing, and the final output
was abstract in nature as the regulatory conclusion was simply that there were no safety concerns
with the impurities, as noted in the summary review:
“There are no safety concerns related to UPA impurities for the proposed dose, duration,
and patient population” (FDA, 2019f)
This review issue was straightforward, but the collaboration, even if routine, between the
pharmacology/toxicology and chemistry disciplines led to the cross-disciplinary nature of the
output. And, it was comprehensive with the single input fully incorporated into all process
activities and the output. With that said, this was a relatively localized issue and did not impact
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review of the application outside of this issue. Additional supporting data, including excerpts
from the review documents and quotes interviews can be found in the appendix 4.C.
Based on these data, the integration found in this review issue can be modelled as follows
in the below figure. Process activities 1 and 2, while appearing equal to process activity 3, should
be noted as not assessable for integrative nature due to only a single discipline perspective being
brought to bear on the input in the process activity.

Figure 22: RINVOQ Impurities Review Issue Sankey Integration Model

Review Issue 4: CYP3A4 Coadministration
The fourth review issue identified in the RINVOQ multidisciplinary case was related to
the effects of coadministration of the new drug product with other CYP3A4 inhibitors or
inducers. This issue was identified by the clinical pharmacology discipline and was described as
follows in the clinical pharmacology review:
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“Ketoconazole (strong CYP3A4 inhibitor) increased upadacitinib exposure by 75%
(StudyM13-401). Rifampin (strong CYP3A4 inducer) decreased upadacitinib exposure
by 61% (Study M13-540). Therefore, upadacitinib should be used with caution if patients
receive chronic treatment with strong CYP3A4 inhibitors and is not recommended to be
co-administered with strong CYP3A4 inducers.” (FDA, 2019a)
This issue included two inputs from the clinical pharmacology discipline. It is important to note
that the analysis of the impact on CYP3A4 was conducted independently by the clinical
pharmacology reviewer, as noted during their interview: “That's based on our own data analysis”.
These two inputs were concrete analyses and also the results from clinical pharmacology studies
and are listed in the table, below. Again, the inputs were commensurable in that they were of
similar source, type, and findings.
Table 16: RIVNOQ Review Issue 4 Inputs

Input #
1
2

Discipline
Clinical Pharmacology
Clinical Pharmacology

Input Description
Independent CYP3A4 Analysis
Sponsor submitted Drug-Drug
Interaction Studies

These two inputs, both from the clinical pharmacology discipline, for review issue 4 were
processed in a single activity, which was the assessment by the clinical pharmacology discipline
and an alignment discussion with the clinical discipline. While the assessment of the issue was
led by clinical pharmacology, an emergent collaborative discussion, and the perspective of
clinical was needed in order to arrive at the final labeling recommendation due to the need to
determine clinical significance of the finding. In this instance and other similar instances, if the
discipline only joined the integration process during a process activity, then the discipline was
not reflected in the inputs. The clinical significance in this instance relates to the impact on the
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effectiveness of the drug, as indicated in the final determination on this issue found in the
summary review:
“Coadministration with strong CYP3A4 inducers are not recommended because that may
result in ineffective concentrations of upadacitinib” (FDA, 2019f)
The change in inputs was considered combinatorial in that clinical made the determination of
clinical significance of the finding once that finding was presented to the team. This process step
is described in the table, below.
Table 17: RINVOQ Review Issue 4 Process Step

Process
Step #
1

Process Description
(Inputs involved)
Finding of decreased exposure of UPA
when co-administered with strong
CYP3A4 inducers and increased exposure
with strong CYP3A4 inhibitors discussed
with clinical and recommended for
labeling by the clin pharm reviewer.
Clinical agreed.
(1, 2)

Purposive
No

Integrative
Nature
Combinatorial

While there was a change in the inputs through the addition of clinical’s determination of
clinical significance, this change is considered low because the inputs remained mostly intact and
conserved in the output, and this process of combining clinical’s determination with the findings
of the clinical pharmacology’s assessment led to a concrete cross-disciplinary labeling
recommendation (output) that the product should be prescribed to patients with caution when coadministered with CYP3A4 inhibitors and should not be used with strong CYP3A4 inducers. As
the output included the inputs in a mostly unchanged form it is considered an instance of
comprehensive but combinatorial integration, however, quite local in that this only had to do
with the co-administration of the drug with CYP3A4 inhibitors and inducers. Additional

120
supporting data, including excerpts from the review documents and quotes from interviews can
be found in the appendix 4.D.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure, below. As with review issue 3, what is not reflected in this model is the additional
clinical discipline perspective that was brought to bear in the process activity based on how
inputs were characterized in this study.

Figure 23: RINVOQ CYP3A4 Coadministration Review Issue Sankey Integration Model

Review Issue 5: JAK Safety
The fifth review issue found in the RINVOQ multidisciplinary case was related to the
class safety of Janus Kinase (JAK) inhibitors. This issue was rather unique in that the initial
identification of the issue was through the experience of the review team members with previous
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products in the same class as indicated by the signatory reviewer and medical reviewer in their
interviews:
Medical Reviewer: “this drug is a JAK kinase inhibitor, and we saw a signal with the first
in class, tofacitinib, that there was a malignancy signal and then later, possibly with
another drug that was being developed, baricitinib, we saw that there was a deep vein
thrombosis or a thromboembolic signal. So that's what we were really starting to focus
on.”
Signatory Reviewer: “One of the issues had been the design of studies and analysis of the
safety data. This is, I think, the third JAK inhibitor with toxicities for the class. We had a
very gnarly second JAK inhibitor, Baricitinib, that had a unique safety signal of venous
thromboembolism for that.”
This issue involved two inputs, one concrete that involved the integrated safety analyses from
clinical and statistics and one abstract that involved, as mentioned above, the clinical knowledge
of known class safety signals for the JAK inhibitors. Commensurability of the inputs was low in
this review issue in that the concrete data from the integrated safety analyses suggested no
findings of safety risks, whereas the clinical discipline’s belief was that the class of JAK
inhibitors would have these safety issues. These inputs are described in the table, below.
Table 18: RINVOQ Review Issue 5 Inputs

Input #
1

Discipline
Clinical

2

Clinical and Statistics

Input Description
Known class safety signals with JAK
inhibitors but lack of finding of
thromboembolic events
Integrated Safety Analyses

These two inputs were processed via two activities. The first activity was disintegrative
as it intended to breakdown the findings from the integrated safety analyses and then validate the
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negative findings against the expected safety events from the clinical discipline’s experience. The
validation of results would normally be a routine activity, but in this case the initial evidence did
not warrant the additional interrogation of data and so the process was disintegrative in that the
team was attempting to break down the safety data and analyses into separate antecedent inputs
to search for the potential signal, as noted in this quote from the medical reviewer interview:
“So, we basically identified it because there was none. There wasn't a signal in the data,
but we were looking for it because of baricitinib.”
The second activity was more integrative and included discussions with the sponsor of the drug
product to align on the ultimate regulatory decision. It would take these discussions with the
sponsor to ultimately arrive at the output. These two process steps reflect a high degree of change
since even though the initial concrete input of negative findings of thromboembolic events led to
a labeling recommendation of the events based on the abstract input of the clinical discipline and
negotiations with the Sponsor. These process steps are described in the below table.
Table 19: RINVOQ Review Issue 5 Process Steps

Process
Step #
1
2

Process Description
Purposive
(Inputs involved)
Validation of the safety analyses to confirm Yes
no findings of the class safety signals
(1)
Discussion with the Sponsor to align on
No
class labeling for the product even though
there was a negative finding for TE events
(2)

Integrative
Nature
Disintegrative
Integrative

As mentioned above, these process activities led to the cross-disciplinary regulatory
decision to include class safety labeling for thromboembolic events and other known JAK
inhibitor class safety adverse events. As this output did not include the original safety analysis
input, only the new disintegrative perspective that was formed and the potential expected signal
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from the class (see below excerpt from the summary review), the comprehensiveness of the
integration is considered low.
“Given that two JAK inhibitor programs have identified thrombosis as a safety signal,
thrombosis is now considered a class safety issue and the upadacitinib product label will
include a Boxed Warning regarding VTE.” (FDA, 2019f)
This output is also considered to be localized as it was related only to the JAK inhibitor
class safety. Additional supporting data, including excerpts from the review documents and
quotes interviews can be found in the appendix 4.E.
Based on these data, the integration found in this review issue can be modelled as follows
in the below figure. As discussed above, it should be noted that in the below model process
activity 1 (P1) was disintegrative and would not normally be reflected as carrying the input
through to the output. But, due to the way Sankey models are developed and the requirement for
them to conserve all elements within the system, the model reflects P1 in this way.
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Figure 24: RINVOQ JAK Safety Review Issue Sankey Integration Model

Review Issue 6: Teratogenicity
The sixth and final review issue found in the RINVOQ multidisciplinary case was related
to the identification of embryofetal toxicity, and the strength of the signal in comparison to other
products in the class, as indicated in the following excerpt from the summary review:
“the embryo-fetal toxicity finding with upadacitinib is more concerning compared to
tofacitinib and baricitinib because of the relatively low exposure margins” (FDA, 2019f)
This issue involved three inputs from the pharmacology/toxicology discipline. While two of
these inputs were concrete findings from nonclinical studies, the third was abstract and was a
judgment by the reviewer that the signal was much more significant than that found in other JAK
inhibitor programs. These inputs were rather commensurable, all coming from the
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pharmacology/toxicology domain. The inputs from review issue 6 are further described in the
table below.
Table 20: RINVOQ Review Issue 6 Inputs

Input #
1
2
3

Discipline
Pharmacology/Toxicology
Pharmacology/Toxicology
Pharmacology/Toxicology

Input Description
Teratogenicity signal in rabbit study
Teratogenicity signal in rat study
Signal was considered more significant
than that found in other JAK inhibitor
programs

These three inputs were processed in two activities that incorporated all inputs. The first
was the discussion of the issue at multiple team meetings, which would be routine for such issues
in a multidisciplinary review approach, as noted by the pharmacology/toxicology reviewer
during their interview:
“we raised this pretty early on, I think, and discussed it at various meetings.”
These discussions were integrative in that the team validated the significance of the finding and
generated additional recommendations on how to proceed (i.e., consult the division of pediatric
and maternal health) and the final recommendation on regulatory action. The consult to the
division of pediatric and maternal health was considered combinatorial in that it led to an
independent assessment from the consult team member and the clinical discipline that
contributed to the output, as indicated by the following statement in the
pharmacology/toxicology review:
“An additional bullet statement regarding the potential for embryo-fetal toxicity with
upadacitinib was added to the Warnings and Precautions based on a consultation with
DPMH and discussions with the Clinical Team.” (FDA, 2019c)
These process steps are described in the table below.
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Table 21: RINVOQ Review Issue 6 Process Steps

Process
Step #
1

2

Process Description
(Inputs involved)
Discussed at several meetings, including
early safety scoping meeting and midcycle meeting
(1, 2, 3)
Consulted with Division of Pediatric and
Maternal Health, and Clinical
(1, 2, 3)

Purposive
Yes

Integrative
Nature
Integrative

No

Combinatorial

The discussions of the embryofetal toxicity signal led to a change of the inputs to the
concrete recommendation for labeling (output) that a Warning and Precaution to use the product
in pregnant and lactating women should be added. However, this output did include all inputs
identified so is considered comprehensive and cross-disciplinary even though it is still localized
to this specific safety issue, as indicated by the following statement in the
pharmacology/toxicology review:
“The review team agreed that the observed embryo-fetal toxicity data with upadacitinib
represented a significant safety concern that potentially warranted inclusion in the
Warnings and Precautions.” (FDA, 2019c)
Additional supporting data, including excerpts from the review documents and quotes interviews
can be found in the appendix 4.F.
Based on these data, the integration found in this review issue can be modelled as follows
in the below figure. The interesting dynamic on display in this model is between process activity
1 and 2. While process activity 1 was integrative, and including additional discipline perspectives
during the process activity, it appears similar to the combinator process activity 2 due to the way
inputs were characterized in this study based on how they originated.
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Figure 25: RINVOQ Teratogenicity Review Issue Sankey Integration Model

Description of overall integration in RINVOQ case
As described above and seen in the models of integration, the instances of integration
surrounding the six identified cross-disciplinary review issues were mostly cross-disciplinary
from the outset (i.e., at the inputs stage). Two review issues, review issue 4 and 6 began as
unidisciplinary issues, but over the course of the process of integration became crossdisciplinary. These review issues had on average two to three disciplines involved and as many
as six inputs contributing to the outputs. The average number of process steps or integrative
activities was two. The majority (15 of 17) of the inputs were concrete. Outputs were evenly
either concrete or abstract (3 and 3). The integrative nature of the process activities was mostly
combinatorial (6 of 13) and integrative (4 of 13), with the remaining either being disintegrative
(1) or not applicable since there was no change (2).
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TAUVID Case
Description of interdisciplinary case
The interdisciplinary case for this comparative case study was NDA 212123 for TAUVID
(flortaucipir F-18) for use with PET imaging of the brain to estimate the density and distribution
of aggregated tau neurofibril tangles (NFTs) in adult patients with cognitive impairment who are
being evaluated for Alzheimer’s disease (AD). The NDA was submitted by Avid
Pharmaceuticals, Inc. on September 30, 2019 and approved on May 28, 2020, via a priority
review timeline of 8 months. TAUVID (flortaucipir F-18) is a new molecular entity (NME), of
which the drug substance is flortaucipir F-19, a benzimidazole-pyrimidine derivative small
molecule labeled with fluorine 18 for imaging.
The NDA for TAUVID was reviewed in the Division of Medical Imaging and Radiation
Medicine. Like with the NDA review of RINVOQ, because TAUVID was an NME, the
signatory, for the application was from the division’s parent office, the Office of Specialty
Medicine. The review team for TAUVID was similarly made up of a regulatory project manager,
a clinical reviewer and team leader, a statistical reviewer and team leader, a clinical
pharmacology reviewer who was also acting as the clinical pharmacology team leader, a
nonclinical pharmacology/toxicology reviewer and team leader, and a dedicated quality team
with a drug substance reviewer and supervisor, a drug product reviewer and supervisor, and a
process/microbiology/facility reviewer and supervisor. This application lacked the additional
pharmacometrics and pharmacogenomics reviewers and team leaders, and biopharmaceutics
reviewer and supervisor. These differences are mostly due to the nature of the development
program, dosage and administration, and the information submitted in the application. For this
application, as with the RINVOQ application, the clinical team leader served as the cross-
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disciplinary team leader. Of this large review team, the following disciplines were represented in
the interviews: signatory, clinical, statistics, clinical pharmacology, regulatory project manager,
and nonclinical pharmacology/toxicology.
The TAUVID review team utilized a new approach to conducting its review of this
application, known as the interdisciplinary assessment of marketing applications. This review
approach is still new and little public documentation is available, however, it has been described
by FDA staff as a more interdisciplinary, issue-focused approach to conducting the review of a
new drug product application (Woodcock et al., 2020). This approach to the review is similar to
and builds on the traditional multidisciplinary review of a new drug application in that it involves
a review team of multiple disciplines working together, but in the interdisciplinary review
approach, the disciplines work more collaboratively from the outset to identify review issues and
resolve them as a team throughout the whole review process. As such, the review team works
collaboratively to document their assessments in a single review document, known as the
Integrated Review. The Integrated Review is to be completely drafted approximately one to two
months prior to the action but is finalized just prior to action. A diagram of this new process is
below.
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Figure 26: Integrated Review Process
(FDA, 2020b)

In this case, the Integrated Review was completed on May 27, 2020. The Integrated
Review document used in the document analysis is listed in the table below.
Table 22: TAUVID Review Document

Document
Integrated Review

Length in
pages
272

In the interdisciplinary approach, review teams follow the existing multidisciplinary
process and in addition also conduct a benefit-risk scoping meeting prior to filing, and then for
each review issue identified, conduct a joint assessment meeting, which is an issue focused
meeting including all team members relevant to the issue. Noteworthy of these new process
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activities, is that the signatory of the application is also included. Similar to the multidisciplinary
review approach, recommendations for final decision are made by the review team members to
the signatory at the wrap-up, but due to the early and more frequent involvement of the signatory
during the interdisciplinary review process, there is less likely to be misalignment.
Description of cross-disciplinary review issues identified
In contrast to the RINVOQ application review documents, and as noted above, only one
review document is generated by the review team. In addition, the integrated review is much
more focused on documenting the review issues identified over the course of the review. As a
result, the review issues were easily identified from the initial document analysis of the
integrated review. The six review issues identified in the TUAVID review were described
concisely in the introduction to the Interdisciplinary Assessment of the document and were listed
as follows:
“Issues Relevant to Evaluation of Benefit
The team identified the following issues relevant to the evaluation of benefit (see Section
6.4):
•

User Guide [for image interpretation] for Tauvid PET Image Display (see Section
6.4.1)

•

Limitations of Efficacy Evidence for

•

Lack of Substantial Evidence for

(see Section 6.4.2)
(see Section 6.4.3)

Issues Relevant to Evaluation of Risk and Risk Management
The team identified the following issues relevant to the evaluation of risk and risk
management (Section 7.7):
•

CTE Misdiagnosis (see Section 7.7.1)
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•

Effect of MAO Inhibitors on FTP Binding (see Section 7.7.2)

•

QT Interval Prolongation (see Section 7.7.3)” (FDA, 2020a)

Within the Integrated Review alone, these six review issues were mentioned, and coded,
extensively throughout the document, as illustrated in the following figure.

Figure 27: TAUVID Review Issue Mentions in the Integrated Review

These review issues were regularly mentioned in most interviews with the review team, further
strengthening the apparent focus in the review of the review issues. This is illustrated in the
following exploration of codes for the

issue across interviews.

133

Figure 28: TAUVID

Issue Across Objects

Review Issue 1: MAO Inhibitors
The first review issue identified in the TAUVID interdisciplinary case was related to the
effects of TAUVID off-target binding that was similar to other MAO inhibitors, and described as
follows in the Integrated Review:
“FTP binds to MAO-A, MAO-B, and tau-NFTs with low nanomolar affinities. This
binding of FTP to MAO-A and MAO-B could potentially affect the interpretation of FTP
PET images.” (FDA, 2020a)
This issue involved four inputs and three disciplines. All inputs were concrete, including data and
information from submitted literature and studies, except for one input which was abstract and
related to the clinical pharmacologist’s knowledge of the chemical structure of other compounds
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that bind MAO, as indicated by the following quote from the interview of the clinical
pharmacologist:
“Well, from the very beginning we noticed that the structure, the chemical structure of
[TAUVID] was slightly similar to some of the others of the compounds that bind to MAO
inhibitors bind to monoamine oxidase enzymes and the structurally similar to some of
those inhibitors. So, it was clear that there's a potential that the drug could inhibit.”
These inputs were relatively commensurable, but there was some conflict, as reflected in the
misalignment of potential significance between the abstract clinical pharmacology input and
other more concrete inputs related to this issue. The inputs are described in the table below.
Table 23: TAUVID Review Issue 1 Inputs

Input #
1

Discipline
Clinical Pharmacology

2
3

Clinical Pharmacology, Clinical, and
Pharmacology/Toxicology
Clinical Pharmacology and Clinical

4

Pharmacology/Toxicology

Input Description
Chemical structure of TAU similarity to
other compounds that bind MOA
inhibitors
Literature on MAO inhibitor binding
Applicant submitted clinical study
(unpublished but presented at a
scientific meeting) with 50 patients to
study MAO inhibitor effects on scans
Secondary Pharmacology Studies

These inputs were processed via four activities that involved a varying degree of
involvement from the inputs in each activity. Two of these process activities were purposive, or
expected, including an early discussion at a benefit-risk scoping meeting and then a later midcycle meeting discussion. The other two activities were more emergent and occurred because of
the need to discuss the issue with the Sponsor and within the team during collaborative writing of
the Integrated Review. Both the early scoping and collaborative writing discussions were
considered integrative. In the early scoping discussion, while one discipline, in this instance
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clinical pharmacology, brought up the issue, the decision to further analyze the issue was one
made by consensus. And the final collaborative writing appears to have driven further consensus
on the review issue and the final recommendation is team-based and cannot be identified as
being driven by any single review discipline in the integrated review. This may be a sign that
real, meaningful integration is occurring along the way. The mid-cycle discussion was
considered combinatorial as multiple disciplines summarized and presented their findings. The
shift to more integrative nature of the collaboration post mid-cycle discussion was indicated in
the pharmacology/toxicology reviewer interview, and can be seen in the following quote about
the writing process:
“Well, there was a lot of collaborative writing at later stages to try to document this both
in like relevance in the clinical, clin/pharm, and nonclinical sections.”
Lastly, the discussions with the sponsor were considered disintegrative in that the discussions
were intended to break down each of the contributing pieces of evidence (i.e., literature,
unpublished study, chemical structures) on this issue. In other words, the discussions were
focused entirely on the specific evidence or inputs rather than the significance of the issue. These
process steps are described in the table below.
Table 24: TAUVID Review Issue 1 Process Steps

Process
Step #
1

2

Process Description
Purposive
(Inputs involved)
Early discussions with the review team, led Yes
by Clinical Pharmacology, to scope out the
issue and agree on significance to the
review
(1, 2)
Mid-cycle team discussions to review team Yes
members’ conclusions on additionally
submitted data and literature
(3, 4)

Integrative
Nature
Integrative

Combinatorial
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3

4

Discussions between the review team and
the Sponsor on significance of the MAO
inhibitor similarity
(1, 2, 3, 4)
Collaborative writing and discussions on
how to label for this issue accurately
without over alarming clinicians
(1, 2, 3, 4)

No

Disintegrative

No

Integrative

There was a high degree of change seen in the processing of the inputs to the output, in
that the abstract perspective on how the chemical structure of TAU was transformed into a
meaningful review issue. With this said, the reviewers were careful about the output of the
integration and how this would be communicated, as indicated by the clinical pharmacology
reviewer in their interview:
“We didn't want to alarm people too much either because the issue is still being
researched and still not clear so more studies need to be conducted.”
This ultimately led to the concrete conclusion that there was a potential effect of MAO inhibitors
and this was described in section 12 of the labeling (output). This output was cross-disciplinary
and not overly comprehensive in that the final output in labeling did not fully include all inputs.
Because this review issue was also considered local and did not impact the overall benefit-risk
determination of the application. Additional supporting data, including excerpts from the review
documents and quotes from interviews can be found in the appendix 5.A.
Based on these data, the integration found in this review issue can be modelled as follows
in the below figure. Noteworthy in the below diagram is the similar representation of process
activity (P3) and process activity 4 (P4). While they appear similar due to their inclusion of all
four inputs, P3 was disintegrative in that the Sponsor’s perspective was divergent and the goal of
the activity was to convert as opposed to incorporate that perspective. The flow from P3 to the
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output would more appropriately be represented as fractured if not for the dynamics of Sankey
diagrams.

Figure 29: TAUVID MAO Inhibitors Review Issue Sankey Integration Model

Review Issue 2: User Guide
The second review issue in the TAUVID interdisciplinary case was related to the
accuracy and usability of the sponsor-submitted user guide for the interpretation of medical
imaging results following use of the drug. This issue was most simply described by the signatory
during their interview in the following quote:
“[The] issue, which was identified early on, was the user manual and the team leader who
still reads nuclear scans, the user guide. Because they use different platforms for this, to
be able to read them. There's different software out there that helps you read the digital
image, but you have to put settings into it to be able to read it correctly. They had labeling
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that sort of explained how to do it, and he couldn't understand how to do it, and he's a
very experienced nuclear medicine person. If he thought that he would have problems, he
knew that was going to be a problem if it was going to get approved.”
This review issue included three inputs from five disciplines, two of which were abstract and
based on expert perspective or knowledge. One discipline team member was from another center,
the Center for Devices and Radiologic Health (CDRH). One of the review issue’s inputs was the
proposed user guide itself, a concrete input. Commensurability was considered neither low nor
high, with only some conflict seen between the regulatory requirements (Input 3) with the other
inputs, in that the regulatory and policy input would have it (initially) that the review issue was
outside the purview of the review team. The inputs are further described in the table below.
Table 25: TAUVID Review Issue 2 Inputs

Input #
1
2
3

Discipline
Clinical
Clinical, Division of Medication
Errors Prevention, and CDRH
Regulatory and Policy

Input Description
Proposed User Guide
Expert perspective on usability
Regulatory requirements for User
Guides as labeling

These inputs were processed over a series of three activities, only one of which was
purposive or planned, which was the review of the proposed user guide by the clinician as this is
standard practice. Two of the process activities were integrative. In one activity multiple experts
had to share their experience and expert opinions regarding the usability of the user guides—this
was then integrated into a shared team view that the user guides were deficient. In the second,
multiple external stakeholders' perspectives were brought to bear. This process was nicely
described in the Integrated Review, excerpt below:
“In response, the Applicant contacted professional societies and also conducted a poll of
image readers/imaging sites that participated in the Tauvid efficacy studies to gain insight
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into which software platforms are commonly used for image review and analysis in a
clinical setting. Based on the survey, the Applicant determined that the most commonly
used image viewing software platforms in the US are MIM, GE, Siemens and Hermes.
Subsequently, the Applicant created and submitted step-by-step user guides for the MIM
and Siemens image viewing software platforms for review and comment on their
adequacy.” (FDA, 2020, p. 40)
These process steps are described in the table below.
Table 26: TAUVID Review Issue 2 Process Steps

Process
Step #
1

2

3

Process Description
(Inputs involved)
Identified very early by experienced
clinician (a practicing nuclear radiologist)
and shared with Sponsor
(1, 2)
Sponsor conducted multiple tests with
experts via professional societies with
revised user guides
(2)
Regulatory and policy issue with the use of
a user guide vs official instructions for use
required discussion with ORP and CDRH
(1, 2, 3)

Purposive
Yes

Integrative
Nature
Integrative

No

Integrative

No

Disintegrative

Over the course of the process activities, there was a medium level of change because of
the input from professional societies and the team, including colleagues from the Office of
Regulatory Policy (ORP) and the CDRH. The integration ultimately led to a cross-center, crossdisciplinary and concrete revision to the product’s labeling to reflect updated instructions for
image interpretation (output). This output was mostly comprehensive but not completely in that
it did not include or reflect the input related to the regulatory requirements. In the end, the
regulatory policy determination was that labeling did not need to include the User Guide,
however, it was referenced in labeling. This output is reflected in the Integrated Review:
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“The Applicant, in consultation with the Agency, added the following language in Section
2.4 (Image Display) of the PI: If additional guidance on image display is needed, refer to
the TAUVID User Guide for PET Image Display available by request from the
manufacturer.” (FDA, 2020a, p. 40)
This issue did have an impact on the overall benefit-risk determination in that image
interpretation is highly dependent on the user guide to avoid misinterpretation, but this issue was
localized to the user guide alone. Additional supporting data, including excerpts from the review
documents and quotes from interviews can be found in the appendix 4.B.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure below. Process activity 3 (P3), as discussed above, was considered disintegrative in
that the regulatory and policy disciplines sought to focus on the regulatory and legal bases for
requiring or regulating a “user guide”, which was considered beyond the otherwise regulatable
Instructions for Use. In the Sankey diagram below, P3 appears to consume half of the process
activity and contribute to half of the output. This is an interesting illustration in this model, but
potentially misleading in that P3 was disintegrative and as such likely does not contribute
significantly to the integrative output.
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Figure 30: TAUVID User Guide Review Issue Sankey Integration Model

Review Issue 3: QT Prolongation
The third review issue identified in the TAUVID interdisciplinary case was related to QT
interval prolongation. This issue was initially identified by the applicant in their application, as
noted in the Integrated Review:
“The Applicant reported small but statistically significant increases in QTcB and QTcF
intervals around 2 hours following IV administration of FTP when compared to baseline
predose measurements.” (FDA, 2020a, p. 21)
This issue involved two inputs, one abstract and one concrete, and four disciplines. The fourth
discipline is a self-described inter-discipline: “This issue was also reviewed by FDA’s QT
Interdisciplinary Review Team (QT-IRT)…” (FDA, 2020a, p. 22). Commensurability was high
between the two inputs given that the input, while of an abstract or cognitive nature, was from a
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discipline that is focused entirely on the subject matter of the concrete input. The inputs are
described in the table below.
Table 27: TAUVID Review Issue 3 Inputs

Input #
1
2

Discipline
Clinical Pharmacology, Statistics, and
Clinical
Inter-discipline of QT Team

Input Description
QT Signal reported by Sponsor
Expert input from the QT
Interdisciplinary Review Team

These inputs were processed via two purposive activities, consultative review from the
QT Interdisciplinary Team (QT-IRT) which was then combined with the inputs of the review
team, and a more integrative discussion with the entire review team. The QT-IRT is routinely
consulted when a QT signal is of interest and, as a safety issues, would be discussed at the
benefit-risk scoping meeting. The discussion was considered highly integrative by the clinical
pharmacology reviewer, as indicated in the following interview quote:
“So, again I want to emphasize it was a, a nice integration between clin pharm team, QTIRT and then discuss with the, the medical officer [medical reviewer], our medical team
leader and the division director and everybody chimed in and looked at the evidence.”
These process steps are described in the table below.
Table 28: TAUVID Review Issue 3 Process Steps

Process
Step #
1
2

Process Description
(Inputs involved)
QT Interdisciplinary Review Team was
consulted for input
(1, 2)
Discussed with clinical and clinical
pharmacology reviewers and signatory of
the review team
(1, 2)

Purposive
Yes

Integrative
Nature
Combinatorial

Yes

Integrative
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There was very little change seen in the integration process. While the QT signal was
found early because it was statistically significant, the output of the process was nothing more
than confirmation that the signal existed, and no regulatory action was taken. The review team
was not worried about the risk here, as indicated by the following comment made by the
signatory during their interview:
“[QT issue was pretty benign as well. There was something identified, but] Yeah, it was.
…I didn't think much of it.”
All inputs were incorporated making this a comprehensive instance of integration. It was
considered local in scale. Additional supporting data, including excerpts from the review
documents and quotes from interviews can be found in the appendix 5.C.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure below. What is most interesting about the model below is the comparison of the
disciplinary contributions to the input. As mentioned above, the QT interdisciplinary review
team, is a novel discipline dedicated entirely to the study of QT prolongation safety issues (Input
1).
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Figure 31: TAUVID QT Prolongation Review Issue Sankey Integration Model

Review Issue 4: CTE Misdiagnosis
The fourth review issue found in the TAUVID interdisciplinary case was related to the
potential to misdiagnose chronic traumatic encephalopathy (CTE), and was mentioned early in
the integrated review, in the benefit risk assessment: “There is a potential for inappropriate use of
Tauvid in patients with CTE and other non-AD tauopathies” (FDA, 2020a, p. 8). This issue
involved three inputs and two disciplines. Two of the inputs were concrete data sets and literature
articles. The other input was abstract and involved the clinical reviewer’s knowledge of how this
product might be used given its ability to detect similar tau pathologies. These inputs were from
similar sources and input types, so are considered commensurable. Descriptions of the inputs can
be found in the table below.
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Table 29: TAUVID Review Issue 4 Inputs

Input #
1
2
3

Discipline
Clinical
Pharmacology/Toxicology
Clinical and
Pharmacology/Toxicology

Input Description
Potential for off-label use
Nonclinical Data
Published Literature (Falcon et al 2018,
2019; Marquie et al 2019; Mantyh et al
2020)

These three inputs were processed through an unplanned assessment by the review team in an
emergent, integrative fashion that there was a lack of evidence to support the use of TAUVID for
CTE diagnosis, so labeling would be needed to mitigate the risk of off-label use. This is
reflective in the following excerpt from the Integrated Review:
“Potential off-label use of Tauvid in chronic traumatic encephalopathy (CTE) and other
tau-related neurodegenerative disorders is a concern because preliminary nonclinical and
clinical investigations suggest differences in tau conformation and distribution may limit
FTP binding in CTE.”
The process step is described further in the below table.
Table 30: TAUVID Review Issue 4 Process Step

Process
Step #
1

Process Description
(Inputs involved)
Team assessed that due to lack of evidence
for CTE diagnosis but the potential offlabel use, the labeling needs to address this
risk
(1, 2, 3)

Purposive
No

Integrative
Nature
Integrative

The team’s assessment led to the concrete, cross-disciplinary determination (output) that
a limitation of use and a Warning and Precaution was needed in labeling to prevent off-label use
of TAUVID for CTE. This output is further confirmed by the following statement during the
signatory interview:
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“The CTE misdiagnosis was really something that was based on what had been published
already in the literature. It turns out there's different isoforms of tau protein and this drug,
the one that is generally present in CTE is somewhat different from, in terms of the type,
than in Alzheimer's disease. Apparently, there was already evidence out there that this
drug may not be good in trying to use it in patients that are thought to have that diagnosis.
I don't recall that being as much of an issue, it came down more to a labeling issue.”
This output fully incorporated all inputs and therefore was comprehensive in its integration, but
of a local scale since the CTE claim was not a proposed indication for the product. Additional
supporting data, including excerpts from the review documents and quotes interviews can be
found in the appendix 5.D.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure, below.
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Figure 32: TAUVID CTE Misdiagnosis Review Issue Sankey Integration Model

Review Issue 5:
The fifth review issue in the TAUVID interdisciplinary case was related to the detection
of Tau pathologies and involved four inputs and three disciplines. This issue was rooted in

”
Three of the inputs for this issue were concrete in nature and included clinical studies, case
report forms, line listing data, literature, and the sponsor’s proposed labeling. The abstract input
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related to the clinical reviewer’s knowledge of the disease pathology was best described by the
signatory in their interview as follows:
“

.”
There was some conflict in the inputs because the sponsor’s proposal included broad labeling
claims for Tau pathology detection and the evidence seen in studies and literature, so
commensurability was low. The inputs are further described in the table, below.
Table 31: TAUVID Review Issue 5 Inputs

Input #
1

Discipline
Clinical, CDRH, and Statistics

2

Clinical

3
4

Clinical, CDRH, and Statistics
Clinical, CDRH, and Statistics

Input Description
Two phase 3 neuropathologic
correlation studies (A16 and FR01)
including study reports, case report
forms, and line item data
Understanding of disease pathology,
particularly earlier forms of disease
Published Literature (Hyman et al 2012)
Proposed labeling (Indication: to help
establish a diagnosis of AD)

These inputs were processed in three purposive activities that would be routine or
expected in the interdisciplinary review. The early scoping meeting and mid-cycle meeting
discussions were considered integrative process activities in that multiple disciplines not only
shared findings from their assessments but also focused their discussion on the significance of
the issue(s) and impact on the potential regulatory action. The final output of these discussions
reflects the integrated team position. The other two activities were combinatorial in that
additional perspectives on the inputs were provided by colleagues in CDRH or by the Applicant
and considered, as they routinely would be, but these were not integrated with the other members
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of the team. This is indicative in the following comment made during the division director
interview:
“So, we negotiated with the company and they agreed to basically claims indication
statement that was really consistent with the evidence that we had. And so, it was pretty
much a routine kind of an approach.”
These process steps are described in the table, below.
Table 32: TAUVID Review Issue 5 Process Steps

Process
Step #
1
2
3

Process Description
(Inputs involved)
Discussed at early scoping meeting and
mid-cycle meeting with review team
(1, 2, 4)
CDRH was consulted to assess the devices
used in the clinical studies
(1, 2)
Discussed with Sponsor during
development and early in the review cycle
(2, 3, 4)

Purposive
Yes

Integrative
Nature
Integrative

Yes

Combinatorial

Yes

Combinatorial

The integration process led the team to the cross-disciplinary conclusion that while tau
neurofibrillary tangles (NFTs) associated with AD could be identified,
This decision was described in the Integrated
Review as follows:
“The team concluded that the results of the submitted phase 3 studies support the efficacy
of TAUVID to estimate the density and distribution of aggregated Tau-NFTs in the
indicated patient population (efficacy for tau pathology detection).” (FDA, 2020a, p. 39)
This abstract output was coupled with the concrete cross-disciplinary recommendation to revise
labeling to reflect an Indication of detection of NFT beta-3 (B3) pathology (i.e., late stage AD
pathology) and a Warning and Precaution was added to the labeling to warn clinicians about the
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potential to misinterpret a negative finding. Concrete evidence was assessed by the team and the
applicant's proposal for indication and labeling was changed to reflect
, representing a high
degree of change. These two outputs factored in all inputs and had a global impact on the review
team’s determination of the marketing application’s overall benefit risk profile. Additional
supporting data, including excerpts from the review documents and quotes from interviews can
be found in the appendix 5.E.
Based on these data, the integration found in this review issue can be modelled as follows
in the figure, below. Two details stand out from the below model of integration. First, that
Clinical contributed to all inputs, but that it appears these contributions were not equal (i.e., see
differences in the flows to input 2 and inputs 1, 3, and 4). This likely reflects the degree of
influence on the input and subsequent process activities that incorporated the inputs. Second,
there is a substantial crossing of flows in both the disciplinary contributions to inputs and in the
incorporation of inputs in the process activities, which may indicate a high degree of activity in
the integration process for this review issue.
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Figure 33: TAUVID

Review Issue Sankey Integration Model

Review Issue 6:
The final review issue found in the TAUVID interdisciplinary case was the Sponsor’s
. The division director
aptly described this issue as follows in their interview:
“the second component of the clinical development was going to be an assessment
. The
study did not succeed”.
This review issue included four inputs and four disciplines. Three of the inputs were concrete in
nature and include clinical studies, data, analyses, and additional information submitted by the
Sponsor during the review. There were pre-submission discussions with the Sponsor related to
this issue which influenced the integration process by way of influencing early review team
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perspectives. The Regulatory Project Manager (RPM) really stressed how early this issue was
known to the team, and can be seen in the following quote from the RPM interview:
“Because of the pre-NDA and the prior meetings, one of the biggest subjects that was
constantly being brought up is how they had difficulty in getting their objective. Their
objective was being able to

.”

There was little conflict between the inputs and therefore considered highly commensurable.
These inputs are further described in the table, below.
Table 33: TAUVID Review Issue 6 Inputs

Input #
1

Discipline
Clinical, CDRH, and Statistics

2
3
4

Statistics
Regulatory, Clinical, and Statistics
Clinical and Statistics

Input Description
Two phase 3 studies (A05C and PX01),
including study reports, case report
forms, and line item data
Sensitivity Analyses
Pre-submission meeting discussions
Additional data and information
requested by the review team

These inputs were processed in three purposive or expected activities ranging from
disintegrative, to combinatorial, to integrative. For the combinatorial process activity, the
combination occurs by the addition of the consult to CDRH (also seen in Review Issue 5) to
assess devices used in the studies and their subsequent findings to the rest of the team’s
assessment. For the disintegrative activity, based on interviews, the applicant attempted to
differentiate between their interpretation of the efficacy findings from the studies and that of the
review team, representing a disintegrative change. Such negotiations are anticipated to occur
when there is a difference of opinion between the FDA and the Sponsor. This is illustrated in
quote from the signatory interview, below.
“[the Applicant]

153

”
Similar to process step 1 of review issue 5, the team held multiple integrative discussions to align
their views on the path forward on this issue. These discussions involved primarily clinical and
statistics. Further information on the process steps can be found in the table below.
Table 34: TAUVID Review Issue 5 Process Steps

Process
Step #
1

2
3

Process Description
(Inputs involved)
Multiple review team discussions primarily
between clinical and statistics, led by
clinical
(1, 2, 3)
CDRH was consulted to assess the devices
used in the clinical studies
(1)
Review team held negotiations with the
Applicant

Purposive
Yes

Integrative
Nature
Integrative

Yes

Combinatorial

Yes

Disintegrative

(1, 3, 4)
The resultant output of the integration process for review issue 6 was twofold with the
abstract recommendation from the review team that an

This was explicitly stated in the Integrated Review in the
conclusions section of the benefit risk assessment:
“
” (FDA, 2020a, p. 9).
There was a low degree of change in the integration process of the inputs for review issue 6, with
the output being somewhat expected and reflected all inputs, making the integration
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comprehensive. This was also an issue of global scale due to the impact on the overall benefitrisk determination. Additional supporting data, including excerpts from the review documents
and quotes from interviews can be found in the appendix 5.F.
Based on these data, the integration found in this review issue can be modelled as follows
in the below figure. While this model is similar to the model of review issue 5, it is worth
mentioning that process activity 3 (P3) was disintegrative and if the Sankey diagram could
reflect the lack of conservation of inputs’ contributions to this process activity and subsequent
output then the model might look much more different for review issue 6.

Figure 34: TAUVID

Review Issue Sankey Integration Model

Description of overall integration in TAUVID case
As described above and seen in the models of integration, the instances of integration
surrounding the six identified cross-disciplinary review issues were cross-disciplinary from the
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outset (i.e., at the inputs stage). Review issues from the TAUVID case had on average three to
four disciplines involved and as many as four inputs contributing to the outputs. The average
number of process steps or integrative activities was three. The majority (14 of 20) of the inputs
were concrete. Outputs were mostly concrete (6 of 8). The integrative nature of the process
activities was mostly integrative (8 of 16) and combinatorial (5 of 16), with the remaining being
disintegrative (3).
Differences between Cases and Integration
Key differences between cases
Cross-disciplinary integration in FDA new drug product review teams occurs in response
to the review issues or problems that the teams must tackle during their reviews. Therefore, the
integration seen is directly related to the uniqueness of each review issue (micro level), the team
that tackles it (macro level), and the context of the application in which the issue is found (meso
level). As such these micro, macro, and meso level factors and the differences between and
among them are important to consider.
At the meso or application level, both applications were for new molecular entities. These
were new products that had not been reviewed by the FDA before and therefore would require a
comprehensive degree of research and development to understand the full safety and
effectiveness aspects of each product to support an initial market registration. This is important
because the comprehensiveness of the research and development program translates to the
comprehensiveness of the data package submitted to the FDA new drug product review team.
These applications did differ substantially in the therapeutic areas of interest, one being for
rheumatoid arthritis and the other for imaging in Alzheimer’s disease, and in terms of product
attributes (i.e., a monoclonal antibody and the other a small molecule delivered in a micro-dose).
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In addition, the data package submitted was quite difference in that the RINVOQ product
included five well-controlled and adequately powered trials. The TAUVID application included
several studies, but none were randomized controlled trials due to the nature of the product and
disease. In addition, the TAUVID application included, during the review, several reports from
additional published and unpublished studies.
At the macro or team level, both applications were managed and signed off by a review
team that was overseen by an OND office director due to the applications each being submitted
for an NME. However, because the RINVOQ review utilized the traditional multidisciplinary
approach to marketing application reviews the office director may not have been involved until
late in the review; whereas with the TAUVID interdisciplinary review the office director would
have been involved early and often, beginning with scoping meetings with the review team. At
the next level of leadership for the team, both teams were managed by a cross-disciplinary team
leader from the clinical discipline. The cross-disciplinary team leader (CDTL) is responsible for
integrating the various disciplines viewpoints and final recommendation into a comprehensive
benefit-risk determination and recommendation to the signatory for regulatory action. In the case
of the interdisciplinary review the CDTL is also responsible for guiding the team through the
collaborative writing process. In the multidisciplinary review, the CDTL may be involved in the
discipline-specific review document writing but only routinely for the clinical discipline (or the
discipline they represent).
Both teams were similar in make up with clinical, pharmacology/toxicology, clinical
pharmacology, statistics, and quality disciplines participating. But, the RINVOQ application had
a much larger team involved from the clinical pharmacology and quality perspective, with
multiple sub-disciplines being integrated within these two disciplines, such as pharmacometrics,
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pharmacogenomics, biopharmaceutics, and microbiology. However, on the TAUVID application,
additional experts outside of the routine new drugs disciplines were required to assess review
issues, such as regulatory policy experts and colleagues from the Center for Devices and
Radiologic Health. In the TAUVID review, it is also noteworthy that the Regulatory Project
Manager played a more important role in the writing sections of the integrated review.
In addition, there are several planned or purposive process activities in the
interdisciplinary review case that likely had an impact on integration. For example, in the
TAUVID interdisciplinary case, a benefit risk scoping meeting took place. This meeting occurs
early in the review and includes all members of the review team and the signatory, with the focus
being on identifying and confirming any review issues that need to be reviewed collaboratively
by the review team. As seen in the TAUVID case, multiple review issues included inputs that
originated from these discussions, including more abstract inputs.
At the micro or review issues level, the review issues were dissimilar between cases as
would be expected, with the exception that the issues were all related to either the potential
benefits or risks and the benefit-risk assessment associated with use of the new drug product.
Review issues are emergent and highly dependent on the deficiencies seen in the development
program that informed the marketing application. In the RINVOQ multidisciplinary case, the
review issues were specific to manufacturing or formulation changes and safety or toxicity
signals. The TAUVID interdisciplinary case illustrated a few similar safety signal issues but also
introduced more complex efficacy issues and issues related to treating physician’s and
radiologist’s use of labeling for the safe and effective use of the product.
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Key differences in Integration
The next section walks through the key differences in the integration seen in the
RINVOQ and TAUVID review cases using the O’Rourke et al cross-disciplinary integration
framework, or IPO model, as a tool for making analytical comparisons.
Inputs
The RINVOQ multidisciplinary case included a total of 17 inputs across six review issues
with a mean and median number of inputs per review issue of three and three, respectively.
Inputs per RINVOQ review issue were unidisciplinary 33% (2/6) of the time. For the 67% of
review issues that began cross-disciplinary, the mean and median number of disciplines
contributing to inputs was four and two, respectively. All review issues, including those that
began as unidisciplinary became cross-disciplinary through process. The vast majority of
RINVOQ review issues included concrete inputs 88% (15/17). In those instances of integration
that included an abstract input, it was a lone input.
The TAUVID interdisciplinary case included a total of 20 inputs across six review
issues, with a mean and median number of inputs per review issue of three and four, respectively.
Inputs were cross-disciplinary 100% of the time in the TAUVID case, with the mean and median
number of disciplines contributing to inputs being four and four, respectively. 70% (14/20) of the
TAUVID inputs were concrete and all instances of integration (i.e., review issues) included an
abstract input. As noted above, the addition of the benefit risk scoping meeting in the
interdisciplinary review approach may offer additional opportunities for disciplines of the review
team to offer their subject matter expertise (an abstract input) to the discussion of review issues.
As can be seen in the table below, the TAUVID interdisciplinary case involved a larger
number of inputs than the RINVOQ multidisciplinary case, but the mean and median number of
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inputs per issue was similar. There is a significant increase in the number of abstract inputs in the
TAUVID interdisciplinary case. This may reflect a more interdisciplinary process where experts
are communicating earlier and with more abstract contributions to the integration. In addition,
the median number of disciplines that contributed to inputs in the instances of integration for the
TAUVID interdisciplinary case was substantially higher, double, that of the RINVOQ
multidisciplinary case. This may reflect that more discipline expertise is being brought to bear
for review issues through more deliberate collaboration (i.e., review team discussions,
collaborative writing). That the RINVOQ multidisciplinary case included more than one instance
of integration around a review issue where the issue began as unidisciplinary is also an
interesting difference and this may finding reflect a key temporal difference in review process
between the two cases, where earlier interdisciplinary interactions in the interdisciplinary review
case avoid late review cycle collaboration and integration.
Table 35: Comparison of Inputs

Variable

Number of Inputs
Number of Inputs per Issue
Number of Abstract Inputs
Number of Concrete Inputs
Number of Disciplines Contributing
Degree of Discipline Involvement by
Input Contributions

RINVOQ

17
Mean: 3
Median: 3
2 (12%)
15 (88%)
Mean: 4
Median: 2
Clin Pharm (9)
Clinical (4)
Pharm/Tox (4)
Statistics (3)
Biopharm (3)
Chemistry (1)

TAUVID

20
Mean: 3
Median: 4
6 (30%)
14 (70%)
Mean: 4
Median: 4
Clinical (14)
Statistics (8)
CDRH (5)
Clin Pharm (4)
Pharm/Tox (4)
Regulatory (2)
DMEPA (1)
Policy (1)
QT IRT (1)
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Process
The RINVOQ multidisciplinary case included a total of 13 process activities across its six
review issues or instances of integration. The mean and median number of process activities per
review issue was two and two, respectively. In the RIVNOQ case, the abstract inputs were
involved in all review issue process activities. In addition, in the RINVOQ case the inputs were
shared across multiple process activities in 50% (3/6) of the review issues or instances of
integration, with 54% (7/13) of the total process activities including multiple inputs. Eight of the
process activities included cross-disciplinary inputs. The majority (5/6) of review issues in the
RINVOQ case contained purposive or deliberate and planned process activities, with 61% (8/13)
of the process activities being purposive. Of these process activities, a small majority were
combinatorial (6/13).
The TAUVID interdisciplinary case included a total of 16 process activities across its 6
review issues or instances of integration. Of these 16 process activities, the mean and median
number of process activities per review issue was 3 and 3, respectively. In the TAUVID case, the
abstract inputs were involved in all process steps only 66% (4/6) of the time. Inputs were shared
across multiple process activities in the majority (4/6) of review issues or instances of
integration, with 14 of the 16 process activities including multiple inputs. All 16 process
activities included cross-disciplinary inputs. The majority (5/6) of review issues in the TAUVID
case contained purposive or planned and deliberate process activities, with 69% (11/16) of the
process activities being purposive. The majority (8/16) of the process activities were integrative
in the TAUVID case.
As can be seen in the table below, the TAUVID interdisciplinary case involved a greater
number of process activities in total and per review issue. There is a dramatic increase in the
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number of process activities that involved multiple inputs and multiple disciplines, which again
hints at the increase in collaboration in the interdisciplinary review approach of the integrated
review. This also suggests a greater degree of interdisciplinarity in the integration process. There
was also a much larger – double, in fact – number of integrative process activities in the
TAUVID interdisciplinary case than in the RINVOQ multidisciplinary case.
Table 36: Comparison of Outputs

Variable

Number of Process Activities
Number of Process Activities per
Review Issue
Multi-input Process Activities
Cross-disciplinary Process Activities
Purposive Process Activities
Combinatorial Process Activities
Integrative Process Activities
Disintegrative Process Activities
Process Activities with no change

RINVOQ
13
Mean: 2
Median: 2
7 (54%)
8 (62%)
8 (62%)
6 (46%)
4 (31%)
1 (8%)
2*

* Represents 13% of the process activities and were not assessable for integrative nature

TAUVID
16
Mean: 3
Median: 3
14 (88%)
16 (100%)
11 (69%)
5 (31%)
8 (50%)
3 (19%)
0

Outputs
In the RINVOQ multidisciplinary case, six outputs—three abstract and three concrete—
were observed. And, each review issues or instance of integration terminated in a single output.
In the TAUVID interdisciplinary case, eight outputs were observed—six concrete and two
abstract. And, in two separate instances of integration, or review issues, in the TAUVID case
there were 2 outputs, which was an interesting difference between the TAUVID case and the
RINVOQ case. This may suggest that in the TAUVID case, the review team was more efficient
and could create additional outputs. However, this is also more likely to represent the nature of
the decisions that were made and the necessary companion regulatory actions.
Integration Parameters
At the instance or review issue level, as mentioned earlier, several parameters exist in the
O’Rourke et al framework for cross-disciplinary integration that allow the integration’s context
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to be assessed. In the RINVOQ case, inputs in four of the cases were highly commensurable
compared to three of the cases in the TAUVID case. In the RINVOQ case, the vast majority (5/6)
of review issues were local in scale compared to only half of the issues (3/6) in the TAUVID
case. The majority of review issues in both cases experienced integration that was
comprehensive.
Table 37: Comparison of Integration Parameters

RINVOQ Review
Issue 1
RINVOQ Review
Issue 2
RINVOQ Review
Issue 3
RINVOQ Review
Issue 4
RINVOQ Review
Issue 5
RINVOQ Review
Issue 6
TAUVID Review
Issue 1
TAUVID Review
Issue 2
TAUVID Review
Issue 3
TAUVID Review
Issue 4
TAUVID Review
Issue 5
TAUVID Review
Issue 6

Commensurability
High

Scale
Global

Comprehensiveness
High

High

Local

High

NA

Local

High

High

Local

High

Low

Local

High

High

Local

High

Medium

Local

Low

Medium

Medium

Medium

High

Local

High

High

Local

High

Low

Global

High

High

Global

High

Findings
As noted above, there were key differences between the integration seen in the crossdisciplinary review issues from the RINVOQ and TAUVID case studies, but more importantly,
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there was integration seen in both cases. The similarities related to the integration, except for one
review issue in the RINVOQ case (RINVOQ review issue 3), all instances of integration
experienced some form of integration in all process activities suggesting that both cases are
collaborative and seek integration. This finding is also supported by a similar percentage of
process/changes that were found to be purposive or planned. Lastly, that review issues across
both cases were mostly found to be comprehensive suggests the integration is occurring
effectively. While these two cases may not be generalizable to all multidisciplinary and
interdisciplinary FDA new drug product reviews, this finding of widespread integration in
process activities suggests that integration is an expected activity in all new drug reviews and not
a unique feature of either case or approach.
While integration appears common to both cases, the degree of cross-disciplinary
integration and the nature of integration (i.e., combinatorial, integrative) appears more
integrative in the TAUVID interdisciplinary case. This is reflected in the greater number of
disciplines observed to contribute to each review issue and the greater number of crossdisciplinary and integrative process activities in the TAUVID case. This can be seen visually in
the Sankey diagrams of the review issues where clearly there are more crossing of flows in a
greater number of the diagrams, with three instances in the RINVOQ case and five instances in
the TAUVID case. This is even more interesting considering the larger number of review team
members participating in the RINVOQ review compared to the TAUVID review. It is noteworthy
that with a smaller team, there was greater cross-disciplinary integration observable in the
TAUVID case.
In addition, a few key findings related to differences in the parameters of integration were
noted. First, there was a slight increase in conflict seen in the TAUVID review issues as seen in
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less commensurability. Secondly, there was also a slight increase in the global nature of the
review issues and the integration, suggesting the review issues were more impactful on the
overall new drug product application review in the TAUVID case. These two parameters,
however, are expected to shed light on the context of the integration more than the integration
itself. In other words, these two parameters of commensurability and scale reflect the nature of
the review issues more than the specific integration. Nevertheless, these two parameters are
helpful to understanding the integration and some differences between these two cases.
With regards to context, there are several key differences between the applications or
cases that may have impacted the integration and should be noted. The RINVOQ application was
submitted by a large and highly experienced pharmaceutical company, AbbVie, Inc, with gross
earnings of $33.3 billion in 2019 (ABBV | AbbVie Inc. Annual Income Statement | MarketWatch,
n.d.). Whereas, Avid Pharmaceutical, Inc. reported gross earnings of $59.7 million in fiscal year
2020 (CDMO | Avid Bioservices Inc. Profile | MarketWatch, n.d.). This is an order of magnitude
in difference. It might be expected that the experience of the Sponsor can have a large impact on
the quality of both the drug development program and the corresponding application that is
submitted to the FDA.
It may have also been the case that the Sponsor of the RINVOQ application, through their
experience worked out most of the challenging issues that could have impacted benefits and risks
during development and as such those issues did not emerge over the course of the FDA’s review.
Even the review issue associated with the doses of 30 mg and 15 mg appear to have been well
worked out by the Sponsor and in fact the Sponsor did not even propose the 30 mg in their
labeling. As one RINVOQ team member remarked, “this was a very clean application”.
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Another key difference between the cases was in the new drug products reviewed. While
both products are generally expected to have a minimal risk profile due to their nature (i.e., a
monoclonal antibody and a micro-dosed, radio labeled small molecule), the chemistry and
manufacturing sections of the marketing applications are quite different. Monoclonal antibodies,
like RINVOQ, are biologically synthesized in living cells whereas small molecules, like
TAUVID, are chemically synthesized. This mostly translates to the complexity of the quality
review issues seen, such as the formulation changes in the RINVOQ case, but could also impact
safety as noted in this review with the additional need to assess minor but unexpected safety
signals for such a micro-dose product, such as the QT signal for TAUVID, or known class safety
signals for RINVOQ given the proposed chronic administration of the product. Given that the
integration was evaluated in these cases by assessing the emergent review issues, much of the
interpretation of integration from this comparative case study may be dependent on some of
these specifics of the product or application that drove the review issues. This makes it
challenging to fully extrapolate these findings to all multidisciplinary and interdisciplinary
reviews as the review issues will be quite unique and may vary by nature of application, Sponsor,
or product. Additional cases may need to be evaluated using this model to establish replicability
and validity for more rigorous evaluations.
It is also worth mentioning the importance of differences in review process, see figure 26,
and in the writing of the review document. As discussed earlier, in the interdisciplinary review
there were earlier and more frequent planned review team meetings and involvement from the
signatory or decision-maker for the application. These new meetings were seen in the data and
appeared to contribute to additional inputs and to the integrative of process activities. In addition,
as figure 35 below illustrates, the shift to a more collaborative document is likely to promote
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greater integration due to the requirement to write collaboratively and speak with a single, issue
focused voice. In previous forms of reviews, such as the traditional review or the Unireview,
disciplines still focused on their separate documents or sections of a review document.

Figure 35: Shift in Review Documentation
(FDA, 2020b)

The final interesting finding worth noting is related to the greater clarity of integration
found in the documentation for integrated review for the TAUVID review compared to the
multiple reviews for the RINVOQ case and the ease of navigating the documentation. A much
larger quantity of information was analyzed in the RINVOQ case (736 pages) compared to the
TAVUID case (272 pages). In addition, it was more difficult to identify the review issues in the
RINVOQ case until the summary review was analyzed. In contrast, the TAUVID integrated
review had a heightened focus on review issues in its documentation and even called them out in
the executive summary and regularly referred to them in the interdisciplinary assessment section
of the review document. As a result, more reliance on interviews in the RINVOQ case was
needed to supplement the review documents and help home in on the key review issues.
However, while it was easy to identify the review issues in the TAUVID documentation it
may make identifying conflict between disciplines in the documentation more challenging. For
example, even though there was bit more conflict/scientific disagreement in review issues seen in
the TAUVID case, this lower commensurability was not necessarily seen in the documentation. It
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was found through interviews with team members. It is not clear if this is case specific or related
to the approach to the review (i.e., multidisciplinary, or interdisciplinary) or related to other
factors. It is possible that the earlier and increased focus on collaboration shifted the conflicts to
earlier in the review process activities and as such at the time of documentation these issues were
resolved. If that is the case, FDA may need to consider increased awareness of the importance of
contemporaneous documentation of review issues earlier in the review cycle, particularly when
there is conflict within the review team.
To conclude, these findings support the assertion that collaborative cross-disciplinary
integration is present in both the RINVOQ multidisciplinary case and the TAUVID
interdisciplinary case, as illustrated by the presence of integrative process activities,
multidisciplinary inputs. Furthermore, the observed collaboration and integration was more
integrative and cross-disciplinary in the process activities in the TAUVID interdisciplinary case.
This can be visually observed by placing the most integrative and cross-disciplinary review issue
from the RINVOQ case side-by-side with an input and output-matched TAUVID review issue
below. The process for the TAUVID review issue is visibly more active, with more flows and
more crosses, reflecting greater cross-disciplinary collaboration in the process activities.
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Figure 36: Side-by-Side Integration Comparison

With the finding that collaborative cross-disciplinary integration was found in both the
multidisciplinary and interdisciplinary FDA new drug product review cases in this study, but that
it is more collaborative in the interdisciplinary review, FDA should feel confident that its new
approach is operating as intended and headed in the desired direction. FDA might consider
evaluating integration with this IPO framework in additional multidisciplinary and
interdisciplinary reviews to understand validity of these findings and guide its further
implementation. For the Science of Team Science practitioners, the IPO framework and approach
used in this study should be used to further characterize the integration seen in other
collaborative cross-disciplinary ventures to promote both generalizability and additional
sensitivity to evaluating integration. In time, building a repository of instances of integration
evaluated using this approach could inform future research.
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Chapter 5
Introduction
Cross-disciplinary integration is a key feature of interdisciplinary research and the
collaborative form is often a desired outcome of Team Science (Bammer, 2013; Klein, 2012;
O’Rourke et al., 2013). In 2019, the FDA sought to increase integration in its new drug product
marketing application reviews with the implementation of the new interdisciplinary assessment
process and integrated review document (Woodcock et al., 2020). The FDA’s intention was to
support integration more collaboratively and early on to avoid the “last minute”, often
individually led integration of discipline reviews common in the traditional multidisciplinary
approach.
However, FDA lacked an approach to evaluate integration and would be unable to
evaluate the implementation of its new approach. The Science-of-Team-Science (SciTS) has
similarly sought to evaluate integration in Team Science, but many of those efforts have often
used too contextually specific approaches or sought to mostly evaluate the outputs of crossdisciplinary research and its antecedents. And so, a more objective, flexible, and process-focused
method for evaluating integration was developed based off of O’Rourke et al.’s crossdisciplinary integration framework and applied in this research study (O’Rourke et al., 2016).
This study deployed a phenomenological descriptive comparative case study approach to
identify and characterize the nature of the collaborative integration occurring in FDA review
teams for two new drug product application using two different forms of cross-disciplinary
research. As Julie Thompson Klein articulated in her 2014 discussion of interdisciplinarity, this
integration increases across the continuum of cross-disciplinary research from unidisciplinary to
transdisciplinary and is characterized heuristically by different forms of integration (Thompson
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Klein, 2014). For this reason, integration in a multidisciplinary and interdisciplinary case is
expected but should be different.
The O’Rourke et al. framework and associated model (i.e., Inputs > Process > Outputs)
for integration was adapted for the FDA context to both characterize integration found in key
review issues in the two cases and facilitate analytical comparisons. Contextual adaptation came
through the coupling of the IPO model with the FDA’s benefit-risk framework for determining
that a new drug product was approvable. The two research questions for this study were:
1. What are examples of integration in a “multidisciplinary review” and an “integrated
review” of an FDA new drug product?
2. What are the specific differences in integration between a “multidisciplinary review” and
an “integrated review” of an FDA new drug product?
These research questions were explored via a document analysis and semi-structured
interviews. Following a validation of data collection using member checking with participants,
data was organized using the cross-disciplinary integration framework, to enable granular
comparative analyses, and then modelled as both logical models and Sankey models. This
approach to analyzing integration was found to be effective and practical. As noted above,
integration was expected in both cases since the approaches that the two teams utilized were
cross-disciplinary. This was indeed confirmed, and the study also found that the approach to
evaluating integration was sensitive enough to enable comparisons of the integration between
both the instances of integration with each case and between the two cases overall. And it was
found that the interdisciplinary review, at least in this case, and in comparison to the
multidisciplinary review in this case, was more integrative.
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Considering these findings, FDA can feel confident that its traditional multidisciplinary
and the new interdisciplinary approaches to conducting team-based marketing application
reviews are both integrative and that the new approach is leading to the desired outcome of
increased integration. In addition, FDA and Team Science may have now have an objective
method for evaluating collaborative cross-disciplinary integration. It will be important to
continue to apply this evaluation method to additional FDA and non-FDA teams to continue to
refine and validate it. The sections that follow review the findings from the study, discuss
implications for practice, both in the field of SciTS and in FDA where great value is expected,
and finally discuss implications for future research.

Summary of Findings
As mentioned above, this study successfully identified and characterized multiple
instances of integration in two cases of new drug product application reviews, the RINVOQ
multidisciplinary review and the TAUVID interdisciplinary review. This finding confirms that
integration is indeed occurring in FDA new drug product reviews. In addition, the approach to
characterizing the collaborative cross-disciplinary integration using the adapted O’Rourke et al.
cross-disciplinary integration framework enabled enable objective, analytical comparisons
between the two cases.
That integration occured in both cases of FDA new drug product application review
approaches is noteworthy because it confirms that FDA review teams are effectively integrating.
Second, that the nature of the integration was collaborative and cross-disciplinary is also
important in that it demonstrates FDA is truly engaged in Team Science.
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In the RINVOQ case, integration was found in six review issues and observed as mostly
cross-disciplinary from the beginning of the process. There were two instances of integration that
originated from a single discipline, but over the course of the integration became crossdisciplinary through the collaborative involvement of other disciplines in process activities.
Most process activities for RINVOQ were characterized as combinatorial, which would align
with a multidisciplinary form of collaboration (Thompson Klein, 2014), an expected finding.
In the TAUVID case, integration was cross-disciplinary in all six identified review issues
and comprehensively cross-disciplinary (i.e., from beginning to end). The TAUVID integration
process activities were found to be mostly integrative, which aligns with an interdisciplinary
form of collaboration, another expected finding.
Both of these findings confirm that per the framework from O’Rourke et al. for
collaborative cross-disciplinary integration and the continuum of integration heuristic from Julie
Thompson Klein, that FDA new drug product review teams using either a multidisciplinary or
interdisciplinary approach operate in collaborative cross-disciplinary ways to effectively
integrate their insights and perspectives related to review issues that impact the benefit-risk
determination (O’Rourke et al., 2016; Thompson Klein, 2014).
Numerous comparisons of the two cases were enabled by use of the cross-disciplinary
integration framework and Sankey modelling approach. There was a relatively similar number of
inputs in the multidisciplinary and interdisciplinary cases (17 and 20, respectively) across all
review issues. One difference in inputs between the two cases was that of the input types,
abstract and concrete, with three times as many inputs being abstract in the TAUVID
interdisciplinary case. Given the operational definitions used in this study for concrete and
abstract, this would suggest a greater cognitive dimension to the interdisciplinary case, which
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would require greater communication and collaboration in processing (Bergmann., 2012;
Frodeman et al., 2017). While the number of process activities overall and per issue was only
slightly more in the TAUVID case, the process activities were otherwise quite different. In the
TUAVID case, process activities involved multiple disciplines and multiple inputs twice as often
as in the RINVOQ case. These two differences resulted in starkly different integration “flows”
when modelled in Sankey diagrams, as seen in the figure below, which illustrates a comparison
of integration in two other review issues from the two cases.

Figure 37:Side-by-Side Integration Comparison

In addition to the quite “visible” differences in process activities, differences in the
outputs of the integration in the two cases were also found. These differences related to the
increased occurrence of multiple outputs for review issues. One instance is illustrated in the
figure above. And outputs tended to be more concrete in the TAUVID case, with six of the eight
outputs in TAUVID being concrete and only three of the six outputs in the RINVOQ case being
concrete. Given the nature of FDA recommendations and actions, these outputs might be more
driven by the direction of the FDA action (e.g., an approval or a recommendation not to approve)
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rather than some finding related to integration. However, it might be the case that simply the
integration is more efficient in the interdisciplinary case and so more concrete outputs and
multiple outputs are created. Finally, there were some interesting findings related to the
integration parameters (i.e., commensurability, scale, and comprehensiveness). There were slight
increases in the number of global review issues and the conflict seen in the TAUVID case. As
noted in Chapter 4, this reflects the context of the integration (i.e., the review issues), but might
connect to other observed differences in the integration.
As noted in Chapter 2, much of the literature on cross-disciplinary research and
integration focuses heavily on the individual approach to cross-disciplinary integration or in the
evaluation of either integrative capacity or integration in its outputs. The findings from this study
contribute to the ongoing research in these spaces by providing a more objective way to model
and subsequently evaluate the integration that occurs over the course of collaborative crossdisciplinary research in teams.

Recommendations for Research
This study identifies several important recommendations for future research in crossdisciplinary research, collaborative cross-disciplinary research (i.e., team science), and FDA
team science in particular. At the most fundamental level, the approaches to collaborative crossdisciplinary research and even specific process activities that contribute to integration can now
be modelled. This modelling of integration in collaborative cross-disciplinary research should
continue in different teams to further characterize and refine the use of this modelling approach.
In addition, understanding the influence of time on the collaborative cross-disciplinary
integration process, or simply how the integration unfolds over time, could also lead to several
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impactful new findings. Lastly, exploring improvements to the collaborative approaches or
processes of Team Science in conjunction with the objective approach to evaluating integration
utilized in this study could lead to a much greater understanding of differences between
integrative teams that truly make a difference in outcomes.
As mentioned, the FDA took a page from the team science playbook and chose to further
promote integration in its team-based reviews for new drug product marketing applications. FDA
believed that greater integration of its scientific and technical staff would be needed to assess the
benefits and risks of the growing complexity of new drug products and diseases it is responsible
for regulating. In its pursuit of greater integration, the FDA identified new collaborative activities
for its teams to follow during marketing application reviews, such as a team-based benefit-risk
scoping of the application early with senior leadership involvement, interdisciplinary joint
assessment meetings, and a collaborative template for the team’s final work product. As seen in
this study these pre-determined collaborative activities and template led to greater crossdisciplinary interactions and more integrative outcomes, as if by design. This “Team Science by
Design” approach to promoting integration should be further explored by SciTS researchers to
see if simple built-in collaboration for Team Science endeavors can similarly drive collaborative
outcomes.
An interesting observation from this study was that of the variable of time. Because this
study focused on the collaborative process that led to integration, it was able capture data and
information that spanned a longer than normal observed period of cross-disciplinary integration.
In this study, the integration process unfolded for some review issues or instances of integration
from the beginning of the team’s time together (i.e., at the benefit-risk scoping meeting) and
terminated only at the recommendation for the final labeling of the product, which occurs at the
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end of the review process. In other review issues, the integration may have only unfolded from
early on and terminated around the mid-way point of the review process, or some other variation.
In previous SciTS research, instances of integration evaluated were typically contained
either in a final work product or from a conversation/discussion that unfolded over a much
shorter period (Frodeman et al., 2017; Laursen, 2018; MacLeod & Nagatsu, 2016; O’Rourke &
Crowley, 2013). That this study, and its methods, was able to capture integration unfolding over
such a longer period of time would be worth further exploration since the variable of time was
not thoroughly evaluated or considered in the design of this study. A future study would require a
greater degree of documentation of the process or perhaps a more ethnographic approach. Future
studies should consider the impact of time on the integration process and track it to see how it
might affect the integration. For example, did earlier onset of integration in the process result in
some unique outcome or phenomenon? Or would the amount of time that elapsed from the start
of the integration process to the end of it have any impact on outcomes? At the very least, SciTS
researchers should consider the importance of time and tracking collaboration over the course of
Team Science activities to enable future studies on the effect of this variable on collaboration or
the integration process.
As seen in this study, the new interdisciplinary review process and documentation
template in the integrated assessment that the FDA has begun implementing for its new drug
product marketing application reviews has somewhat increased the collaborative crossdisciplinary integration and FDA is still early in the implementation process. As FDA continues
to implement the new integrated assessment it should be expected that FDA’s integration in these
reviews would improve. However, this would be worthwhile to study. In this study, it appears
both the new process activities and the template, which drove the team to write collaboratively,
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contributed to the integration. It would also be interesting to explore these two key features (i.e.,
the process and template) of the interdisciplinary assessment separately to determine the impact
of each.
Revisiting the O’Rourke et al. cross-disciplinary integration framework, this study has
confirmed that in at least the context of FDA Team Science that the IPO framework for thinking
about integration can be applied in a universal way as was hypothesized (Laursen & O’rourke,
2019; O’Rourke et al., 2016). The universality is derived from the contextualization of the
model, which was mostly in the building of familiarity with the subject matter area rather than
any fundamental change to the IPO framework. In addition, the pragmatic methodology
deployed in this study to both analyze the teams’ work products and speak to team members
enabled the description of each integrative cross-disciplinary issue and the objective comparison
of the integration across issues in quantitative and qualitative means. Future studies of
integration would be wise to include a similar pragmatic approach prospectively to enable
objectivity and rigor in the evaluation. This could serve as a nice complement to more traditional
qualitative approaches for describing integration.
Even so, the use of the IPO framework and the approach to using it analytically in this
study would benefit from continued use in additional contexts to validate the universal claim.
Replication of its sensitivity to integration, sufficient to distinguish between different forms of
integration, would be a worthwhile investigation. The application of Sankey diagrams, an
approach borrowed from Laursen, to evaluate interdisciplinary reasoning has proven quite useful
in visually modelling the dynamics of collaborative cross-disciplinary integration (Laursen,
2018). But SciTS researchers should continue to explore this approach to modelling integration
and collaborative cross-disciplinary research to address any shortcomings. For example, the
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Sankey diagram’s strict principle for the conservation of elements within system may not fully
lend itself to cross-disciplinary research, where inputs may leave or enter the system at different
times based on the dynamics of the collaboration, especially over time. This aspect of the model
might need to be improved.
Lastly, it is worth noting the uniqueness of the disciplines and disciplinary interactions
within the FDA. While there is a great diversity of disciplines at FDA involved in the new drug
product marketing application review (e.g., clinical, statistical, chemistry, regulatory,
pharmacology, etc), these disciplines, when engaged in the assessment of benefits and risks of a
new drug product, may become more similar than they are different. This phenomenon may have
even led to the creation of new inter-disciplines at the FDA, such as clinical pharmacology,
clinical research science, regulatory science, and so on. This phenomenon alone warrants further
research to study the sameness or distance between these internal FDA disciplines and compare
them to external, more academically derived, disciplines. This disciplinary re-focusing over time
may also be contributing to the team science outcomes at FDA, such as those observed in this
study. Therefore, further research on the impact of this phenomenon is critical to fully
understanding collaborative cross-disciplinary integration at the FDA.

Implications for Practice
This research has several implications for the practice of SciTS and for FDA Team
Science. The utility, sensitivity, and universality of the collaborative cross-disciplinary
integration framework and associated modelling approaches is a useful tool in the SciTS toolbox.
The findings from these two cases also add meaningful new data to the evidence base of SciTS
related to the impacts of communication and collaboration on integrative capacity and
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integration. And, for FDA Team Science, the ability to better characterize and evaluate
integration in its team science ensures it can measure the progress and impact of its new team
effectiveness programs and improvements, create improved records or documentation of these
increasingly team-based activities, and proceed confidently towards full implementation of the
integrated assessment of marketing applications.

Implications for the Science-of-Team-Science
SciTS is continuously seeking to further understand the circumstances that lead to the
effectiveness of collaborative research or team science and manage those circumstances to
promote improved outcomes for teams (National Research Council, 2015). This study has
addressed both by confirming the theoretical basis of integration described in the O’Rourke et al
philosophical framework for cross-disciplinary integration and the practical application of the
framework via an analytical framework and modelling approach. In addition, in scientific
endeavors the providence of new evidence is almost as important as the evidence itself. With the
increasing use of teams for scientific research to achieve interdisciplinary and transdisciplinary
solutions to complex problems it is important to be able to describe the collaborative process that
led to the integrative outputs of the collaborative research.
In the case of FDA Team Science, and new drug product marketing application reviews
specifically, stakeholders are increasingly interested in the providence of FDA’s decisions and on
the individual perspectives of scientists on the FDA review teams (Herder et al., 2020;
MacGregor et al., 2020). As FDA shifts to more collaboratively based documentation some of
the documentation of this providence may be lost. The use of the integration framework and
model to characterize the processes that led to decisions related to key review issues could be
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used to augment the collaboratively written integrated review to make up for any decrease in
written review documentation and help stakeholders both within the FDA and those external to
better understand the review team’s thinking and decision-making process. In fact, during this
study several participants remarked during the member checking (validation) of the integration
models that this research study’s approach led to a remarkable grasp of the application and its
issues in a short period of time.
The integration framework and models also enabled a robust comparative analysis of the
integration for key review issues or “problems” encountered by the teams thanks to the
operationalization of variables and parameters within each instance of integration.
Operationalization in this sense means the use of pre-defined contextualization of quantitative
and qualitative features of the expected inputs, process, and outputs of the team science activity.
Equipped with this operationalized analytical framework, the integration can be logged and then
analyzed across multiple instances of integration in an objective way. For those interested in
either understanding integration generally across cases and contexts, or more specifically within
select types of collaborative research endeavors, the use of this pragmatic integration modelling
approach and the analytical framework is a major step forward in objectivity and replicability.
In addition, visualizing the integration or integration process is also helpful and sought
after in SciTS to help understand interdisciplinarity and cross-disciplinary research (Klein, 2012;
Laursen & O’rourke, 2019). By cataloguing the variables and parameters of integration in this
study using the cross-disciplinary integration framework and IPO model, data becomes readily
available for further manipulation and can be then subsequently modelled in other forms that are
amenable to the logic of an IPO model. For example, the Sankey flow diagrams, initially used by
Laursen to study collaborative interdisciplinary reasoning, were an effective tool for visualizing
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collaborative cross-disciplinary integration. These Sankey diagrams were only possible due to
the use of the framework and IPO model and the richness and structure of the data collected in
this study that the framework enabled (Laursen, 2018). Given the origins of the Sankey diagram
in industrial ecology this is also a rather remarkable example of translation and disciplinary
boundary spanning in its own right (Schmidt, 2008).
These implications for SciTS are enabled by the universality of the cross-disciplinary
integration framework and IPO model discussed earlier. Researchers interested in
interdisciplinarity and collaborative research have long sought to understand and assess
integration. Previous models have proved insightful but seemed to lack the ability to be used in a
more diverse set of contexts without great adaptation, which limits practical utility. This was
perhaps due to the heavy influence of the Principle of Variance from a leading thinker on
integration, Julie Thompson Klein, that drove early evaluations of integration far too into the
concrete details of the circumstances of each case of integration that was sought to be understood
(Klein, 2012; Laursen & O’rourke, 2019). With the more abstract O’Rourke et al framework and
IPO model able to accommodate the overall process of integration and adapt to new contexts
through the specification of parameters and variables at the input and output level, there does
appear to be a more universal approach to thinking about integration emerging.
It is important to mention that while the parameters and variables of the crossdisciplinary integration framework and IPO model enable a certain universality there is no loss
of sensitivity. With a focus on the overall process, inclusive of inputs and outputs, the model was
quite effective at teasing out small differences in the integration between separate instances of
integration within teams and among differing teams working on similar problems, as confirmed
by this study. With that said, the approach may lack some sensitivity when used only on the
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outputs of a collaborative research endeavor (e.g., an article or a study finding) and as such calls
for either prospective data collection or a phenomenological approach. This study found
incredible value and necessity in speaking with the team members of each case to fill in details
related to key inputs and process activities. Future research using this framework and modelling
approach should be sure to collect and analyze data directly on the inputs and process activities
whenever possible.
Beyond integration and studying this feature of science teams, this study also has several
broader implications for the practice of SciTS. As a reminder, this study took advantage of the
fact that the FDA has begun implementing a new interdisciplinary process and collaborative
documentation template for its marketing application review. As such, it was able to evaluate the
impact of these interventions designed to increase collaboration and communication on the
team’s ability to achieve its goals—one of which was scientific integration.
In the traditional multidisciplinary review, review teams would by standard operating
procedure routinely engage in team meetings to discuss major review decisions, such as whether
the application was suitable for filing or ultimately approvable. Absent a shared mental model or
collaboration principles, the individual members of the teams would come together at these team
meetings and make recommendations, based on their discipline’s perspective, to a single
decision-maker. However, the new interdisciplinary review introduced a more collaborative
approach to these interactions by anchoring review decisions and issue identification around the
benefit-risk framework (FDA, 2018b; Woodcock et al., 2020). This was done by building new
activities into standard operating procedures for the team, specifically new benefit-risk oriented
team meetings (e.g., benefit risk scoping meeting, joint assessment meetings) with more
deliberate and purposeful collaboration that focused on the benefit and risk issues as opposed to
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individual disciplinary recommendations. In addition, decision-makers or signatory authorities
were involved earlier and more frequently in these team meetings to ensure team alignment and
the benefit of their experience. While this study only examined one case from a traditional
multidisciplinary review and an interdisciplinary review respectively, these new meetings were
cited by participants from the interdisciplinary case multiple times as the origin of inputs for
issues, for the integrative resolution as a team of issues, and for increasing the sense of
collaboration and communication of the team.
Furthermore, the new interdisciplinary review introduced a new template for
collaboratively documenting the assessment of the new drug product marketing application. A
stark shift from the traditional multidisciplinary review which amounted to individual
disciplinary review documents (i.e., reviews) and a summary review. This “Team Science by
Design” approach to guiding the team to collaborate with an end in mind for its documentation
further increased the collaboration and communication on the team because the teams now
needed to align on the outline for their collaborative writing and collaborate effectively to ensure
all team members’ perspectives were incorporated in the final document. Team Science and
SciTS practitioners should consider how to build in similarly appropriate activities, procedures,
or templates/tools to guide teams to more collaborative and integrative outcomes.

Implications for FDA Team Science
As discussed previously, FDA is currently engaged in a modernization of the new drugs
regulatory program and as part of this modernization in 2019 began implementing a new
interdisciplinary approach to the assessment of new drug product marketing applications (Bugin
et al., 2020; FDA, 2019h; Woodcock et al., 2020). Implementation Science and Program Theory
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both call for a thorough evaluation of new programs and initiatives to ensure the design and
expected outcomes are achieving the desired impact (Damschroder et al., 2009; Funnell &
Rogers, 2011). As the FDA continues to implement the interdisciplinary process and integrated
review template for its integrated assessment of marketing applications it will need to rely on the
cross-disciplinary integration framework and IPO model to objectively evaluate integration, an
expected outcome, in the completed new drug product reviews.
Evaluating integration in more cases and over time in review teams implementing the
new interdisciplinary assessment of marketing applications will be an important measure of
implementation and could internally guide change management initiatives to help teams
successfully adopt the new process and template. As discussed in a public workshop on October
30, 2020, review teams are experiencing some challenges with implementing the new
interdisciplinary approach and collaborative template for documentation (FDA, 2020b). FDA
may need to deploy new training or provide coaches to teams to assist them with
implementation. This training and coaches can leverage these objective measurements of
integration to inform and track the effect of these initiatives to improve integration or
collaboration.
With integrated assessments and integration being a key strategic objective and expected
outcome of the new drugs regulatory program modernization and its initiatives, respectively, the
evaluation of integration is also critical to measuring the success of this organization
development program (Bugin et al., 2020; FDA, 2019h; Funnell & Rogers, 2011). With a now
tested and proven approach to measure integration, the FDA will be able to detect changes in
integration and therefore evaluate this aspect of the theory of change of the modernization
(Funnell & Rogers, 2011). This necessity to evaluate integration is even further strengthened by
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the finding in this study that integration is already occurring in FDA traditional reviews. If there
are tradeoffs to seeking “more integration”, such as the loss of individual reviews, then FDA
must track and qualify the change in integration to weigh what is gained.
Furthermore, conflict or scientific disagreement is neither unexpected in FDA new drug
product reviews nor in collaborative cross-disciplinary research more broadly. “The very nature
of scientific work requires a certain degree of conflict” (Fiore et al., 2015, p. 277). And SciTS
research points to a moderate level of task-conflict, or differences in opinion, viewpoint, and/or
ideas, as having several advantages for teams. A recent analysis of FDA reviews completed
between 2011 and 2015—well before the integrated assessment of marketing applications was
implemented—suggests that FDA teams are no different with nearly a quarter (24.1%) of
approvals having at least one scientific disagreement found in their documentation (MacGregor
et al., 2020). As FDA seeks more collaborative cross-disciplinary means for its review activities
and approaches to documentation, these task-conflicts will still occur and may even increase due
to increased collaboration. But the conflicts would be expected to be better managed, perhaps
even earlier, during the review.
A downside of increased integration and earlier conflict resolution from the new
integrated assessment might lead to less explicit documentation of disagreements since the final
documentation would reflect the final more integrative output and be less obvious of earlier
disagreement. Given that this study found that integration is best understood using data and
information related to the inputs and process activities in addition to the outputs, and to avoid the
potential lack of information related to scientific disagreements resolved early in the review
process, the FDA is strongly advised to consider implementing a means similar to that employed
in this study to capture the information associated with the “rise and fall” of review issues in
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either its workflows or templates. This would not only boost the FDA’s ability to understand the
integration occurring in its review issues but also create a more accurate and thorough record of
the review issue for posterity. Therefore, it is highly recommended that FDA adopt and
standardize the use of the integration framework and IPO model in the integrated assessment and
other interdisciplinary initiatives at the FDA for both evaluation and routine documentation.

Conclusion
This study of collaborative cross-disciplinary integration in either a case of FDA’s
multidisciplinary or interdisciplinary assessment of a new drug product marketing application
has validated the use of an approach to thinking about and studying cross-disciplinary integration
from the O’Rourke et al. framework and associated IPO model in a new context. It has identified
multiple well-characterized instances of integration in both a multidisciplinary case and
interdisciplinary case of FDA cross-disciplinary team science. And, it has found that the process
and collaborative documentation of the interdisciplinary assessment for marketing applications
has led to more integration in this interdisciplinary case. Future SciTS and FDA Team Science
research can benefit from using this framework and modelling approach for evaluating
integration and benefit-risk review issues. And, practitioners of team science, SciTS,
organization development, implementation science, and program evaluation can take advantage
of a new tool in their toolboxes.
In the future, exploring additional contexts for the application of the philosophical crossdisciplinary integration framework and expansion on this method will greatly add to both the
origins in the philosophy of science but also lead to the application of this knowledge more
practically. Applying learned scientific knowledge in the more practical sense to the goals and
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objectives of real-world problems has the potential to return greater impacts on society and
future science. For future expansions, it will be important to identify a contextually relevant
framework, such as the benefit-risk framework in this study, to couple with the cross-disciplinary
integration framework. This was the key to practical adaptation seen in this study. Seeking out
these additional contextual applications will further confirm potential universality and
generalizability and add to a growing playbook for practical uses in the future. Furthermore,
using similar methods to collect and inventory qualitative data per the analytical IPO framework
should be deployed in future cases to enable more empirical evaluations of this sort, add to a
growing evidence base of cross-disciplinary integration, and potentially identify noteworthy
themes across contexts.
In addition to expanding on the original framework and methods, it is worth further
exploring the study of the Science-of-Team-Science in the space of drug development and
regulatory science, as was done in this study. This space is rich with cross-disciplinary and
collaborative cross-disciplinary endeavors. And its proximity to public health impact makes it of
key import. In addition, this space, while full of exciting, emerging science and innovation, has
not traditionally seen this level of scholarship and external invitation to the exploration and
improvement of its internal processes for conducting regulatory science. Typically, this sort of
work would be done internally or only in partnership with consultant organizations. Beyond the
FDA environment, there is a near mirror image of the collaborative cross-disciplinary research
on drug development occurring in industry that could similarly benefit from the research
methods in this study.
Future utilization of the cross-disciplinary integration framework and IPO model from
this study in more everyday documentation of internal FDA activities could open the door to a
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new age of understanding for those external to the FDA and for the FDA itself lead to greater
enhancements of its internal processes. As was noted, many external researchers seek to better
understand the rationale for FDA decision-making. And, while documentation has been extensive
in the past, it has never quite focused on the processes of internal FDA staff. And, never quite on
the transformation of information into decisions or knowledge such as was seen in this study.
The IPO framework, coupled with the benefit risk framework, as used in this study has the
potential to revolutionize how the FDA communicates the bases for its decisions and details
related to benefit-risk review issues.
Lastly, the field of organization development, change management, implementation
science, and program evaluation will benefit greatly from the methods used in this study and the
associated case studies. The FDA has embarked on a major organizational transformation via its
New Drugs Regulatory Program Modernization. That it has thoughtfully crafted program
objectives, outcomes, and anticipated impacts, communicated those to staff, designed
interventions around them, and set to evaluate these sets a great example for future organization
development efforts and translational scientists. This example can serve as a case study for these
additional fields for years to come.
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Appendix 1: Recruitment Email
Example
Dear NDA 212123 Tauvid Review Team,
I hope all is well with you during these unusual and difficult times. I fully recognize and
appreciate that this is a challenging time and that you may be busy managing with this new
normal under the COVID-19 pandemic and its impacts on your work. But, I hope you will afford
me a few minutes of your time to consider this request to help me and the CDER better
understand a key feature of our reviews.
You may already know me but for those who do not, I’m Kevin Bugin, director of special
programs from the Office of New Drugs. As part of my doctoral research at the George
Washington University, and in support of the center’s interests to improve the review of new
drugs, I am conducting a study of cross-disciplinary integration in FDA review documents. I am
particularly interested in comparisons between multidisciplinary reviews (i.e., individual
discipline reviews that are integrated into a summary review) and the new interdisciplinary
reviews (i.e., the collaboratively written Integrated Assessment). The key research questions of
this case study are: (1) What are examples of integration in FDA new drug product reviews? (2)
What are the specific differences between integration in a multidisciplinary review and an
interdisciplinary review?
You have been identified as a potential participant for this study due to your role as
a reviewer/TL or a signatory for the completed integrated review of NDA 212123 for
Tauvid (fluoroestrdiol F18) that was approved on May 28, 2020. I’d like to invite you to
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share your perspective on the integration that occurred in this integrated review related to
key review issues that impacted the benefit-risk assessment by joining a one-time 30-minute
interview. The interviews will occur in July per your availability. Due to the ongoing COVID-19
situation, the interview will be conducted virtually (i.e., phone and/or video conference) for
everyone’s safety.
Disclaimer: It is possible that your participation in this study will not remain anonymous.
This is because publicly available reviews are the subject of this study and your information may
already be public as a result of routine public disclosure practices of FDA. However, your
specific participation (i.e., the information you share during the interview and focus group) will
be kept strictly confidential and any attributions to you will be protected. The only person that
will be aware of your participation is myself. Please also note that this study has been reviewed
and exempted by the IRBs of GWU and FDA—your participation in this study has been
determined to be of minimal psychological risk. You do not have to take part in this research. You
can agree to take part and later change your mind. If you choose not to take part or choose to
stop taking part at any time, there will be no penalty to you or loss of benefits to which you are
otherwise entitled. And as an employee of the FDA, if you decide not to take part in this study,
your choice will have no effect on your employment status. For a complete description of benefits
or risks, please refer to the Detailed Consent Form which you will be provided should you agree
to participate.
This research is supported by Dr. Peter Stein (copied) and CDER/OND. It is being
conducted in collaboration with the George Washington University via the principal investigator,
a Science of Team Science researcher from GW and President of the International Network for
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the Science of Team Science, Dr. Gaetano Lotrecchiano, (glotrecc@gwu.edu; 202-994-9855).
Please visit the International Network for the Science of Team Science for more information on
the Science of Team Science.
Please let me know if you have any questions and/or would be willing to participate
in study and I will follow-up with more information. Thank you!
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Appendix 2: Informed Consent
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Appendix 3: Interview Slide Deck
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Appendix 4: RINVOQ Review Issue Inventory
4.A. Review Issue 1

Input 1 Data:
•
CP Transcript: “reviewer has done the provided exposure response analysis.”
•
CP Review: “Overall, results from Phase 3 studies and exposure-response analysis support the proposed 15 mg QD dosing regimen as it provides the optimal benefit-risk
balance in patients with moderately to severely active RA”
•
CP Review: “The applicant’s exposure response analysis for safety is consistent with the observed safety data.”
Input 2 Data:
•
CP Review: “the safety profile of upadacitinib has demonstrated a dose-dependent increase in the number of reported adverse events.”
•
Med Review: “Analysis of the overall safety database demonstrated that UPA-treated subjects experienced a greater proportion of AEs and SAEs compared to PBOtreated subjects. “
•
Med Review: “Analysis of the phase 3 UPA 15 mg and 30 mg analysis set (Studies M13-542, M13-545, M13-549, M15-555) showed a higher proportion of serious
infections in the UPA 30 mg treatment arm compared to the UPA 15 mg treatment arm”
•
Stats Review: “Based on the integrated safety analyses during the placebo-controlled or MTX-controlled period,”
Input 3 Data:
•
CP Review: “Overall, results from Phase 3 studies “
•
Med Review: “Similar to the results observed in Study M13-542, the results of this study demonstrate a clinically meaningful benefit from treatment with UPA 15 and 30
mg but do not support a dose-dependent increase of clinical efficacy with the higher dose of UPA in this patient population. Consequently, the overall benefit-risk
assessment for UPA 30 mg will need to be determined in the context of the overall safety evaluation.”
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Process 1 Data:
•
Med Review: “it is worth noting that the safety analyses included comparisons of AEs between the UPA 15 mg and 30 mg doses but only the UPA 15 mg dose is being
sought for approval by the Applicant. “
Process 2 Data:
•
Summ Review: “There was lack of numerical trends towards greater mean change from baseline in F ACIT-F at Week 12 for patients treated with the higher dose of UP
A for studies M13-542 and M13-545”
Process 3 Data:
•
Summ Review: “While both doses of upadacitinib are effective, comparisons between the two dosing regimens did not suggest a consistent trend in favor of a particular·
dose. Given these results, the Applicant is only requesting approval of the upadacitinib 15 mg QD dose.”
•
Sig Interview: “which really comes down to the safety assessment and whether there's any dose related toxicities, and then the efficacy assessment as well, to sort of
balance out and determine which dose is appropriate”
Output 1 Data:
•
Summ Review: " The benefit-risk profile of the upadacitinib 15mg dose is more favorable than the 30mg dose. The small incremental benefit of the 30mg dose does not
outweigh the dose-related safety findings with the 30mg dose of upadacitinib."
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4.B. Review Issue 2

Input 1:
•
CP Transcript: “BE, the sponsor submitted their own data set”
•
Chem Review: “in vitro dissolution comparison and an in vivo BE study”
Input 2:
•
CP Transcript: “critical … to repeat the data analysis”
Input 3:
•
BP Transcript: “release profiles. Like if they can show the release profiles “
Input 4:
•
Chem Review: “in vitro dissolution comparison and an in vivo BE study”
Input 5:
•
Chem Review: “the Applicant has performed a bioavailability study under fasting conditions according to a randomized, 2-period crossover design in 40 healthy subjects
comparing the Phase 3 formulation to the Commercial formulation”
•
CP Review: “Upadacitinib PK was compared between using IR formulation and ER formulation in a dedicated, randomized, open-label, two period, two-sequence,
crossover, relative bioavailability study (Study M14-680)”
Input 6:
•
CP Review: “PBPK analysis has adequately bridged the clinical DDI effect of strong CYP3A4 modulator (inducer or inhibitor) observed with upadacitinib IR
formulation to the ER formulation.”
Process 1:
•
CP Transcript: “I normally discuss with the team leader first to finalize the slides, and then we presented with the whole review team”
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Process 2:
•
BP Transcript: “communications were between both clinical and clinical pharmacology teams in trying to make sure that the plus or minus 10% is okay in terms of
establishing the boundaries”
•
Chem Review: “The Biopharmaceutics Reviewer consulted the Clinical Reviewer for establishing the acceptable boundaries for efficacy and safety.”
Output 1:
•
BP Transcript: “The applicant did submit the release, but I think the release profile is common for any kind of change, be it level one, level two, level three [inaudible
00:15:10] and for level three, in addition to the release profile, we need the B study. So once we integrate all this part, we'll say, okay, bridging”
•
CP Review: “PBPK analysis has adequately bridged the clinical DDI effect of strong CYP3A4 modulator (inducer or inhibitor) observed with upadacitinib IR
formulation to the ER formulation.”
•
CP Review: “Bioequivalence was established between the to-be-marketed ER tablets and the ER tablets used in Phase 3 studies”
•
CP Review: “Cmax, AUCO-t, and AUCO-inf are well within 80-125% limit, indicating the to-be-marketed tablet is bioequivalent to the clinical study tablet”
•
Summ Review: “The biopharmaceutics team has determined based on the submitted information that bridging of the two formulations has been adequately established
and the two formulations are similar to each other.”
•
Summ Review: “The clinical pharmacology team has determined, and we agree, that the to-be-marketed formulation is bioequivalent to the clinical study tablet”
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4.C. Review Issue 3

Input 1:
•
PT Transcript: “I guess the other complexity to this one was there was, compared to some applications, kind of a lot to sift through regarding impurities.”
•
PT Transcript: “yeah, so the impurities are often one thing that really can't be completely resolved until the NDA is in house because it's a combination of data sources on
the quality side and the nonclinical side”
Process 1:
•
PT Review: “safety assessment was conducted on a range of observed and potential impurities and degradants”
Process 2:
•
PT Transcript: “also our internal computational toxicology experts, they offer a consult service so I'm quite certain we consulted them as well”
Process 3:
•
PT Transcript: “requires collaboration with the CMC review team “
Output 1:
•
PT Review: “There are no safety concerns related to UPA impurities for the proposed dose, duration, and patient population”
•
Summ Review: “Pharmacology/Toxicology team evaluated 35 impurities [redacted] and concluded these did not present any safety concern”
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4.D. Review Issue 4

Input 1:
•
CP Transcript: “That's based on our own data analysis.”
Input 2:
•
CP Transcript: “so yeah, in the DDI study, they also have in one DDI study”
Process 1:
•
CP Interview: "normally discuss with the team leader first to finalize the slides, and
then we presented with the whole review team"
Output 1:
•
CP Review: “Therefore, we recommend that upadacitinib should not be co-administered with strong CYP3A4 inducers.”
•
Summ Review: “Coadministration with strong CYP3A4 inducers are not recommended because that may result in ineffective concentrations of upadacitinib.”
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4.E. Review Issue 5

Input 1 and Input 2:
•
Summ Review: “JAK inhibitors are potent immunosuppressants and there are a number of well-known safety issues associated with use of this class of medications,”
•
Summ Review: “Given that two JAK inhibitor programs have identified thrombosis as a safety signal, thrombosis is now considered a class safety issue.”
•
Sig Transcript: “One of the issues had been the design of studies and analysis of the safety data. This is, I think, the third JAK inhibitor [inaudible 00:03:43] toxicities for
the class. We had a very gnarly second JAK inhibitor, Baricitinib, that had a unique safety signal of venous thromboembolism for that.”
•
Med Transcript: “o this drug is a JAK kinase inhibitor, and we saw a signal with the first in class, tofacitinib, that there was a malignancy signal and then later, possibly
with another drug that was being developed, baricitinib, we saw that there was a deep vein thrombosis or a thromboembolic signal. So that's what we were really starting
to focus on. “
•
Med Transcript: “We know what to expect. But it was basically the thromboembolism and malignancy that we were looking at.”
•
Med Transcript: “So we basically identified it because there was none. There wasn't a signal in the data, but we were looking for it”
Process 1:
•
Med Transcript: “So we basically identified it because there was none. There wasn't a signal in the data, but we were looking for it because of baricitinib. Since it did
occur at both doses, not necessarily dose-dependent, we still wanted to analyze that information. So we had stats help us look at the different levels that we could parse
out to see about the thromboemboli.”
Process 2:
•
Med Transcript: “Did AbbVie give pushback on that? A lot. Yeah, [inaudible 00:09:07]. But I think they're understanding. I'm not in pharma, but I'm pretty sure what
their strategy is is get it out in the market and then just market it. It's all marketing.”
Output 1:
•
Summ Review: “Given that two JAK inhibitor programs have identified thrombosis as a safety signal, thrombosis is now considered a class safety issue and the
upadacitinib product label will include a Boxed Warning regarding VTE.”
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4.F. Review Issue 6

Input 1:
•
Sig Transcript: “I think it was identified because it was a nonclinical study that identified the risk. I can't recall. I think they might've recommended a
contraindication, and this would've been different than the other JAK inhibitors. “
•
PT Transcript: “we get full GLP study reports for all these pivotal studies on the nonclinical side and those reports include all the raw data. So yes, while the
reports have a summary, but we're not parroting the sponsor's summary. This is why nonclinical review is so intensive at times because we're reviewing the
data ourselves “
•
Med Review: “The nonclinical review team identified a teratogenicity signal in rats and rabbits at clinically relevant exposures that represent a potential serious
risk for human fetal toxicity. “
•
PT Review: “In embryofetal development studies, upadacitinib was teratogenic with skeletal malformations observed in rats and rabbits; other findings and
decreased fetal body weights and increased postimplantation loss in rabbits.”
•
Summ Review: “Animal studies with upadacitinib showed teratogenicity findings (skeletal malformations and death), but these findings were more concerning
compared to other JAK inhibitors because teratogenicity was noted at lower exposure margins considered clinically relevant exposures.”
Input 2:
•
PT Transcript: “we get full GLP study reports for all these pivotal studies on the nonclinical side and those reports include all the raw data. So yes, while the
reports have a summary, but we're not parroting the sponsor's summary. This is why nonclinical review is so intensive at times because we're reviewing the
data ourselves “
•
Med Review: “The nonclinical review team identified a teratogenicity signal in rats and rabbits at clinically relevant exposures that represent a potential serious
risk for human fetal toxicity. “
•
PT Review: “In embryofetal development studies, upadacitinib was teratogenic with skeletal malformations observed in rats and rabbits; other findings and
decreased fetal body weights and increased postimplantation loss in rabbits.”
•
Summ Review: “Animal studies with upadacitinib showed teratogenicity findings (skeletal malformations and death), but these findings were more concerning
compared to other JAK inhibitors because teratogenicity was noted at lower exposure margins considered clinically relevant exposures.”
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Input 3:
•
PT Transcript: “One was the reproductive risks based on the nonclinical data. We felt the data was substantially worse than the previous class members and so
we wanted the fetal risk to be included in the warnings and precautions section of the label, which would be a difference between this and its competitors in the
class. “
•
Med Review: “ The nonclinical reviewer, Brett Jones, PhD, considered the embryo-fetal toxicity data with UPA as comparatively more concerning than that
observed with previously approved JAK inhibitor products, namely tofacitinib and baricitinib, based on the observed lower exposure margins to proposed
clinical dose levels.”
•
Summ Review: “The embryo-fetal toxicity finding with upadacitinib is more concerning compared to tofacitinib and baricitinib because of the relatively low
exposure margins.”
Process 1:
•
PT Transcript: “So we raised this pretty early on, I think, and discussed it at various meetings.”
•
Med Review: “concerns were discussed at the March 4, 2019 Safety Mid-Cycle Meeting and the review team agreed that safety signal potentially warranted
inclusion in the Warnings and Precautions section of the label, particularly in light of the large number of women of childbearing potential in the RA patient
population.”
•
PT Review: “Mid-Cycle Meeting on March 4, 2019, the nonclinical safety concerns regarding the observed teratogenicity of upadacitinib at exposures similar
to the proposed clinical dose levels in both rats and rabbits were presented and subsequently discussed with the clinical review team and other associated
review team members. The review team agreed that the observed embryo-fetal toxicity data with upadacitinib represented a significant safety concern that
potentially warranted inclusion in the Warnings and Precautions “
Process 2:
•
PT Review: “An additional bullet statement regarding the potential for embryo-fetal toxicity with upadacitinib was added to the Warnings and Precautions
based on a consultation with DPMH and discussions with the Clinical Team.”
Output 1:
•
Sig Transcript: “I think it was identified because it was a nonclinical study that identified the risk. I can't recall. I think they might've recommended a
contraindication, and this would've been different than the other JAK inhibitors.”
•
PT Transcript: “One was the reproductive risks based on the nonclinical data. We felt the data was substantially worse than the previous class members and so
we wanted the fetal risk to be included in the warnings and precautions section of the label, which would be a difference between this and its competitors in the
class.”
•
Med Review: “given the embryo-fetal toxicity observed in animals at the to-be-marketed dose, the Agency recommends labeling for UPA should include a
Warning and Precaution statement regarding potential teratogenicity.”
•
PT Review: “Mid-Cycle Meeting on March 4, 2019, the nonclinical safety concerns regarding the observed teratogenicity of upadacitinib at exposures similar
to the proposed clinical dose levels in both rats and rabbits were presented and subsequently discussed with the clinical review team and other associated
review team members. The review team agreed that the observed embryo-fetal toxicity data with upadacitinib represented a significant safety concern that
potentially warranted inclusion in the Warnings and Precautions “
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Appendix 5: TAUVID Review Issue Inventory
5.A. Review Issue 1

Input 1:
•
CP Transcript: “Well, from the very beginning we noticed that the structure, the chemical structure of [TAUVID] was slightly similar to some of the others of the
compounds that bind to MAO inhibitors bind to monoamine oxidase enzymes and the structurally similar to some of those inhibitors. So it was clear that there's a
potential that there's a drug could inhibit.”
•
PTS Transcript: “clinical pharmacology raises substantial issue about the effect of MAO”
Input 2:
•
CP Transcript: “ there was one paper that reported the binding for MAO the subtypes in these enzymes. One is MAO A and another one is MAO B and there were
comparative reports in the literature, whether it really binds to MAO A or not”
•
RPM Transcript: “I believe it was the MAO inhibitor issue, that there was something known from literature, it didn't necessarily come up in the studies, but it was known
in literature, and that triggered a lot of investigation by the review team into the impact”
Input 3:
•
CP Transcript: “And then the company came back to us with a, the results of a clinical study that was being conducted currently, and the results they said that are not
published.”
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Input 4:
•
PT Transcript: “I contributed some amount to the MAO inhibitors for TAUVID, flortaucipir binding because they actually, the sponsor, Avid, submitted a lot of
secondary pharmacology data to evaluate the effect of MAO inhibitors”
•
Integrated Review: “TAUVID PET signal was slightly reduced by rasagiline, a MAO-B inhibitor, in vivo in low tau, high MAO-B areas of the brain such as the nucleus
accumbens, putamen, and caudate.”
Process 1:
•
PT Transcript: “we had these like a scoping meeting and then a kind of introduction to the integrative review and how to use the review tracker. And it might've been the
scoping meeting, or it could have even been during the filing meeting where I discussed with the clinical pharmacology team new data that was included within the NDA
to evaluate off-target binding. And then we kind of initiated some discussions on that and then those discussions wound up, so then I had reviewed a lot of those studies
to include in my, we do a mid-cycle and includes several slides to discuss, summarize all the data for the NDA, from the nonclinical perspective.”
Process 2:
•
PT Transcript: “so then I had reviewed a lot of those studies to include in my, we do a mid-cycle and includes several slides to discuss, summarize all the data for the
NDA, from the nonclinical perspective.”
•
RPM Transcript: “If I recall, there wasn't a lot of data on it, and so there was discussions primarily with the clin pharm group as to how that could be addressed in
labeling more than anything else. It wasn't necessarily a huge concern.”
Process 3:
•
PT Transcript: “what it boiled down to was what in vivo, in humans, what really would be the end result of that? Would it be of significant concern that it would affect
the interpretation of a scan? And there was some contention between the agency and the sponsor as to how to capture that in the labeling”
Process 4:
•
PT Transcript: “Well, there was a lot of collaborative writing at later stages to try to document this both in like relevance clinical Clin/Pharm and nonclinical sections”
•
Integrated Review: “These findings suggest that flortaucipir binds with low affinity to MAO-A and very weakly to MAO-B in postmortem normal human tissue and that
MAO-B would not contribute much to FTP uptake in PET imaging.”
Output 1:
•
CP Transcript: “We didn't want to alarm people too much either because the issue is still being researched and still not clear so more studies need to be conducted”
•
Integrated Review: “Therefore, it appears that there is little potential for MAO binding to affect Tauvid PET image interpretation. The language in the proposed label
Image Interpretation (2.4) and Warnings and Precautions (5.1) sections states that “only uptake in neocortex should contribute to the interpretation of a positive Tauvid
scan” would be adequate to mitigate any putative effect of MAO inhibitors on scan interpretation.”
•
Integrated Review: “The team concluded to include the off-target binding potential of FTP to MAO-A and MAO-B in Section 12 of the prescribing information.”
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5.B. Review Issue 2

Input 1:
•
DD Transcript: “I think that the issue of a user guide that was an issue that came up during the review that we had not anticipated. “
Input 2:
•
DD Transcript: “The question of the image guide was actually something that did require discussion with the colleagues from CDRH. We also had to have policy people
involved and the issue is whether this should be considered labeling and so there was a fair amount of discussion about how to incorporate this into the labeling.”
•
Sig Transcript: “The other issue, which was identified early on was the user manual and the team leader who still reads nuclear scans, the user guide. Because they use
different platforms for this, to be able to read them. There's different software out there that helps you read the digital image, but you have to put settings into it to be able
to read it correctly. “
•
Integrated Review: “For the assessment of image interpretation, the team, including experts from the Center for Devices and Radiological Health (CDRH), viewed a set
of images from the pivotal studies provided by the Applicant as reviewer aids, reviewed and tested the instructions in the proposed prescribing information (PI) to image
readers for Tauvid image interpretation.”
•
Integrated Review: “The team, including members from CDRH and DMEPA, assessed that Tauvid readers will need more detailed instructions for image display to
supplement the high-level instructions provided in the Tauvid PI.”
Input 3:
•
DD Transcript: “The question of the image guide was actually something that did require discussion with the colleagues from CDRH. We also had to have policy people
involved and the issue is whether this should be considered labeling and so there was a fair amount of discussion about how to incorporate this into the labeling.”
•
RPM Transcript: “regulatory policy definition that had to be discussed with ORP, and so that to me was the interesting review issue, “
•
Sig Transcript: “You're also writing a user guide for a device, in essence, and so it raised some legal issues, and we brought them [OND Policy] in towards the end once
we saw a clear path of how to proceed with being able to address this issue”
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Process 1:
•
Sig Transcript: “So that was identified early on in the first couple weeks, I'd say. So that issue was brought to the company's attention quite early on. “
Process 2:
•
Integrated Review: “In response, the Applicant contacted professional societies and also conducted a poll of image readers/imaging sites that participated in the Tauvid
efficacy studies to gain insight into which software platforms are commonly used for image review and analysis in a clinical setting. Based on the survey, the Applicant
determined that the most commonly used image viewing software platforms in the US are MIM, GE, Siemens and Hermes. Subsequently, the Applicant created and
submitted step-by-step user guides for the MIM and Siemens image viewing software platforms for review and comment on their adequacy. “
Process 3:
•
RPM Transcript: “RPM Transcript: “regulatory policy definition that had to be discussed with ORP, and so that to me was the interesting review issue, “
Output 1:
•
Sig Transcript: “They had labeling that sort of explained how to do it, and he couldn't understand how to do it, and he's a very experienced nuclear medicine person.”
•
Integrated Review: “the Applicant, in consultation with the Agency, added the following language in Section 2.4 (Image Display) of the PI: If additional guidance on
image display is needed, refer to the TAUVID User Guide for PET Image Display available by request from the manufacturer.”
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5.C. Review Issue 3

Input 1:
•
Integrated Review: “The Applicant reported small but statistically significant increases in QTcB and QTcF intervals around 2 hours following IV administration of FTP
when compared to baseline predose measurements.”
Input 2:
•
CP Transcript: “so QT, as you know whenever we see a QT signal, this was first identified early in the... Our review meetings and then a consult we'll send to the QT
IRT team”
•
Integrated Review: “This issue was also reviewed by QT Interdisciplinary Review Team (QT-IRT) and they concluded that no additional regulatory action was
indicated.”
Process 1:
•
CP Transcript: “And essentially I did my own analysis as well, and QT IR team. They did their analysis as well. And for the most part even though the assessments were
independent,”
•
Integrated Review: “We do not propose QT-related labeling language for the small increases in QTcF observed in the safety database”
Process 2:
•
CP Transcript: “So again I want to emphasize it was a, a nice integration between clin pharm team, QT IRT and then discuss with the, the medical officer medical
review, our medical team leader and the division director and everybody chimed in and looked at the evidence. And I think I agreed with clin pharm that it's something
that we don't need to be concerned”
Output 1:
•
Integrated Review: “The team concluded that this observation is not clinically important.”
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5.D. Review Issue 4

Input 1:
•
Integrated Review: “Potential off-label use of Tauvid in chronic traumatic encephalopathy (CTE) and other tau-related neurodegenerative disorders is a concern because
preliminary nonclinical and clinical investigations suggest differences in tau conformation and distribution may limit FTP binding in CTE.”
•
Integrated Review: “There is a potential for inappropriate use of Tauvid in patients with CTE and other non-AD tauopathies.”
Input 2:
•
PT Transcript: “CT misdiagnosis, I mean, that's clear from both published studies and some of the nonclinical data.”
•
DD Transcript: “Concussions and so on. And so it was clear based on preclinical data that the binding of this drug was not going to be, it was going to be specific only to
the Alzheimer type of neurofibrillary tangles.”
Input 3:
•
PT Transcript: “CT misdiagnosis, I mean, that's clear from both published studies and some of the nonclinical data.”
•
Sig Transcript: “CTE misdiagnosis was really something that was based on what had been published already in the literature.”
•
Integrated Review: “the tau aggregates in CTE contain all six isoforms with the presence of both the 3R and 4R repeats of the microtubule binding domain that is similar
to AD but no other tauopathies, electron cryomicroscopy studies show the tau filament conformation in CTE differs from the tau filaments in NFTs of AD (Falcon et al.
2018; Falcon et al. 2019).”
•
Integrated Review: “Marquie et al. explored the correlation between FTP binding patterns in pathologically confirmed CTE tissue using phosphor screen and highresolution autoradiography and quantitative tau measurements obtained through immunohistochemistry, Western blotting, and tau seeding activity in the same samples
(Marquie et al. 2019).”
•
Integrated Review: “Another study (Mantyh et al. 2020) compared in vivo FTP activity with phosphorylated tau immunohistochemical analysis of postmortem brain
tissue (Mantyh et al. 2020).”
Process 1:
•
Integrated Review: “To mitigate risk, the Applicant agreed to accept addition of a Limitations to Use in prescribing information (PI)”

237
•

Integrated Review: “Potential off-label use of Tauvid in chronic traumatic encephalopathy (CTE) and other tau-related neurodegenerative disorders is a concern because
preliminary nonclinical and clinical investigations suggest differences in tau conformation and distribution may limit FTP binding in CTE.”

Output 1:
•
Integrated Review: “To mitigate risk, the Applicant agreed to accept addition of a Limitations to Use in prescribing information (PI). This limitation emphasizes that
Tauvid is not indicated for evaluation of patients for chronic traumatic encephalopathy (CTE) and cross-references an added Warning and Precaution under the heading
“Risk of Chronic Traumatic Encephalopathy Misdiagnosis.””
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5.E. Review Issue 5

Input 1:
•
DD Transcript: “One was sort of a study that looked at the accuracy of the reading, PET imaging, with a truth standard consisting of autopsy diagnosis and so that was a
standard portion that succeeded.”
•
•

Integrated Review: “To assess the utility of Tauvid to estimate the density and distribution of aggregated tau NFTs in patients with cognitive impairment being evaluated
for AD, the Applicant conducted two neuropathologic correlation studies—the A16 autopsy study and the FR01 reader study.”

Input 2:
•
Input 3:
•
Integrated Review: “To illustrate this issue, consider the publication cited by the Applicant for support of the AD neuropathological criteria used in Study A16 (Hyman et
al. 2012)."
Input 4:
•
DD Transcript: “The other issue, maybe that it also is important that the sponsor

.“
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•

Integrated Review:

Process 1:
•
RPM Transcript: “Because of the pre-NDA and the prior meetings, one of the biggest subjects that was constantly being brought up is how they had difficulty in getting
their objective. “
Process 2:
•
Integrated Review: “For the assessment of image interpretation, the team, including experts from the Center for Devices and Radiological Health (CDRH), viewed a set
of images from the pivotal studies provided by the Applicant as reviewer aids, reviewed and tested the instructions in the proposed prescribing information (PI) to image
readers for Tauvid image interpretation.”
Process 3:
•

Output 1:
•
Integrated Review: “The team concluded that the results of the submitted phase 3 studies support the efficacy of Tauvid to estimate the density and distribution of
aggregated tau-NFTs in the indicated patient population (efficacy for tau pathology detection).”
Output 2:
•
DD Transcript: “
.”
•
Integrated Review: “To address this issue, the PI was revised in Section 5 WARNINGS AND PRECAUTIONS to alert the prescribing clinicians of the limitation of a
Negative Tauvid scan read by including the following: 5.1 Risk of Misdiagnosis in Patients Evaluated for Alzheimer’s disease TAUVID does not target β-amyloid, one
of two required components of the neuropathological diagnosis of AD.”
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5.F. Review Issue 6

Input 1:
•
CDTL Transcript: “Well, the module five, the [inaudible 00:11:51] data submissions. I mean, at least from my perspective, the most viable affect is a submission in order
or the … line item data, the key support forms that get informed that line item data, and then the [inaudible 00:12:18] study reports that sort of represent the applicants on
and out and write up of that data.”
•
DD Transcript: “And then the second component of the clinical development was going to be an assessment

”
Input 2:
•
Stats Transcript: “you will not see any exploratory analysis that the stat team did regarding prognostic indication.”
•
Stats Transcript: “The stat team interacts with clinical team a whole lot, and we shared our analysis with them and go from there. So we identified this issue much earlier
in the review cycle and shared, we identified but it took some time to learn all those exploratory analysis and to convince ourselves first and then clinical team that this
was the serious issue. “
Input 3:
•
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Input 4:
•
RPM Transcript: “So a lot of data were missing, that they found out, and that sort of helped them gel or solidify what this issue really was. Because a lot of what was
discussed in the pre-NDA meetings didn't come through when they actually came in for the NDA. There were things that were just- did not get presented when they were
asked. So a lot of it was internal meetings, data analysis, and gathering more information that was just not there when they submitted the NDA.”
Process 1:
•
RPM Transcript: “I think they just couldn't
•
•
•

RPM Transcript: “ it wasn't quite until mid-cycle that they started to put pen to paper on how they actually all agreed about some particular issue. Right, and then that's
sort of when all the other jam meetings and mid-cycle meetings, that's sort of when it started to be more pressure, "get this on paper,””
Sig Transcript: “it was a close interaction between the statisticians and the clinical staff that helped sort through all the deficiencies, and that's why it got resolved it is.”
Stats Transcript: “The clin and stat meetings took place lot of time. There were many clin stat meetings. And through those meetings we decided eventually

Process 2:
•

Process 3:
•
DD Transcript: “So we negotiated with the company and they agreed to basically claims indication statement this were really consistent with the evidence that we had.
And so it was pretty much a routine kind of an approach.”
•
Sig Transcript: “[the Applicant] were trying to take individuals who would be characterized as having a very positive scan, sort of the extreme of the pathology and
follow them for a year and a half and measure cognitive function and be able to prognostically say whether the individuals who fell into this group based on their reads,
you can project their cognitive decline. That was the issue with the controversy about prognosis, and that was which was going to be discussed at the advisory
committee, which ultimately was canceled because the team conveyed to the company that this was going to be the discussion. They were understanding of that, agreed
that it could be discussed at the advisory committee, and then the advisory committee was canceled, and they agreed to withdraw that indication.”
Output 1:
•
Output 2:
•
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Appendix 6: RINVOQ IPO Models for Member Checking
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Appendix 7: TAUVID IPO Models for Member Checking
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